Experimental studies of silk and silk composites for biomedical application by Plowright, R
  
 
 
 
EXPERIMENTAL STUDIES OF SILK AND 
SILK COMPOSITES FOR 
BIOMEDICAL APPLICATION 
 
 
 
Robyn Plowright 
 
 
 
 
A thesis submitted in partial fulfilment of the requirements of the 
Nottingham Trent University 
for the degree of Doctor of Philosophy 
July 2017 
Dedication 
 
To Marc, for providing me with unconditional love and the support that I needed to complete 
this.  
Acknowledgements 
 
I would like to thank my supervisors both past and present, Prof Carole Perry for giving me 
this opportunity and providing guidance, support and patience throughout. Dr David Belton, 
whose passion for science has inspired me daily and whose advice was always appreciated. I 
would also like to thank my supervisors from my undergraduate studies, Dr Muriel Funck and 
Dr Gary Hix for giving me the confidence to go into research.  
My sincere thanks go to the entire Perry research group for putting up with me over the last 
three years; Graham Hickman, Marion Limo, Mithun Parambath, Zayd Westcott, 
Veeranjaneyulu Thota, Mathew Nicklin, Ben Hanby, Mohamad Abou Shamat, Monika 
Michaelis, Daniel Oliver, Aneeqa Fayyaz, Igor Effimov and Victor Volkov. I would also like 
to thank our collaborators at Tufts university and the NIH for permitting me be part of this 
project.  
It is undeniable that without my friends this would not have been possible, so in no particular 
order I would like to thank; Jacob Spear, Danielle Pearson, Anna Sola Rabada and Cheryl 
Smith who are all wonderful people who made me laugh when I needed it and made my 
experience extra special by allowing me to be part of their lives.  
Lastly, I would like to thank my family, specifically my cousin Kathryn Chivers who is more 
like a sister to me, and my mum and dad who have always believed their strange little girl 
would grow up to be something special, well hope I made you proud.  
Abstract 
 
Genetic engineering has been utilised to produce a range of silk based biomaterials capable of 
promoting mineralisation to aid bone regeneration via biomimetic routes. Silk fusion proteins, 
where the silk domain is a derivative of the major ampullate dragline Spidroin 1 from Nephila 
Clavipes, consisting of a 15mer repeat of a 33-amino acid consensus sequence 
(SGRGGLGGQG AGAAAAAGGA GQGGYGGLGSQGT)15, were designed to bind to 
target minerals, silica and hydroxyapatite, through the incorporation of specific binding 
peptides.  
The R5 silicifying peptide (SSKKSGSYSGSKGSKRRIL) found in diatoms, was selected for 
silk-silica composites, the location of the R5, N vs C terminal on the silk repeating unit, was 
assessed with respect to silicifying capabilities. The VTK peptide (VTKHLNQISQSY), 
identified via phage display was selected for hydroxyapatite binding, samples compared had 
the VTK peptide attached to the N, C and both termini of the silk repeating unit. Location and 
number of binding peptides was evaluated for mineralising capabilities.  
Samples were primarily studied as films, it was shown that the naturally occurring beneficial 
physical properties of silk, high tensile strength and versatility, were not affected by the 
addition of binding peptides for both R5 and VTK containing samples. Further, we could 
manipulate the mechanical properties of the films by annealing them in the presence of 
methanol to increase the crystalline beta content, modifying their; hydrophobicity, stiffness and 
resistance to degradation.  
After mineralisation studies were completed, chimeric samples were implemented as coatings 
on both silk and titanium scaffolds. The R5 domain silicifying capabilities were proven to be 
effective at silicification on the silk scaffold, however comparison to the titanium scaffold 
showed a more than 10-fold reduction in silica presence, a likely cause being the inert nature 
of the titanium being exhibited. 
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Chapter I 
Introduction 
Provided here is a brief literature review intended to cover all background information 
for this investigation. Topics include discussion of silk as a biomaterial and its 
applicability towards forming composite biomaterials with silica and hydroxyapatite.   
1.1 Silk as a biomaterial 
Silk is a naturally occurring fibrous protein produced by epithelia cells in certain 
worms from the Lepidoptera order and spiders (Arachnida).1 All silks have 
impressive qualities such as high tensile and mechanical strength rivalling high 
performance steel and polymeric fibres,2-12 versatility towards use in different 
material states such as gels,13 scaffolds,14-18 films,19 membranes20 and powders21 and 
they are bioacceptable22,23 making them ideal candidates for biomedical application. 
Work completed here has focused on the spider silk, particularly the dragline silk 
from N. clavipes spiders. Spiders produce several diverse types of silk as shown in 
Figure 1.1, each having different properties tailored for specific applications.24 The 
variance in mechanical properties arises from the differing amino acid sequences 
present.  
 
Figure 1.1 The seven distinct types of silk spiders can produce. Each has different 
physical properties depending on its use, ranging from strength to support webbing 
and protect eggs, elasticity to produce web interiors or stickiness for anchoring points. 
Adapted from24 
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Similar to silkworm silk, the dragline silk of the N. clavipes is largely formed from 
glycine and alanine with arginine, glutamic acid and proline also present.25 Dragline 
silk consists of two large proteins (approx. 300 KDa), spidroin 1 and spidroin 2.24 
Repeating units of alanine and glycine form crystalline domains (secondary β 
structures) that give silk it’s impressively high tensile strength. Figure 1.2 shows the 
production of silk in the proximal region of the glands that line a spider’s lumen and 
the self-assembly process resulting in the formation of liquid crystals26 a prerequisite 
to form highly ordered fibrils. Regions containing GGX termed a glycine helix, where 
X is likely Leucine, Tyrosine or Glutamic acid, give rise to heightened elasticity.27 
In addition, the ability to manipulate the secondary structure of silk in vitro, to induce 
a higher percentage of β conformers, gives an added level of control most beneficial 
for biomedical application. The increased level of crystallinity results in increased 
resistance to degradation and mechanical strength. Many annealing processes have 
been employed to achieve greater levels of β secondary structure in silks such as: 
methanol vapour,28,29 water vapour,4 and high pressure/high termperatures.30,31  
Dragline silk is one of the strongest naturally occurring materials, with a Young’s 
modulus of 7.38 – 22 GPa,32 it is used for safety and web construction, Figure 1.1. 
Despite the superior physical properties of dragline spider silk, wider use, as seen for 
silkworm silk, has been restricted due to the impracticality of domesticating spiders 
coupled with low productivity.  
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Figure 1.2 A) The steps of silk self-assembly: the amino acid sequence is formed, 
beta sheet formation is induced via hydrogen bonding and hydrophobic interactions 
resulting in self-assembly, then inter- and intra- molecular interactions drive the 
formation of micelles where hydrophilic spacer groups result in small region of 
trapped water, finally an increase in concentration results in gelation to form liquid 
crystals. B) The liquid crystals are transformed via environmental factors (for 
example: low pH, methanol, and electric fields) into highly ordered fibrils (webbing) 
as they travel down the spinning ducts. C) Simplified diagram of the structure of silk 
emphasising the ordered crystalline structure embedded in a non-
crystalline/amorphous matrix.33 Adapted.34 
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Silk does have a disadvantage, in some construct forms it can be susceptible to 
compression, meaning added rigidity would improve the material with respect to 
medical application. The production of composite materials allows additional 
properties to be added and any negative aspects minimised. 
To create composites, current research looks to nature for inspiration, the inspiration 
can take the form of inorganic materials that have been utilised by living organisms 
and the methods of production and/or incorporation.35,36 For the proposed application 
in dental tissues, the relevant inorganic materials are the titania surface of the implant, 
hydroxyapatite (HAP) that bones are made from and the small amount of natural silica 
present in the body used in bone regrowth.37 To allow the silk material to bind and 
promote the precipitation of these different materials, peptides identified for having 
high affinities for specific minerals can be attached to the silk to widen the capabilities 
of the material.28,29,38,39 
1.2 Biomimetic approaches for mineralisation 
Biomineralisation is a broad term used to describe any process that results in the 
condensation of inorganic materials involving biological induction and/or control.40 
These biosynthetic routes can be specific or non-specific, it is the first that interests 
researchers, as there are many cases where mineralisation occurs in nature through 
the production of specific (both to the inorganic material and the organism) molecules 
that can control the shape and size of minerals produced, meaning these molecules 
can control the physical and chemical properties of the material being produced. By 
identifying these naturally occurring molecules, they can be synthesised (or a 
derivative can be synthesised) in ordered to be employed for controlled in vitro 
mineralisation, this is termed a biomimetic approach to mineralisation, the mimicking 
or inspiration of mineralisation from nature.41 
Biomolecules for mineralisation work in three different ways; confinement, 
activation and templating to direct the mechanism of mineralisation.42 Self-assembly 
approaches are now widely used for the production of minerals that are controlled on 
the nano- to macroscale resulting in “chemically-diverse, structurally-complex and 
bio-responsive materials and devices”.43-46 
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Hydroxyapatite (HAP) and silica binding peptides have been identified (as discussed 
below) for this purpose, to produce a biomedical material that can control 
biomineralisation to aid bone repair/regrowth. HAP mineralisation is often referred 
to as calcification, and the deposition of silica is known as silicification. 
1.3 Overview of Hydroxyapatite (HAP) and its role as bone mineral  
1.3.1 Structure of bone 
Every mammalian bone consists of osseous (supportive connecting) tissue, 
epithelium, adipose tissue and nervous tissue. Organic material, predominantly a 
three dimensional collagen framework (thought to provide nucleation sites for 
hydroxyapatite growth),47,48 makes up 20-25%, up to 5% is water and the remaining 
75% is inorganic materials, most of which is exclusively HAP.49 Bones are used for; 
support, protection, mineral homeostasis (99% of the bodies’ calcium is found in 
bone),50 blood cell production and triglyceride storage.51 
Bone is not at equilibrium, it is constantly undergoing ‘remodelling’ (the construction 
of new bone and the degradation of old bone tissue), in order to correct imperfections 
in the crystal structure, principally the presence of carbonate, sodium and other ions 
and the deficiency of calcium and hydroxide groups required for bone mineral to be 
metabolically active.49 Cells responsible for bone regrowth are; osteogenic cells 
which are bone stem cells that develop into osteoblasts known as bone building cells. 
Osteoblasts synthesise and secrete collagen fibres, as they become surrounded by an 
extracellular matrix they morph into ‘mature’ bone cells responsible for maintaining 
the daily metabolism of the bone, the latter are known as osteocytes. Lastly, 
osteoclasts release enzymes and acids to digest underlying cellular bone matrix for 
reabsorption. 
The formation of bone, ossification or osteogenesis, occurs under four conditions; as 
an embryo develops, bone growth, remodelling and when repair is needed from bone 
fractures, the forth being the focal point for this investigation. There are serval types 
of fractures that can occur, but for the most part the natural repairing process follows 
these steps52: 
1. Formation of a fracture hematoma, where a mass of blood builds up around 
the fracture site resulting in inflammation and causing the surrounding bone 
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cells to die, this can take up to 8 hours. Phagocytes and osteoclasts remove 
dead or damaged tissue over the course of several weeks. 
2. Fibroblasts produce collagen fibres and chrondroblasts produce fibrocartilage 
to bridge the ends of the broken bone together, this can take up to three weeks. 
3. Osteogenic cells around the healthy bone tissues develop into osteoblasts 
producing spongy bone. Fibrocartilage is converted into spongy bone. 
4. Bone remodelling occurs replacing spongy bone with compact bone, dead 
portions of the broken bone are gradually resorbed by osteoclasts.  
Despite bone having a generous blood supply, healing can take several months as the 
calcium and phosphorous necessary to strengthen and harden new bone are only 
gradually deposited. The levels of calcium and phosphorus surrounding healthy bone 
tissue is kept at a steady concentration governed by the cells on the bone surface.53 
Calcification mechanisms differ between bone and cartilage as bone contains calcium 
binding peptides. Factors that can progress calcification include: 
1. Increasing the Ca2+ and HPO42- concentration in the local environment to 
induce spontaneous mineralisation. 
2. Using substances known to act as nucleation sites. 
3. Removal of mineralising inhibitors  
Based on this, modern medicine now looks to incorporate methods of increasing 
calcium and phosphorous concentrations at breakage sites, work discussed here uses 
the biomimetic approach to accomplish this. 
1.3.2 Crystal structure of bone 
The inorganic calcium phosphate found in bone is hydroxyapatite (HAP), however 
the crystal structure present differs from that of ‘pure’ highly crystalline HAP. The 
general formula for HAP is Ca10(PO4)6(OH)2, ions and groups are arranged in a 
hexagonal system P63/m, with some minor exceptions (only in non-calcified tissue) 
as monoclinic systems.54-57 Cell lattice parameters; a=b=9.432 Å and c=6.884 Å with 
γ = 120°, Figure 1.3. An exact stoichiometric Ca:P ratio would be 1.67. 
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Figure 1.3 Unit cell of HAP. Phosphate ions are found in a tetrahedral arrangement, 
hydroxyl groups are located on the c axis. Ca ions are found in two different sites: 
columns of Ca2+ ion and equilateral triangles. Phosphorous atoms lie in two height 
planes: ¼ and ¾. Adapted.58,59 
Naturally occurring HAP is rarely stoichiometric and the crystals formed are known 
to be small in size forming plates or needles, lack chemical perfection and contain 
many defects. These attributes are surprisingly advantageous as it results in bone 
being insoluble and therefore stable whilst being reactive for resorption.60  
Defects can occur due to the varied chemical constituents of bone. Phosphate groups 
can undergo substitution by carbonates, hydroxyl groups can be replaced with 
fluoride, chloride or carbonate and calcium ions can be exchanged with magnesium 
ions. Other ions present include sodium and potassium.61 The concentrations of each 
vary between the type of tissue with respect to its bioactivity and desired properties. 
The closer the Ca/P atomic ratio is to 1.67 the more biologically stable the compound 
is.62 A decrease in the atomic ratio tends to mean the compound will be more 
bioactive. 
1.3.3 Chemical HAP Synthesis 
Chemical synthesis of HAP has been developed over many years using a variety of 
synthetic routes. Initial growth of hydroxyapatite crystals is rapid, occurring within 
minutes, crystals can then grow slowly over time, Figure 1.4A. In some situations, 
Ostwald ripening can occur where smaller crystals dissolved in solution then 
redeposited onto larger crystals, Figure 1.4B. However, the difficulty of the synthesis 
arises from the wide range of crystal phases that can be produced, Table 1.1 shows 
all biologically significant calcium phosphates, not including substituted variants. It 
is because of this that synthesis methods are intended to be as simple as possible, 
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often using just two reagents for sources of calcium and phosphate in a controlled 
environment. Additional ions present can result in a substituted HAP structure being 
produced or the mechanism of crystallisation being directed toward an alternate 
crystal phase. Table 1.2 shows a selection of chemical methods developed for in vitro 
synthesis of HAP, along with the reported atomic ratio of Ca:P.  
 
Figure 1.4 A) Basic overview of crystal growth where flocculation results in 
nucleation beginning crystal growth and forming a larger crystal structure B) Ostwald 
ripening; dissolution of smaller crystals occurs which are then able to form part of the 
larger crystal.  
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Abbreviation Formula Name (mineral) Ca/P ratio pKsp (250C) pH stability Occurrence in biological tissues 
HA Ca10(PO4)6(O
H)2 
Hydroxyapatite 1.67 116.8 9.5-12 Bone, dentin, enamel, dental 
calcifications, urinary stones, 
atherosclerotic plaques 
OCP Ca8H2(PO4)6∙
5H2O 
Octacalcium phosphate 1.33 96.6 5.5-7.0 Dental and urinary calculi 
β-TCP Ca3(PO4)2 β-Tricalcium phosphate 
(whitlokite) 
1.5 28.9  Dental and urinary calculi, soft-
tissue deposits, arthritic cartilage, 
usually present as β-TCMP 
α-TCP Ca3(PO4)2 α-Tricalcium phosphate 1.5 25.5  Not found 
ACP Ca3(PO4)y)∙n
H2O 
Amorphous calcium 
phosphate 
1.2-2.2   Soft-tissue calcifications 
MCPM Ca(H2PO4)2∙
H2O 
Monocalcium 
phosphate monohydrate 
0.5 1.14 0-2 Not found 
MCPA Ca(H2PO4)2 Anhydrous 
Monocalcium 
phosphate 
0.5 1.14  Not found 
DCPD CaHPO4∙2H2
O 
Dicalcium phosphate 
dehydrate (brushite) 
1.0 6.59 2-6 Dental calculi, urinary stones 
chrondrocalinosis 
DCPA CaHPO4 Anhydrous dicalcium 
phosphate 
1.0 6.90  Not found 
TICP Ca4(PO4)2 Tetracalcium phosphate 2.0 38-44  Not found 
CDHA Ca10-x(HPO4)x 
(PO4)6-
x(OH)2-x 
Calcium deficient 
hydroxyapatite 
1.5 85.1 6.5-9.5 Not found 
Table 1.1 Biologically significant phosphates: properties and natural presence.
Chapter I: Introduction 
10 
 
 
Table 1.2 Chemical routes previously used to produce HAP. 
 
Reagents Conditions Product Ca/P 
molar ratio 
Ref Comment/s Date 
0.33 M 
0.2 M 
Ca(NO3)2∙4H2O 
(NH4)2HPO4 
Constant pH 12 (ammonia CO2 free 
used) 
250C 
Vigorous stirring 2 hours 
1.67 63 Filtering may be aided by 
ten minutes of gentle 
boiling. Heating to 8000C 
to dry and harden 
1963 
0.25 M 
0.75 M 
(NH4)2HPO4 
CaCL2/Ca(NO3)2 
pH 10.5 (NH4OH used) 
250C 
Constant stirring < 2 weeks 
1.71 64 A closed system was used 
to avoid excessive CO2 
absorption 
1965 
1.3 x 10 -2 M CaCl2 
Na2HPO4 
pH 7.4 (0.1 M HCl used) 
seeded see below 
1.6 
(1.2) 
65 Two stage crystal growth 
initiated using a seed 
solution (see next entry) 
1970 
0.5 M 
0.3 M 
CaCl2 
Na2HPO4 
pH 8.5 – 10 (NaOH used) 
700C 
Constant stirring – seed solution 
produced 
 65 Exclusion of CO2 via 
nitrogen pass being 
bubbled through 
- 
Equimolar CaCl2 
NaH2PO4 
pH 7.4 (using NaOH/H3PO4) 
250C / 370C 
1 66 Not stirred 
Calcium chloride always 
added to sodium 
phosphate 
1971 
0.24 M 
0.4 M 
(NH4)2HPO4 
Ca(OH)2 
Microwave irradiated 20 minutes 
In air/under nitrogen 
1.65 67 Equivolumes used, 
microwaving controlled 
to avoid vigorous boiling 
1996 
0.28 M 
0.24 M 
Ca(NO3)2 
NH4H2PO4/(NH4)2HP
O4 
pH 7.4 (using NH4OH for reagent, 
1M Tris-TAM buffer post addition) 
4/380C 
1.45-1.76 68 Two different reagents 
used to maintain pH. 
Initial pH 4.5 increasing 
to a plateau at pH 7.5 
2009 
1 M 
0.6 M 
Ca(NO3)2∙4H2O 
(NH4)2HPO4 
> pH 10 (using NH4OH) 
≤10-minute reflux in microwave 
1.67 69 (NH4)2HPO4 was added 
dropwise (2ml/min) 
2012 
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1.3.4 Biological HAP Synthesis 
The biomimetic approach has been applied to further develop methods for HAP 
synthesis towards being more compatible for biomedical application. However, 
unlike other minerals such as silica (and the R5 peptide), there has been no naturally 
occurring peptide identified that binds and directs mineralisation towards 
precipitation of HAP. 
To address this two different approaches have been employed by several groups, the 
first is the use of single amino acids (both phosphorylated and non-phosphorylated) 
during mineralisation. Table 1.3 shows a selection of developed methods and their 
success measured in terms of atomic ratio of the mineral formed. Results varied 
according to the amino acid used and the molar ratio of the chemical reagents and the 
amino acid present. 
In each case, it can be argued that results were limited due to the small exclusive scale 
of experiments. The isolated results, focusing on one synthetic route and a handful of 
amino acids suggests that optimum conditions for reliable control of mineralisation 
using amino acids has yet to be found.  
The second approach was to employ the phage display technique to identify HAP 
peptide binders. Briefly, phage display uses bacteriophages (viruses that infect 
bacteria) to categorise the binding affinities of proteins and peptides to a specific 
target compound. The process involves the addition of the selected protein onto the 
phage coat gene by inserting an encoding gene into the phage, this causing the phage 
to ‘display’ the selected protein. The displaying phages are then screened by being 
exposed to the target compound. A series of washing, elution and amplification steps 
are then performed before analysis is completed to compare binders, Figure 1.5.70 
 
  
Chapter I: Introduction 
12 
 
Ca Source (mM) P Source (mM) AAs (mM) pH Temp °C Time hrs Year Ca:P ratio Ref. 
CaCl
2
  
(25) 
(NH
4
)
2
HPO
4
  
(15) 
PSer, Glu  
(20-200) 
9.5 37 72 2015 1.69 71 
CaCl
2
  
(3.1) 
NaH
2
PO
4
  
(1.9) 
Arg, Glu  
(10) 
7.4 37 48 2012, 
2015 
1.22-1.35 72 
CaCl
2
  
(0.5) 
KH
2
PO
4
  
(0.3) 
Asp, Glu  
(0.2) 
8.45 25 48-96 2011 1.61 73 
(CH
3
COO)
2
Ca  
(75) 
H
3
PO
4
  
(50) 
Ala, Asp, Arg  
(150) 
10 25 24 2009 1.5-1.62 74 
Ca(NO
3
)
2
·4H
2
O (ns) H
3
PO
4
 (ns) Gly, Ala, Ser, Lys, 
Asn  
(na) 
9 80 18 2007 1.72-1.88 75 
CaCl
2
  
(0.25-0.5) 
KH
2
PO
4
  
(0.17-0.33) 
Leu  
(0-1.52) 
7.4 37 ns 2007 1.67 76 
Ca(NO
3
)
2
  
(33.4-38) 
(NH)
4
HPO
4  
(20) 
Gly, Asp, Glu, Lys  
(4) 
7.5 37 24 2006 1.58-1.67 77 
Ca(NO
3
)
2
·4H
2
O  
(540) 
(NH
4
)
2
HPO
4
  
(320) 
Asp. Glu  
(50-200) 
ns 90 5 2006 1.68 78 
Table 1.3 Biological syntheses used for producing HAP using single amino acids. NS: not specified  
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Figure 1.5 Simplified steps of phage display to identify binding peptides and 
proteins. 
Three peptides: CaP(S) STLPIPHEFSRE,79-82 CaP(V) (or VTK) 
VTKHLNQISQSY,81,83-86 and CaP(H) SVSVGMKPSPRP,79,84,87,88 were all 
identified via phage display as HAP binding peptides. However, as shown in Table 
1.4, the three HAP binding peptides have varrying properties suggesting that 
mechanisms directing mineralisation also vary. CaP(H) and CaP(V) have an overall 
positive net charge with high isoelectric points (>pH 9.5) indicating peptides remain 
mostly unfolded at circumneutral pHs and direct mineralisation through electrostatic 
interactions with the negative phosphate ions.81,87 Conversely, CaP(S) has a negative 
net charge with an isoelectric point of pH 5.2, suggesting that some aggregation may 
occur under in vivo conditions, with mineralisation a result on interaction with 
positive calcium ions.80-82,89 
 Sequence Net charge at 
pH 7.4 
Average 
Hydrophobicity pI 
CaP(H) SVSVGMKPSPRP +2 +13.87 11.71 
CaP(S) STLPIPHEFSRE -1 +16.67 5.23 
CaP(V) VTKHLNQISQSY +1 +13.05 9.54 
Table 1.4 Properties of the HAP binding peptides Cap(S), CaP(H) and Cap(V). 
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Comparison of mineralisation capabilities for the three peptides is observed in 
Chapter V; however, HAP silk binding chimeras could only be produced using the 
CaP(V) sequences. Addition of CaP(S) and CaP(H) to a silk repeating unit did not 
produce samples that could be expressed efficiently, meaning silk-HAP chimeras 
discussed in Chapter IV were limited to only CaP(V) incorporated silk samples. 
The inclusion of all three peptides in the study was planned as seen in Chapter V, 
however due to expression issues, discussed in Chapter IV, it was not possible to 
include all three as silk composite materials. 
1.4 Silica 
1.4.1 Silica in Nature 
Many biomedical devices are made or incorporate silica because of its high 
bioactivity. However, silica’s osteoinductive nature,28 has proven to be not just 
beneficial but essential for bone growth. Animal studies completed in the 1970’s 
showed that a silicon deficient diet resulted in defects in the connective and skeletal 
tissues,90,91 with high levels of silicon found at bone regrowth sites.92 Despite silicon 
being one of the most abundant elements in the body, 1-2g,37 the mechanism of how 
it aids bone regrowth is somewhat unclear. Hench et al. showed that silicon 
substituted HAP and silicon containing implants had a better binding affinity for bone 
than their silicon free counter parts but it was Porter et al. that posed a mechanism for 
silicon aided bone regrowth, the use of silicon substituted HAP produced more 
ordered collagen fibrils with more mature bone formation than when HAP was used 
alone.93,94 It is thought that silicon may be involved in the synthesis and/or 
stabilisation of collagen, and as stated previously collagen is known to provide 
nucleation sites for in vivo HAP formation.49  
The wide and frequent occurrence of silica in nature is well documented.95 The 
morphologies that biogenic silica can take are impressive in their variability, with 
many difficult or even impossible to replicate in vitro. Commonly quoted examples 
include the Equisetum plant that contains silica phytoliths and diatoms (eukaryotic 
cells) that produce shells made of silica for structural support and protection.96,97 
Silicification in nature often involves the utilisation of specific proteins known as 
silaffins that are able to promote and/or control the deposition of silica particles. In 
diatoms, this occurs in a silaffin rich silica deposition vesicle.35 The R5 peptide 
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(SSKKSGSYSGSKGSKRRIL),98-101 has been identified from C. fusiformis diatoms 
as the silica promoting molecule, and has further been proven to be effective with in 
vitro studies.98,99,102  
The key to the R5 peptide’s silicifying power is its ability to direct self-assembly 
using a combination of electrostatic attractions and hydrogen bonding to form 
supramolecular structures with areas rich in amine groups, these structures provide 
nucleation sites for silica deposition, working as catalysts and templates for silica 
formation in vivo.100,103  
1.4.2 Chemistry and Synthesis of Silica 
Silica materials generally include: siloxanes (≡Si-O-Si≡), silanols (≡Si-OH), ionic 
siloxide (Si-O-) and water, figure 1.6. The proportionality of silanol to siloxane 
dictates the physical properties of the material, as silanols are hydrophilic and 
siloxanes are hydrophobic. 
 
Figure 1.6 Silanol chemistry of a silica particle showing; isolated, vicinal (hydrated 
and bridged), germinal, silanol and siloxane groups.  
Silica is produced through the condensation of orthosilicic acid, it can occur 
spontaneously in vivo when there is an excess concentration present (100-200ppm). 
The process is ionic as the rate of condensation is proportional to the concentration 
of OH- ions above pH 2 and H+ ions below pH 2.104 
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The condensation and aggregation process that results in the formation of silicas has 
three general steps. 1) The polymerisation of monomers producing stable nuclei 2) 
growth of nuclei to form spherical particles and 3) the aggregation of particles to form 
branched chains or motifs,104-108 Figure 1.7. Further growth can occur through 
Ostwald ripening as discussed earlier, Figure 1.4B. This mechanism minimises 
uncondensed SiOH and maximises the amount of Si-O-Si bonds by favouring the 
formation of cyclic structures. The addition of salts and control of pH can both be 
used to control aggregation of silica particles during condensation.104 
 
 
Figure 1.7 Initial stage of silica production, starting from single monomers coming 
together to form larger cyclic structures. 
Silica nanoparticles have several beneficial properties making them appropriate for 
biomedical application, such as being: biocompatible, bioresorbable, permeable 
through biological pathways, having large surface areas and being easily 
functionalised. The hydroxyl groups present on the silica surface are the key to 
functionalising these materials, with studies into; carboxyl,109 phenyl110, amine,111 
thiol112 and methyl113 functionalised silica being completed. Silica has also been 
proven to have immunosuppressant,114 hypocholesterolemic,115 anti-apoptotic116 and 
anti-histamine117 functions. 
1.4.3 Bioinspired Silica Studies  
Single amino acids, homo-polypeptides and peptides have all been used to develop in 
vitro methods of silicification with high control over the morphology of the silica 
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particles produced. Table 1.5 below gives an overview of biosynthetic routes that 
have been employed to control silicification and the main finding from each study.  
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Biological influence Sequence Result Ref 
R5 SSKKSGSYSGSKGSKRRI
L 
Silaffin identified 98 
R5 RRIL Essential for silicification, 
directing group for self-
assembly 
100 
Diatom derivative KASK Nanometer scale silica 
particles 
118 
KAEK Grainy silica 
KAAK ~100nm Silica particles 
Amino Acids and 
homo-polypeptides 
S, K, P, D Catalytic effect: Peptides > 
amino acids 
119 
Polylysine Kn 
n = 20 - 222 
Longer chains gave 
hexagonal plates 
Smaller chains gave spherical 
particles 
120 
Range of peptides 
(Isolated by Phage 
Display) 
YITPYAHLRGGN 
KSLSRHDHIHHH 
LDHSLHS 
MHRSDLMSAAVR 
MSPHPHPRHHHT 
RGRRRRLSCRLL 
Positively charged peptides 
strongly attracted to anionic 
silica 
Polar groups can attach via 
silanol or siloxide groups 
through hydrogen bonding, 
ion-dipole, dipole-dipole or 
Van Der Waal interactions 
121 
Range of peptides 
(Isolated by Phage 
Display) 
KLPGWSG 
AFILPTG 
LDHSLHS 
Peptide binding can be 
controlled with subtle 
changes on the silica surface 
97 
Polylysine 
Polyarginine 
Kn (n = 25, 35, 155, 1005) 
Rn (n = 65) 
Positive groups create 
concentrated areas of 
negative silicic acids 
promoting silica condensation 
122 
Polylysine Kn 
n = 56, 264, 300, 400 
Homo-peptide forms helical 
structures that induce silica 
plate formation 
123 
Amino Acids and 
homo-polypeptides 
G, R, N, Q, S, Y, T, P, A, K 
Kn 
n = 1-5 
Gn = 1, 4, 5 
Amino acids could affect 
kinetics. N containing gave 
larger particles, 
hydroxyl/hydrophobic 
containing gave smaller 
particles. No. G present had 
no effect, increasing K 
presence can control porosity 
of silica 
124 
Table 1.5 Bioinspired silicification routes developed using amino acids and/or 
peptides and the influence the biological reagent on silica deposition.  
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The amorphous structures often produced by silica are brittle and lack beneficial 
tensile properties, making their use as the sole material for bone and dental implants 
impossible. By combining low levels of silica (either in vitro or in vivo) with silk to 
produce composite materials, a union of the best attributes of both is created. 
Materials produced by the Perry/Kaplan collaboration previously saw silicifying 
domains attached to a silk repeating units of varying lengths.29,39,125,126 Table 1.6 
below shows the silk and silicifying domains previously used to produce chimeric 
silk biomaterials. 
Silk Domain Sequence Silicifying 
Domain 
Sequence Year Ref 
derived from 
N. clavipes 
dragline silk 
(SGRGGLGGQGA
GAAAAAGGAGQ
GGYGGLGSQGT)6 
A3 MSPHPHPRHH
HT 
2015 126 
A1 SGSKGSKRRI
L 
R5 SSKKSGSYSG
SKGSKRRIL 
N. clavipes 
dragline silk 
(SGRGGLGGQGA
GAAAAAGGAGQ
GGYGGLGSQG)15 
A3 MSPHPHPRHH
HT 
2012 29 
A1 SGSKGSKRRI
L 
R5 SSKKSGSYSG
SKGSKRRIL 
N. clavipes 
spider 
dragline silk 
[SGRGGLGGQGA
GAAAAAGGAGQ
GGYGGLGSQG]n 
n = 6 or 15 
Pep 1 KSLSRHDHIH
HH 
2012 125 
R-Pep1 RKSLSRHDHI
HHH 
R5 SSKKSGSYSG
SKGSKRRIL 
B. mori 
silkworm 
cocoons 
- Silica 
particles 
- 2010 28 
N. clavipes 
spider 
dragline silk 
(SGRGGLGGQGA
GAAAAGGAGQG
GYGGLGSQGT)n 
n = 6 or 15 
R5 SSKKSGSYSG
SKGSKRRIL 
2006 39 
Table 1.6 Previous silaffins and silk repeating units used by the Perry/Kaplan 
collaboration to produce silk-silica composites.  
1.5 Dental Implants 
Dental implants are a semi-permanent realistic-looking solution to missing teeth; by 
filling gaps with supportive materials there is a reduction in strain and an added 
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protection for the surrounding teeth and jaw bone.127 Dental implants are unique in 
the sense they can be employed regardless of the cause of the missing tooth/teeth.128 
An implant gives a more natural feel in the mouth when compared with dentures that 
can often impair a person’s ability to speak and eat. 
The disadvantage of using dental implants is that a surgical procedure is required to 
insert the device, which is abrasive to the surrounding tissue and several follow up 
appointments are required to finish the work leading to more discomfort in the area. 
The process leaves a patient vulnerable to infection and requires a significant amount 
of healing time which can vary depending on the patient. 
Dental implants tend to be made of titanium or a titanium alloy,129-133 due to their low 
density, high strength, non-hazardous nature and high resistance to corrosion.134 
However the insertion process of a pure titanium/titanium alloy often results in an 
inflammatory response from surrounding tissues.135 
The healing process must result in the acceptance of the implant with a strong 
complete bone-titanium interface produced. This process can take 6-12 months and 
is not always successful; a hindrance to this process is the inert properties of titanium 
alloys preventing bone from easily binding to the surface. This can be overcome by 
treating the implant with a coating before insertion.134-144  
Previous work in the Perry group on silk composite materials for bone and dental 
implant coatings, has focused on the incorporation of silica via the use of known 
silicifying peptides attached to the silk, (at the C termini only), that promote 
condensation of silica particles onto silk materials. In vitro studies were conducted to 
assess if combining these two materials will have a significant effect on the physical 
and chemical properties of the silk which would allow it to be produced into feasible 
medical devices.29  
The genetically engineered chimeric silk samples used prior to the current study 
always consisted of: a His6 tag (for purification), a silica binding peptide such as R5, 
A1 or A3, see table 1.7) and a long linker connecting the His tag to the silk. 39 In the 
previous work the peptides were all coupled to the silk at the C-terminus, the 
genetically engineered structures containing additional charge at the N terminus 
(His6), a charged linker between the mineralizing peptide of interest and the silk 
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which makes it very difficult to understand which component binds to the mineral 
phase and which of the many components affects the structure/ mechanical/ 
biodegradation properties of the silk.   
Peptide Sequence Specific target 
mineral 
Reference 
R5* SSKKSGSYSGSKGSKRRIL Silica 29 
VTK VTKHLNQISQSY Hydroxyapatite 145 
A1* SGSKGSKRRIL Silica 29 
A3* MSPHPHPRHHT Silica 29 
Ti-1*Ŧ QPYLFATDSLIK Titanium 146 
Ti-2*Ŧ GHTHYHAVRTQT Titanium 146 
Ag-4* NPSSLFRYLPSD Silver 38 
Ag-P35* WSWRSPTPHVVT Silver 38 
Linker SSGLVPRGSGMKETAAAK
FERQHMDSPDLGTDDDDK
AMA 
N/A - 
His tag HHHHHH N/A - 
Table 1.7 Peptides used in previous silk-silica composite studies by the Perry group. 
*denotes peptides previously used by Perry group in this study Ŧ peptides intended to 
be used in the future. 
  
Chapter I: Introduction 
22 
 
1.6 Motivation and Objectives 
The focus of the investigation was to develop a series of biomaterials suitable for 
coating bone and dental implants building on previous work completed by the Perry 
and Kaplan groups. The materials are designed to aid bone regrowth and implant 
binding through the induction of HAP formation and heightened silicification at the 
implant site, resulting in reduced healing time and limiting the chance of implant 
rejection. 
The inspiration for this work has come from nature, utilising the natural polymer silk 
coupled with specific binding peptides for silica and HAP. 
Objectives 
 Completion of chemical and physical analysis of genetically modified silk 
fusion proteins, evaluating their feasibility as a biomaterial. 
 Mineralisation of chimeras, comparing each on the ability to induce and 
control the deposition of inorganic materials. 
 Development of new methods to analyse silk chimeras. 
 Biodegradability studies to estimate the in vivo life time of silk chimeras pre- 
and post-mineralisation. 
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Chapter II 
Experimental Methods 
This chapter will briefly discuss the theory and parameters of techniques employed 
for analysis of samples. A basic understanding of each technique has been assumed. 
2.1 Atomic Force Microscopy 
Atomic force microscopy (AFM) is one of several scanning probe microscopy (SPM) 
techniques.1 In all SPM methods, a sharp probe is scanned across the sample surface 
producing a nanoscale image from the measured tip-surface interactions. In AFM, 
probes (here the term probe is used to mean a mounted cantilever with tip), are 
brought into close proximity of the sample to analyse the physical forces, both 
attractive and repulsive, between the probe and the sample surface in order to produce 
a topographical 3D image and acquire mechanical information about the surface by 
maintaining a small continual force. A piezoelectric tube scanner controls the motion 
of the tip in a raster pattern, interactions are observed in the reflections of a laser off 
the back of the cantilever by a split photodiode detector. Oscillation amplitude and 
cantilever deflection are determined by the change in photodetector output voltage, 
figure 2.1.2 
Out of the three standard modes for AFM only two are frequently used, contact mode 
and tapping mode.3 The third, non-contact mode, is designed specifically for 
measuring long range interactions, such as Van der Waals and electrostatic forces.4 
In contact mode, the tip is brought into contact with the surface and whilst raster 
scanning a constant set point is maintained. Any movement of the z piezo (caused by 
maintaining the cantilever deflection) is then a result of sample topography that is 
plotted as an image. The disadvantage of this method is the risk of high lateral forces 
being exerted on the sample resulting in damage to the sample. Tapping mode reduces 
this risk by oscillating the cantilever during imaging.5  
During a tapping mode scan the cantilever is oscillated at its resonance frequency 
achieving light periodic contact with the surface. In this case, the laser deflection 
allows the root mean square amplitude of the cantilever’s oscillation to be found. To 
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keep a constant oscillation amplitude set point the scanner moves vertically providing 
topographical information about the surface, Figure 2.1. 
PeakForce QNM (Quantitative NanoMechanics) can give high resolution (≈5nm) 
compositional mapping of composite materials and be used for quantitative 
measurement of nanoscale materials for: modulus, adhesion, deformation and 
dissipation. PeakForce Tapping mode also avoids lateral forces by only having 
intermittent surface contact but differs from standard tapping mode as it functions at 
non-resonant frequencies. Oscillations occur far below the resonance of the cantilever 
eliminating the dynamics of the resonating system thereby allowing for force control 
and continuing avoidance of lateral forces. Information about the force involved is 
outputted as a force volume curve where z position data has been modulated by a sine 
wave not a triangular one, thus preventing resonances at the turnaround points. 
Individual peak force points act as triggering mechanisms that force the z piezo to 
retract. 
There are many advantages of using AFM over typical electron microscopy 
techniques such as being able to scan in air or liquid as opposed to under vacuum as 
well as unparalleled versatility stemming from it being possible to chemically 
functionalise probes for quantitative measurement of specific interactions.6 
 
Figure 2.1 A) General set up of an AFM showing deflection of the laser from the top 
surface of the tip. B) The three modes for AFM, contact mode (tip-surface contact is 
maintained), non-contact mode (measures long range interactions) and tapping mode 
(also known as semi-contact mode, intermittent tip-surface contact). 
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2.1.1 Finding the reduced elastic (Young’s) Modulus of silk films 
Peak force tapping mode produces a force curve at every pixel in the image. The force 
vs time plot, also known as the heartbeat, shows the measured force exerted on the 
probe as it makes contact and retracts from the sample surface. By using the z position 
data, a force curve can be created from the heartbeat. This in turn can be converted to 
a force separation curve where the proportionality of force vs deformation is given 
by the reduced elastic modulus, providing the correct calibration steps have been 
performed, figure 2.2. 
 
Figure 2.2 A) Initial force vs time plot or “heartbeat” produced in PeakForce tapping 
mode B) Incorporation of z data into the heartbeat for data to be output as a function 
of z position C) Final data output form as a force vs tip-sample separation graph 
where the proportionality of the linear region is linked by the samples reduced elastic 
modulus. Adapted from7 
Calibration Step 1: Finding deflection sensitivity, S  
Force-displacement curves measured using the cantilever contain information about 
the applied force, F, and the sample deformation, (d-d0), which can be extracted using 
the measured cantilever deflection, D. 
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To separate the two parameters the deflection sensitivity, S, (response of the 
cantilever on an infinitely stiff surface – sapphire) is determined.  
Once the deflection sensitivity is known, the applied force F and the tip position d 
can be calculated as follows:  
𝐹 = 𝑘𝑆𝐷   1 
𝑑 = 𝑧 − 𝑆𝐷   2 
Where D denotes the cantilever deflection (measured in Volts), z is the vertical 
scanner position and k is the cantilever spring constant, which can be obtained in the 
second calibration step known as Thermal Tune. 
Calibration Step 2: Thermal Tune to find the cantilever spring constant, k 
Self-excitation under ambient conditions, with no sample contact, measures the 
cantilever’s mechanical response to thermal noise allowing a Power vs. Frequency 
plot to be obtained. This is done by measuring the fluctuations of the cantilever over 
time and extracting the frequency spectrum of the cantilever’s mechanical response 
proportional to the power. The data is fitted using the Lorentzian equation and an 
estimation of the cantilever’s spring constant found. 
Calibration Step 3: Finding the Tip Radius 
A tip characterisation sample, e.g. a titania roughness sample, is scanned and the 
image processed using the tip quantification function. An estimate of the size and 
shape of the tip is found by assuming that the extreme physical surface properties of 
the sample exceed that of the tip to such an extent that any feedback from the scan is 
solely from the cantilever, and therefore an image of the tip is produced instead of the 
sample. 
DMT Modulus 
To obtain the reduced elastic modulus from the Force vs. Separation curve, the retract 
curve is fitted using the DMT (Derjaguin, Muller, Toropov) model.8 The DMT model 
looks at the theory of adhesion contact and describes the forces during tip-surface 
separation by: 
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𝐹𝑖𝑛𝑡𝑒𝑟𝑎𝑐𝑡𝑖𝑜𝑛 =
4
3
𝐸∗√𝑅(𝑑 − 𝑑0)3 + 𝐹𝑎𝑑ℎ𝑒𝑠𝑖𝑜𝑛   3 
Where Finteraction is the tip-sample force (also expressed as Ftip, force on the tip), E* is 
the reduced elastic modulus of the tip and the sample, R is the tip end radius, d0 is the 
surface rest position, (d-d0) is the sample deformation which can also be expressed as 
d for tip-sample separation and Fadhesion is the adhesion force.
8,9 
Poisson’s Ratio: Converting reduced elastic modulus to the elastic modulus 
The Young’s modulus of a sample, Es, can be converted from the measured reduced 
modulus, E*, using: 
𝐸∗ = [
1−𝑣𝑠
2
𝐸𝑆
+
1−𝑣𝑡𝑖𝑝
2
𝐸𝑡𝑖𝑝
]−1   4 
Where νs and νtip are the Poisson’s ratio of the sample and tip respectively. Es and Etip 
are the Young’s modulus of the sample and tip respectively. It is assumed that Etip is 
much larger than Es to the extent it is approximated as infinite so the sample modulus 
is calculated using the sample’s Poisson’s ratio. 
Poisson’s Ratio applies when a material is being elastically stretched, linking the 
proportional decrease in a lateral measurement to the proportional increase in the 
length of the sample, in other words the ratio of transverse strain to axial strain.  
As a general rule, the Poisson’s Ratio of a sample can be assumed using data in table 
2.1. As a result, the change from reduced elastic modulus to elastic modulus will be 
within a 4 - 25% difference. The disadvantage of using Poisson’s ratio is an 
assumption must be made about the samples, where interpretation can produce 
varying values of Es, it is for this reason that the reduced modulus of samples is often 
quoted instead of the Young’s modulus.10 
E
s
 ν
s
 
E
s
 < 100mPa 0.5 
0.1 < E
s
 < 1 GPa 0.4 
1 GPa < E
s 
< 10 GPa 0.3 
Table 2.1 Accepted Poisson’s values for materials10 
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Here a Bruker Dimension Icon with ScanAsyst was used to perform all imaging and 
quantum mapping. Data was collected in the Nanoscope software and processed in 
Nanoscope Analysis software. 
2.2 Scanning Electron Microscopy coupled with Energy Dispersive X-ray 
Analysis 
Surface imaging on the nano to micro scale of samples was completed using scanning 
electron microscopy (SEM) where high resolution images can be obtained up to x107 
magnification. Samples are illuminated using a beam of electrons produced by an 
electron gun via electrical heating of a tungsten filament resulting in thermionic 
emission. To allow electrons to escape the positively charged filament and produce a 
beam, a negative voltage is applied between the filament and an earthed anode disc, 
figure 2.4. The velocity of the electrons is then dependent upon the accelerating 
velocity.11  
The filament is encased in a Wehnelt cylinder which manipulates the beam to have a 
diameter between 10-50 μm using electrostatic forces. A disadvantage of SEM is that 
to avoid scattering from gas molecules scanning must be under vacuum. Positioning 
of the beam is controlled using a series of electrical lenses and scanning coils, firstly 
two condenser lenses are used to reduce the beam width to approx. 5nm, then two 
pairs of scanning coils, positioned perpendicular to the beam and one another, direct 
the beam using specific current waveforms. An objective lens then ensures the beam 
has the smallest diameter when striking the surface. 
The electron beam hits the sample and 
interacts with atoms on the surface 
producing secondary electrons with lower 
kinetic energy than those in the incident 
beam. Emitted secondary electrons from 
the surface are then collected by the 
detector and an image generated. This 
image reflects the sample’s surface 
topography as secondary electrons can 
only be detected from the top 10nm of the 
surface due to their lower energy, figure 
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2.3. A portion of the electrons hitting the surface are reflected off the sample surface, 
known as back scattered electrons, these maintain high kinetic energy with an 
intensity that corresponds to specific elements, reflected electrons also emit x-rays 
dependant on the quantity of specific elements present in the sample.  
 
Figure 2.4 layout of a scanning electron microscope coupled to an EDX system, 
adapted.12 
Here a JEOL JSM-A840A scanning electron microscope, equipped with both 
secondary electron and back scattered electron detectors, was used with a 20 kV 
accelerating voltage at varying scan rates and scan sizes. Image and data processing 
was performed in the INCA software (Oxford Instruments). Whilst particle size 
measurements were taken using the ImageJ software. 
2.3 Powder X-Ray Diffraction 
All crystalline compounds have a highly ordered lattice structure comprised of atoms, 
ions or molecules sitting in crystal planes. Powder x-ray diffraction (XRD) can 
identify crystal phases by monitoring the deflection of an incident beam, as the 
uniform scattering of the incoming beam creates a unique diffraction pattern. 
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As seen in figure 2.5, when the incident x-ray beam reaches the sample surface a 
percentage is deflected by the initial crystal plane whilst the remainder penetrates 
further into the sample. At each new evenly spaced crystal plane more of the beam is 
deflected resulting in constructive interference as stated in Bragg’s Law:  
𝑛𝜆 = 2𝑑𝑠𝑖𝑛𝜃   5 
Where the incoming beam has a wavelength λ and an angle of θ (Bragg’s angle) with 
respect to the surface of the sample. The crystal lattice plane separation known as the 
interplanar distance, d, links the distance travelled by scattered x-rays as 2dsinθ. 
Diffracted beam intensity is plotted against 2θ to produce the XRD pattern, where 
each peak is a reflection from a set of crystal planes in the sample.13-15 
 
Figure 2.5 Schematic of XRD technique for identifying crystal phases.  
2.3.1 The Scherrer Equation and crystallite size 
There is a reciprocal relationship between the crystallite size, D, and the broadening 
of peaks in its diffraction pattern, β. This can also be explained as a cumulative effect 
as the larger the crystallites are, the more reflections from atoms, ions or molecules 
occur which results in a greater averaging effect and therefore a sharper peak is 
produced. 
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Figure 2.6 Schematics of A) cumulative effect of crystallite size on peak broadening 
B) SEM crystal measurements vs XRD crystallite measurements. 
The Scherrer equation, equation 6, given below links peak broadening and crystallite 
size,16 where K is the shape factor widely accepted to be 0.9 for spherical crystals. D 
is the crystallite domain size, λ is the wavelength, θ is the Bragg diffraction angle and 
β is the line broadening at half the maximum intensity.  
𝐷 =  
𝐾𝜆
𝛽𝑐𝑜𝑠𝜃
   6 
The Scherrer equation provides only a lower bound on crystal domain size due to a 
number of additional factors that can contribute to the width of a diffraction peak 
besides the instrumental effects and crystallite size. The most common influences 
over peak broadening are crystal lattice defects where there is lower uniformity in the 
overall structure and inhomogeneous strain, figure 2.7, which results in different 
crystallites experiencing different amounts of strain, which gives varied shifts of 2θ 
thus broadening the XRD peaks. Inhomogeneous strain can be caused by: Interstitials, 
vacancies, dislocations and layer faults.17-19 
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Figure 2.7 examples on sample strain and its effect on the peak positon in the XRD 
pattern 
PANalytical X’Pert PRO x-ray diffractometer (CuKα radiation with wavelength 
1.54060 Å) was utilised for identifying crystal phases of solid samples. Aluminium 
sample holders were used to hold powdered samples, multiple sample scans were 
taken where possible and between each scan the samples were remixed to ensure a 
homogenous sample was scanned that represented the bulk. Scans were performed on 
the spinner stage within a range of 5-90° for 2θ, at a 45 kV accelerating voltage, 40 
mA filament current, 0.08 °s-1 scan speed at room temperature. Data analysis was 
completed using X’pret-HighScore Plus (Version 4.6.1) software, where background 
data was subtracted and peaks were identified. Polydimethylsiloxane (PDMS) stubs 
were used as spacers where limited samples quantities were produced allowing for 
smaller sample sizes to be analysed. 
2.4 Fourier Transform Attenuated Total Reflectance Infrared Spectroscopy 
When infrared (IR) radiation is absorbed by samples it results in vibrational and/or 
rotational movement, meaning there can be fluctuations in bond length and bond 
angle. Samples will only absorb specific wavelengths depending on their structure. It 
is therefore possible to distinguish between compounds from the frequency of the 
radiation they absorb as it is equivalent to the vibrational frequencies of the molecules 
present.20,21 
During attenuated total reflectance infrared spectroscopy (ATR-IR) a beam of 
infrared light is passed through an ATR crystal with a relatively high refractive index 
compared to the sample, Figure 2.8, the beam is reflected multiple times off the 
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internal surface creating an evanescent wave that continues into the sample, 
penetrating up to 2 μm, reflected radiation is then collected by the detector.22 
 
Figure 2.8 The general structure of an ATR crystal 
Analysis of infrared data obtained in the study can be separated into two parts, a 
general verification of functional groups present, phosphates for HAP samples,23 and 
in depth peak deconvolution of amide bands to quantify protein conformation 
structure, Figure 2.9. Despite there being up to nine amide peaks present when 
proteins are scanned, only the amide I and amide II are widely used to assess protein 
structure as the others are a result of overtones and resonances of multiple 
functions.24-26 The amide I band, 1600 – 1700 cm-1, has the greatest intensity and is 
predominantly formed from the C=O stretching, (a smaller portion being C-N 
stretching), it’s exact position is dependent on the backbone conformation of the 
sample and hydrogen bonding present.27-30 The amide II band, 1510 - 1580 cm-1, 
appears largely due to N-H bending vibrations from the C-N stretching vibration 
making it conformationally dependent. The amide II is also partially comprised from 
C-N and C-C stretching vibrations giving it a higher complexity compared with amide 
I.26,31-34 
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Figure 2.9 A) The amide I bond B) The vibrations responsible for the Amide I and 
Amide II bands C) IR spectrum: in green general IR bands, blue shows the amide I 
and amide II bands used to obtain information about protein conformation and red 
shows phosphate bonds linking to hydroxyapatite.  
Peak deconvolution assumes that a broad IR band is an accumulation of several 
smaller bands, in this case the amide I band is a compilation of smaller bands 
produced by specific elements of a protein’s secondary structure. As smaller bands 
overlap within the amide I envelope a curve fitting process is applied to separate, 
analyse and identify protein structure. Method development of this curve fitting 
process is discussed further in Chapter 6. 
Here a FTIR-ATR (Frontier, PerkinElmer, Coventry, UK) was employed with a 
minimum average of 32 scans performed with in the wavenumber range of 4000-650 
cm-1. Grams peak fitting software was utilised for peak deconvolution. 
2.5 Dynamic Light Scattering and Zeta Potential 
Size distribution profiles of suspended particles in solution can be found using 
Dynamic Light Scattering (DLS). Fluctuation from Brownian motion is analysed by 
passing monochromatic light from a laser through a polariser and then the sample, 
scattered light then travels through a second polariser to reach a photomultiplier. 
Diffracted light from each molecule in solution is analysed over time for constructive 
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and destructive interference patterns by an autocorrelator and the polarisers are 
adjusted accordingly if necessary. The data collected for fluctuating intensities can 
now be used to calculate the particle size distribution using a size distribution 
processor (SDP), which can be output as a function of volume and number 
distributions, figure 2.10.35 The limitations of this technique are sample specific, DLS 
is a relatively low resolution technique so slight changes in particle sizes may not be 
detected. Sample concentration is key; below the minimum concentration not enough 
data is acquired and above the maximum multiple scatterings can occur giving false 
data. Selection of dispersion medium must be considered carefully to avoid 
sedimentation or solvent scattering.36 
The relationship between Brownian motion of particles in solution and their size is 
described in the Stokes-Einstein equation given below: 
𝐷 =  
𝐾𝐵𝑇
6𝜋𝜂𝑟
   7 
The diffusion constant D is given as a factor relating the; dynamic viscosity η, particle 
radius (spherical) r, the Boltzmann constant KB, absolute temperature T, and constant 
π (3.1415). 
 
Figure 2.10 Schematic of the light scattering experiment. 
Data outputted by the DLS is a standard intensity distribution, this can be converted 
to a volume distribution and a number distribution. Figure 2.10 shows example data 
for a sample with two particle sizes (x and 10x) with the same population displayed 
in the three distributions. The number distribution confirms the populations are the 
same by producing a 1:1 ratio, the volume distribution gives a 1:1000 ratio as the data 
is displayed as a function of the area of a sphere, V= (4/3)πr3. Conversion to intensity 
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includes the increased scattering from larger particles resulting in an even greater 
ratio between the two size distributions. 
Surface charge or electrokinetic potential of particles in solution can be found be 
taking zeta potential measurements. Zeta potential is a known indicator for particle 
stability, it is generally accepted that particles with a zeta potential magnitude of ±30 
mV will be stable due to high electrostatic repulsion from like charged particles 
reducing the likelihood of aggregation. Small zeta potentials, -5 < x < 5 mV, indicate 
an unstable solution where flocculation can occur as attractive intramolecular forces 
outweigh repulsive forces.37 
The technique of zeta potential relies on the theory of an electric double layer being 
produced around each suspended particle in solution. Particles with a net surface 
charge will attract a high concentration of opposing ‘counter’ ions forming the inner 
Stern layer, and a less populated outer layer, the diffusion layer, together these make 
the electric double layer, the boundary of which is called the slipping plane. The 
electric potential at the slipping plane is the zeta potential of the particle, it is at this 
point ions are separated into those within the electric double layer/slipping plane that 
will migrate with the particle in solution and those outside the slipping plane where 
attractive forces have no significant effect over ion, figure 2.11s. Zeta potential can 
therefore by thought of as the potential difference between the stationary layer around 
the particle and the surrounding dispersion medium. 
 
Figure 2.11 Schematic of the electric double layer 
The pH of the solution at which zeta potential measurements are taken has a 
significant impact on the zeta potential and allows for the isoelectric point (pI) of 
particles to be found, as at a particle’s pI the zeta potential will be zero. 
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Similarly, to DLS the disadvantages of using zeta potential measurements stem from 
the sample. Samples with high conductivity lead to polarisation and degradation of 
the electrodes, generally samples below 20 nm diameter cannot be accurately 
measured due to high mobility. There is a working concentration range that is unique 
to each sample, too high and multiple light scatterings can occur, too low and there 
won't be enough signal for an accurate measurement. 
For DLS and zeta potential measurements a Zeta Sizer Nano Series (Malvern, UK) 
was employed. Measurements for both were taken together over a range of pHs, 
proteins were dissolved in deionised water and the pH adjusted accordingly with 1M 
citric acid and 1M bis tris buffer.  
2.6 Wettability and Surface Energy Measurements 
As part of a complete physical property study for biomedical materials an estimate of 
their hydrophobicity is required to allow in vivo interactions to be predicted. The 
desired wettability of samples is dependent on the intended application, here silk films 
are measured to ensure there is a significant level of hydrophobicity to withstand in 
vivo conditions whilst permitting specific interactions to take place.  
Measurements were completed using a Theta Attension Instrument with 
OneAttention v 1.7 software (Biolin Scientific, Staffordshire, UK). The process 
records a water droplet being pipetted onto the silk film surface, and once stabilised 
measurements of the contact angle are taken at both the sides of the droplet twenty 
times and an average taken. These measurements give a direct comparison between 
samples and an indication of the wettability as it is widely accepted that contact angles 
over 900 are hydrophobic and those under are hydrophilic, figure 2.12.  
 
FIGURE 2.12 Diagram of wetting of a water droplet on hydrophobic to hydrophilic 
surfaces. 
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Wettability measurements can be extended to find the surface energy of silk surfaces 
by incorporating the Young’s equation, equation 8. The Young’s equation expresses 
the relationship between the surface free energy of a solid γs, the contact angle θ 
produced with a liquid of surface tension γL and the interfacial tension between the 
liquid and the surface γSL.  
𝛾𝑆 =  𝛾𝑆𝐿 +  𝛾𝐿𝑐𝑜𝑠𝜃   8 
Data for this is collected by repeating the 
experiment described above with liquids of 
varying surface tension, the cosine of the 
contact angle is the plotted against surface 
tension in a Zisman Plot, figure 2.13. By 
extrapolating this graph to cosθ = 1 (0° contact 
angle), the surface energy can found.38 
It is noteworthy that samples measured in the study had a contact angle in excess of 
20°, to avoid measurements being taken below the minimum accuracy level, care was 
taken to ensure there was a minimum variance in droplet size and to overcome the 
disadvantage of only a 2D plane being considered multiple droplet readings were 
performed.39 
2.7 The Molybdenum Blue Assay: Quantifying Silica Presence 
The molybdenum blue assay monitors the formation of polyoxometalates containing 
Mo(V), Mo(VI) and (in this case) silicon using absorbance shifts to find the 
concentration of silicon in solution.40,41 Here it is used to quantify and compare the 
silica uptake of chimeric silk films that include a silicifying domain, the R5 peptide. 
Formation of these molybdenum-silicon complexes requires a series of steps. First 
the monosilicic acid present in solution becomes saturated by binding to two water 
molecules.42  
Figure 2.13 Example of a Zisman 
Plot 
Si(OH)4 + 2H2O → H8SiO6  
           H8SiO6 + 12MoO4
2- + 24H+ → H8[Si(Mo2O7)6] + 12H2O 
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The saturated silicic acid then reacts with molybdate ions from molybdic acid forming 
the yellow silicon-molybdate complex, figure 2.14, with a maximum absorbance of 
400nm. The structure is composed of a single central silicon atom encased in twelve 
MoO6 octahedra (oxygen atoms are 
shared at the edges of these).  
Reduction is then carried out to produce 
the blue silicomolybdous acid complex, 
maximum absorbance 810 nm, which has 
a greater extinction coefficient (the 
strength at which a substance absorbs 
light) than silicomolybdic acid. This 
makes silicomolybdous acid more 
sensitive and therefore able to detect 
smaller concentrations of monosilicic 
acid. 
Standard absorbance spectroscopy is then performed at 810 nm, monochromatic UV 
light, produced using a source and a series of slits or lens, is shone through a sample 
of path length l. The UV-Vis spectrometer compares the intensity of the beam with I 
and without I0 passing through the sample, this ratio is known as transmittance and 
can be used to calculate the absorbance A using the Beer-Lambert Law, equation 9.43 
Sample absorption is then compared against suitable dilutions of 1000ppm SiO2 
standard. Measurements were performed here using a Varian Cary 50Bio UV-Visible 
Spectrometer and the Simple Reads software. 
𝐴 = log (
𝐼
𝐼0
)   9 
2.8 Absorption Colorimetry: The Bradford Assay 
Degradability and solubility of silk protein films under in vivo conditions can be 
estimated by monitoring the protein concentration of the solvent, in this case 
phosphate buffer saline (PBS), over time. The Bradford assay has been used here to 
measure protein concentration by observing the binding of a Coomassie Brilliant Blue 
Dye G-250 dye, as the dye ionically binds to acidic regions on the protein in solution 
as well as undergoing hydrophobic interactions. Once bound there is a metachromatic 
Figure 2.14 Structure of the 
silicomolybdic acid cluster. The silicon 
atom (centre in black) surrounded by 
twelve MoO6 octahedral structures, 
adapted from39 
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absorbance shift in the dye, 465 to 595 nm, due to a stable anionic structure being 
formed.44-47  
The donation of a free electron towards the protein from the red dye alters its native 
state resulting in exposure of hydrophobic regions that can then bind to the dye 
through Van der Waals interactions. This, in turn, alters the tertiary structure of the 
protein further to expose amine groups to the negative areas on the dye. When these 
ionically bind, the blue dye is stabilised and a measurement of protein dye complex 
can be made. 
The response from different proteins can vary greatly, for example when observing a 
protein including arginine groups most of the signal will arise from dye-arginine 
interactions as opposed to other amino acids presents. It is for this reason standards 
and samples must be the equivalent. 
Method development to optimise the parameters of the Bradford assay with the aim 
of reducing samples quantities required are discussed further in section 3.4.7. 
2.9 Inductively Couple Plasma – Optical Emission Spectroscopy 
Inductively coupled plasma optical emission spectrometry (ICP-OES) is widely used 
for quantifying elements present in samples. ICP-OES has some limitations with 
respect to the elements it can detect, for example halogens have too high excitation 
energies and it is also not possible to quantify elements found in air. 
Samples are excited by the plasma resulting in an emission of radiation, the 
wavelength of which is characteristic of a specific element. By measuring the 
intensity of emissions quantification of elements in samples can be made.48 
Here a Perkin Elmer ICP-OES Optima 2100DV was used for element quantification. 
Samples were compared to appropriate dilution of 1000ppm stock solutions. 
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Chapter III 
Silk-Silica Composites for Biomedical Application 
Research presented in this chapter has been published - “Influence of silk-silica fusion 
protein design on silica condensation in vitro and cellular calcification” 1 
3.1 Introduction 
The need for foreign materials as bone and dental implants in the human body has led 
to the growth of research as to how to continue to improve these materials in respect 
of biological outcomes.  
Dental implants are a semi-permanent realistic-looking solution to missing teeth; by 
filling gaps with supportive materials there is a reduction in strain and an added 
protection for the surrounding teeth and jaw bone.2 Dental implants are unique in the 
sense they can be employed regardless of the cause of the missing tooth/teeth.3 An 
implant gives a more natural feel in the mouth when compared with dentures that can 
often impair a person’s ability to speak and eat. 
Dental implants tend to be made of titanium or a titanium alloy,4-8 due to their low 
density, high strength, non-hazardous nature and high resistance to corrosion.9 
However the insertion process of a pure titanium/titanium alloy often results in an 
inflammatory response from surrounding tissues.10 Another hindrance to this process is 
the inert properties of titanium alloys preventing bone from easily binding to the surface. 
This can be overcome by treating the implant with a coating before insertion.9-19   
Silk materials are useful as biomedical devices due to their biocompatibility and their 
extraordinary physical properties.20-22 High tensile strength and elasticity provide a 
useful basis for silk materials with medical and non-medical applications as goals.23-
27 Silk can be formed into gels, sponges, films, membranes and scaffolds28-32 with 
applications from controlled release33 to supportive scaffolding constructs.34,35 
Dragline silk from spiders is the focus of the present study due to its support line and 
framing functions in orb webs.36 The structure consists of protein beta sheet crystals 
distributed via long protein fibres, Figure 3.1.37 
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Figure 3.1 A) The steps of silk self-assembly: the amino acid sequence is formed, beta sheet 
formation is induced via hydrogen bonding and hydrophobic interactions resulting in self-
assembly then inter- and intra- molecular interactions drive the formation of micelles where 
the provision of hydrophilic spacer groups results in small regions of trapped water, finally 
an increase in concentration results in gelation to form liquid crystals. B) The liquid crystals 
are transformed via environmental factors into highly ordered fibrils (webbing) as they travel 
down the spinning ducts. Adapted from 37 
However, to generate mechanically stiffer spider-silk biomaterials, analogies from 
bone composite systems can be made, whereby inorganic components are tightly 
integrated into collagen protein-based components, to generate unique composite 
features. A similar approach was taken here, building on past work completed in the 
Perry group,38 where a range of spider silk fusion proteins were generated to study 
silicification. Silica has good compatibility with silk and biological systems.39  
Silica is also known for its bioactivity particularly with bone tissue, as it binds 
strongly with bone whilst also being osteoinductive.38 However, the hard crystalline 
structures often produced by silica are brittle and lack beneficial tensile properties. 
By combining the silica with silk materials the best attributes of both can be achieved, 
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where fully biodegradable, osteoinductive features with a mechanically robust 
composite system can be achieved. Additionally, the new materials would have 
potential to be doped with constituents such as growth factors and drugs for 
programmed release.40 
Silica is ubiquitous in nature,41 for example, diatoms are eukaryotic cells capable of 
producing silica minerals for structural support and protection in the form of a shell.42 
The processes by which these structures are made involve a specific set of proteins 
(silaffins) that promote the deposition of silica, in a region of the diatoms known as 
the silica deposition vesicle.41 The R5 domain (SSKKSGSYSGSKGSKRRIL), a 
component of a silaffin protein, has been identified as silica promoting in vitro as well 
as in nature. The R5 peptide has been previously used to functionalize recombinant 
spider silk like proteins and did not disrupt the R5 silica deposition ability.43 Other 
peptides including A1 (SGSKGSKRRIL) and the A3 peptide (MSPHPHPRHHHT), 
derived from the R5 peptide and phage display, respectively, showed silica deposition 
activity.44,45 Previously composite silk-silica samples were produced via genetic 
engineering using a 15 repeating unit of a modified version of the 33 amino acid 
consensus sequence of the major ampullate dragline spindroin 1 (MaSp 1) from 
Nephila clavipes (SGRGGLGGQG AGAAAAAGGA GQGGYGGLGSQGT) and 
the three peptides mentioned above were covalently bound to the silk via a linker. In 
previous studies, the ability of each peptide to promote silica condensation in the 
context of β-sheet crystalline structure formation from the silk was determined.43 
The work covered in this chapter is focused on further understanding the role that the 
position or location of the R5 sequence relative to the silk component plays in terms 
of silica formation. The addition of the R5 peptide was performed directly at the C- 
or N-terminal of the silk repeating unit by genetic engineering and the physical and 
chemical properties of the two protein constructs were analysed relative to the 
induction of silica precipitation and compared to previously published data. 
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Figure 3.2 Sample structure of the silk chimeras discussed in this chapter. A 15mer 
silk repeating unit with a His-tag bound at the N or C terminal, and the equivalent of 
these with an R5 silicifying domain occupying the vacant terminal. 
3.2 Methods and Materials  
Synthesis, expression and purification of silk chimeras was performed by 
collaborators at Tufts University. As part of the collaboration, a six week 
microbiology course was completed. 
3.2.1 Construction of recombinant silk and silk-silica chimeras  
The following constructs were designed: 15mer-ch, nh-15mer, R5-15mer-ch and nh-15mer-
R5. 15mer-ch and nh-15mer are spider silk constructs build of 15 repeating units 
(SGRGGLGGQG AGAAAAAGGA GQGGYGGLGSQGT)15 that carry a Histidine tag 
(His6 = h) on the C-terminal and N-terminal end, respectively. R5-15mer-ch is a 15mer-ch 
based construct that has the R5 sequence (SSKKSGSYSGSKGSKRRIL), at N-terminal end, 
whereas nh-15mer-R5 is nh-15mer based construct that has the R5 sequence at C-terminal 
end. Plasmids pET30ch and pET30nh were used as cloning vectors, where the His-tag is 
located at the C- or N-terminal of the genetic constructs, respectively. Both pET-30ch and 
pET-30nh are pET-30a(+) (Novagen, San Diego, CA, USA) derivative vectors. The 
construction of the cloning vectors pET-30ch and pET-30nh was performed in a similar 
fashion to that described previously.46 Briefly, for the construction of pET-30ch linkers 1F 
and 1R were used, whereas for the construction of pET-30nh linkers 2F and 2R were used. 
The cloning cassette linkers 5’TATGGCTAGCGGTGACCTGAATAACACTAGTC3’ 
(linker 1F), TCGAGACTAGTGTTATTCAGGTCACCGCTAGCCA (linker 1R), 
5’TATGCACCATCATCATCATCATGCTAGCGGTGACCTGAATAACACTAGTTAA
AC3’ (linker 2F) and 
TCGAGTTTAACTAGTGTTATTCAGGTCACCGCTAGCATGATGATGATGATGGT
GCA (linker 2R) were generated with NdeI and XhoI sites and prepared by annealing two 
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complement synthetic nucleotides (1F-1R and 2f-2R). Annealing was accomplished by 
decreasing the temperature of a 20 pmol/μL oligonucleotide solution from 95 to 20°C at a 
gradient of 0.1°C/s. Mismatched double strands were denatured at 70 °C followed by a 
further temperature decrease to 20 °C. This cycle was repeated three times. The resulting 
double stranded linker was ligated into pET30a(+) previously digested with NdeI and XhoI. 
Both restriction sites were preserved after ligation. The resulting cloning vectors were 
referred to as pET30ch and pET30nh. The His-tag in the pET30nh vector was integrated as 
an NdeI/NheI fragment using pre-annealed oligonucleotides 
TATGCACCATCATCATCATCATG His-tagF and 
CTAGCATGATGATGATGATGGTGCA His-tagR. Next, a 1485bp DNA NheI/SpeI 
fragment containing genetic sequence coding for artificial silk protein, 15mer 
(SGRGGLGGQGAGAAAAAGGAGQGGYGGLGSQGT)15, was inserted into pET30ch 
and pET30nh to yield pET30ch-15mer and pET30nh-15mer, respectively.47 To prepare the 
chimeras with the R5 sequence fused at the C- and N-terminus of the 15mer, pET30ch-
15mer and pET30nh-15mer were digested with SpeI and then treated by antarctic 
phosphatase (NEB, Ipswich, MA, USA) to prevent self-ligation. The nucleotide sequences 
of R5 were designed with restriction endonuclease sites NheI and SpeI flanked at the 5′ and 
3′ termini, respectively. Codons were optimized for expression in Escherichia coli strain 
BL21(DE3) by using the on-line tool OPTIMIZER and were synthesized commercially 
(Invitrogen, Grand Island, NY, USA). The synthesized nucleotides were annealed to 
generate double strands and then ligated to generate the constructs pET30ch-R5-15mer and 
pET30nh-15mer-R5. E. coli DH5α cells were transformed and positive clones were selected 
on lysogeny broth (LB) plates supplemented with kanamycin (50 μg/mL).  
3.2.3 Expression and purification of recombinant silk and silk-silica chimeras 
The recombinant silk constructs were expressed in E. coli strain BL21 Star (DE3) 
(Invitrogen, Grand Island, NY, USA). A fermenter (Bioflo 3000, New Brunswick Scientific, 
Edison, NJ, USA) was used for the expression. Cells were cultivated at 37°C in LB medium 
with 50 μg/mL kanamycin. Once the optical density OD600 reached 0.8, the isopropyl β-d-1-
thiogalactopyranoside, IPTG (Sigma-Aldrich, St. Louis, MO, USA) was added at a final 
concentration of 1 mM to induce expression. After 5 h cells were harvested by centrifugation 
for 20 min at 8,000 rpm. Recombinant silk protein and chimeras were purified by Ni-NTA 
affinity chromatography as previously described44. Once purified, proteins were dialyzed 
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and lyophilized44. Protein identity and purity were confirmed by SDS-PAGE (Invitrogen, 
Grand Island, NY, USA). 
3.3.3 Silk Films 
Silk Film Production 
Polydimethylsiloxane (PDMS) discs were formed as an inert support material for silk film 
formation. Sylgard 184 PDMS (mlsolar, Campbell, CA, USA) base and curing agent were 
mixed in a 10:1 ratio in a petri dish and then placed under vacuum for 1 hour so that releasing 
the vacuum removed the bubbles. The solution was then placed in an oven set to 57°C for 4 
hours. A 6 mm diameter cork borer was used to produce discs. Next, a 2.5% solution of each 
recombinant protein (nh-15mer, nh-15mer-R5, 15mer-ch, R5-15mer-ch) was produced 
using 1,1,1,3,3,3-hexafluoroisopropanol (HFIP) (Sigma-Aldrich, Dorset, UK), the silks 
were allowed to dissolve overnight at room temperature. A 30 µL aliquot of the silk-HFIP 
solution was pipetted onto the 6 mm PDMS discs and air dried overnight. The silk films 
were then annealed with aqueous methanol using a vacuum oven set to 635 mbar containing 
4 petri dishes: 2 containing a 60% aqueous methanol solution and 2 containing cotton wool 
soaked in a 60% aqueous methanol solution.  
Silicification of films 
For induction of silicification, the recombinant proteins (nh-15mer, nh-15mer-R5, 15mer-
ch, R5-15mer-ch) mounted on a PDMS substrate were placed in a 24 well plate with 1 mL 
of pre-hydrolysed 30 mM tetraethyl orthosilicate in pH 7.4 buffer solution (Sigma-Aldrich, 
Dorset, UK) for 1 hour.44 The films were then rinsed twice with water and left to dry 
overnight in a fume hood. 
Characterisation 
Scanning Electron Microscopy and Microanalysis (SEM-EDX). SEM-EDX at 20 kV 
(JEOL 840,UK with Oxford Instruments Inca X-ray microanalysis, Oxford, UK) was used 
to observe the morphology and size of the particles and obtain information on the elemental 
composition of the films. Each sample was mounted onto electrically conducting carbon 
tape on aluminium stubs before being gold coated using an argon gold plasma at 30mV and 
1.2 kV for 2 minutes. A minimum of 50 particle diameters were measured and averaged to 
determine the particles size. 
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Molybdenum Blue Assay. The concentration of silicic acid remaining in solution was 
measured via a molybdenum blue assay.25 In brief, 10 µL of sample was added to 1.5 mL 
molybdic acid with 15 mL distilled water. After 15 minutes 8 mL of reducing agent was 
added, and the absorbance measured as above within 2-24 hours of reducing agent addition 
and compared against suitable dilutions of 1000ppm SiO2 standard treated the same way. 
Fourier Transform Infrared Attenuated Total Reflectance Spectroscopy (FTIR-ATR). 
Protein conformation was assessed using FTIR-ATR (Frontier, PerkinElmer, Coventry, 
UK), with an average of 40 scans over a range of 4000-650 cm-1. Silk films were analysed 
before and after annealing to observe changes in structure. Thermo Grams A1 software v8.0 
was used for curve fitting, including baseline corrections. Six points were chosen from the 
amide I band (1700-1580 cm-1), and 4 for the conformer absorbances (β-turn 1690−1662 
cm−1, α-helix 1662−1645 cm−1, random coil 1645−1637 cm−1, β-sheet 1637−1613 cm−1).48,49 
The remaining 2 bands were introduced to correct for sidechain carbonyl groups and non-
baseline resolution of the amide I and II bands. Absorbance bands were restricted to these 
parameters with the width limited to between 8 and 30 cm-1 (at half height).  An iteration 
was carried out forcing all peaks to have a positive area with a linear baseline and then up 
to a further 1,000 iterations carried out for curve fitting. The sum of the areas under the 
relevant peaks was found and each conformer expressed as a percentage of the total. 
Wettability and surface energy measurements. The wettability and surface energy of each 
silk sample was measured using a Theta Attension Instrument with OneAttention v 1.7 
software (Biolin Scientific, Staffordshire, UK). A silk film mounted on a PDMS substrate 
was placed on the stand, and using a syringe a 5 μL droplet of water, dimethyl formamide 
or ethylene glycol was placed on the surface and the contact angle at each side of the droplet 
measured ten times and an average taken. It was not possible to measure contact angles of 
the non-annealed films with DMP and ethylene glycol as they dissolved in the solvents.  
3.3.4 Solution Studies 
Zeta Potential 
The charge of each protein sample was determined by zeta potential measurements (NanoS 
Zetasizer, Malvern, UK) over a pH range of 5 to 9. A 1 mg/mL solution of each chimeric 
protein sample was prepared using 0.1 M citric acid, the solutions were then filtered using a 
200 nm membrane. Five measurements were collected at each pH and an average taken. The 
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pH adjustment was achieved by addition of 0.1 M bis tris propane buffer and the 
measurements repeated. 
Particle Size Measurements 
The average particle size was measured using a Malvern NanoS Zetasizer (UK), over a pH 
range of 5 to 9 on samples prepared as above. Five measurements were collected per protein 
at each pH and an average taken. 
Silicification in aqueous media 
The effect of the chimeras on silica precipitation from a metastable monosilicic acid system 
was investigated. In a 96 well plate 200 μL of 1.0 mg/cm3 silk/chimera solutions buffered 
to pH 3−9 with 0.1 M tris bis propane/citric acid mixtures were pipetted and then 6 μL of 
prehydrolyzed tetraethoxysilane (TEOS) solution added (2.23 cm3 TEOS dispersed in and 
diluted to 9.9 cm3 with 50% aqueous ethanol, 100 μL of 1 M HCl added and allowed to 
hydrolyse for 10 min) to give a final [Si(OH)4] of 30 mM. The progress of the condensation 
process (conversion of monosilicic acid to silica) was monitored by turbidity measurement 
at 595 nm in a Tecan Infinite M200 pro plate reader to ensure that the process was complete 
before isolation of the siliceous material produced. The silica was then sedimented by 
centrifugation (5 minutes at 3000 RPM) and washed three times with water before freeze 
drying after flash freezing in liquid nitrogen. The reaction supernatant was retained for 
analysis of residual monosilicic acid by the molybdenum blue method described 
previously25 and protein content by a modified Bradford assay. 
3.3.5 Statistical Analysis 
All data provided are taken from averages with the total number of data points denoted by 
N=x and the error plotted as a function of standard deviation. The molybdenum blue assay 
data is reported for 10 replicate measurements. The protein conformation data is based on 3 
separate measurements on different samples, all zeta potential measurements were repeated 
5 times and contact angle measurements were performed 20 times, 10 at each of the left and 
right contact angle. 
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3.4 Results and Discussion 
3.4.1 Recombinant production of silk-silica fusion proteins 
Recombinant spider silk-silica chimeras were cloned by fusing spider silk 15mers with the 
R5 domain at either C- or N-terminal domain of the spider silk. A similar chimeric protein 
was designed previously by fusing 15 repeating units of MaSp 1 and R5 peptides via a linker 
sequence.29 The ability of this sequence to induce silica precipitation was demonstrated.43 
However, to improve the silicification process and to avoid possible effects of the 
interconnecting linker sequence a new set of chimeric proteins was designed without the 
linker sequence. In addition, this novel approach allowed insight to be gained on the 
influence of the position of the R5 domain relative to the spider silk sequence and its impact 
on protein structure, silicification and cell mineralisation. Figure 3.3 illustrates the 
successful expression and purification of the recombinant constructs nh-15mer (40 kDa), 
nh-15mer-R5 (43 kDa), 15mer-ch (40 kDa) and R5-15mer-ch (43 kDa).  
 
Figure 3.3 SDS-PAGE of purified recombinant silk-silica chimeric proteins. A) nh-15mer 
(~40 kDa), nh-15mer-R5 (~43 kDa), 15mer-ch (~40 kDa) and R5-15mer-ch (~43 kDa), were 
run on the 4%-12% Bis-Tris acrylamide gel and stained with Simple Blue dye. Marker (M) 
sizes are indicated on the left. B) Schematic representation of silk-silica fusion proteins 
design strategy; His-tag (green box) has been added to spider silk 15mer at N-terminal end 
of nh-15mer and nh-15mer-R5 constructs, and C-terminal end of 15mer-ch and R5-15mer-
ch constructs; R5 domain (purple circle) has been added to the C-terminal of nh-15mer-R5 
and N-terminal of R5-15mer-ch. 
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3.4.2 Solution Studies 
Silicification in solution 
Using a model silicifying system, mineralising capabilities towards silica of the four silk 
constructs was assessed with respect to one another and a blank (no protein containing) 
system. 
Response to pH was observed using a control construct, nh-15mer, where optimum 
conditions to allow the greatest control over silicification were shown to be at circumneutral 
pHs, pH 6.9 and pH 7.5, based on particle size uniformity measurements, Figure 3.4A. 
Silicification carried out under moderately basic conditions saw a decrease in particle size 
uniformity, whereas at acidic pH 5 two particle populations were formed (averaging approx. 
200 nm and 1400 nm) well below and above the average particle sizes produced in controlled 
systems at circumneutral pHs, suggesting in vivo environments, with respect to pH, would 
permit control over the size of silica particles deposited by the materials. This finding is 
supported by previous work in the Perry group completed on a silk chimera containing a 
linking domain between the His-tag and the silk domain.124 
The beneficial effects of the silk proteins were reflected in the much greater silica particle 
sizes produced compared with the blank system (2-4 nm) and the much greater monosilicic 
acid uptake from solution at circumneutral pHs. 
All silk constructs produced spherical silica particles however there is a significant 
difference in size uniformity between samples with varying location of the R5 peptide when 
silicification was carried out at the optimum pHs discussed above, Figure 3.4B. Constructs 
with a ch bound His-tag produced particles with a larger size distribution than those with an 
nh bound His-tag, indicating poorer control over the silicification mechanism. This 
correlation is paralleled in measured protein concentrations at equilibrium, samples that 
exhibit the most control over silica deposition also saw the most protein removed from 
solution. The highest uniformity and therefore greatest control was seen from the nh-15mer-
R5 chimera at pH 7.5 with an average particle size of approx. 400 nm, Figure 3.4B. 
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Figure 3.4 Particle size analysis in solution of A) nh-15mer condensed silica pH 5.0 – 7.9 
(grey scale intensity indicates level of control shown at each pH (darker scale - more 
control)), B) silica condensed at pH 7.5 in the presence of the different chimeras; solution 
concentration of C) residual monosilicic acid and D) silk chimeras at equilibrium. Error 
analysis based on standard deviation on 5 separate samples E) and F) example SEM images 
of nh-15mer at pH 5 and pH 6.8 respectively G) Zeta potential data over a range 
circumneutral pH's for aqueous solutions, 1mg/ml of the nh-15mer, nh-15mer-R5, 15mer-
ch and R5-15mer-ch, N=5 for all methods other than particle size measurement by SEM 
where a minimum of 50 particles were measured. 
Chimeric silk proteins are removed from solution via entrainment into condensed silica 
particles as part of the silicifying mechanism. Under basic conditions protein is seen to a 
lesser extent, it is believed this is due to the reduced positive charge on the nitrogen side 
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chains of the silk samples lowering silica affinity with the increased solubility of silica 
allowing for re-dispersion of proteins back into solution. 
Protein charge in solution: Zeta Potential measurements  
Aggregation of silk proteins in solution to give particles can occur due to hydrophobic 
interactions. A stable colloidal solution requires sufficient repulsion of particles from 
surface charges to prevent aggregation. With sufficient charge, proteins tend to form stable 
colloids of isolated molecules, but as charge is removed by changes in pH these tend to be 
increasingly replaced by aggregated systems. This aggregation and the forming of larger 
aggregates has been proposed as the mechanism by which silk chimeras have been able to 
influence the morphology of the silica produced when the colloidal instability and maximum 
silica condensation rates coincide.43  
The charge on the proteins as measured via zeta potential showed that all samples, over the 
pH range explored, contained non-stable particles prone to aggregation with values in the 0 
≤ ± 5 mV region, Figure 3.4G. All samples had an isoelectric point between 5 and 6 (Figure 
3.4G). The location of the R5 peptide on the silk repeating unit appeared to have negligible 
effect on the zeta potential at any pH. Comparable results were obtained previously for 
samples that contained the linking unit.25 The data also suggests that lower pH offered 
greater stability for all silk samples with respect to particle aggregation, Figure 3.4G. 
3.4.3 Silk films 
Silicification: Particle Size and Morphology 
Silica particles formed with these proteins should be homogeneous within the material and 
large enough to strengthen the material. For practical use, a ‘good’ material will be capable 
of inducing accelerated silica deposition to give a high silica presence with controlled silica 
particle size to aid the regrowth of bone and not obstruct the formation of the bone-implant 
interface. These features can be exploited for bone growth and improved resilience to 
deformation under compression.  
Figure 3.5A-D shows the effect of the presence and position of the R5 construct on the extent 
of silicification. EDX data for all four constructs confirm the presence of protein (via 
detection of ‘N’) and ‘Si’ on all films, Figure 3.5A-D panel iv. Only films prepared from 
constructs containing the R5 moiety show recognisable silica particles on the surface, with 
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those for nh-15mer-R5 being the surface with the highest overall coverage of particles, 
Figure 3.5B, D. Measurement of the particle sizes on these two surfaces, Figure 3.5D 
showed that particles formed on the surface of the nh-15mer-R5 chimera films were smaller 
(average ca. 300nm diameter) and more monodisperse than silica particles formed on the 
R5-15mer-ch films, Figure 3.5B (average ca. 600nm diameter). A comparison to silica 
formation on films containing the additional linker in addition to the nh-15mer-R5 construct 
presented a monolayer of small silica particles of approximately 100 nm diameter (data not 
shown).25  
Additional support for silicification taking place on all surfaces is given from analysis of the 
silica remaining in solution after the films had been silicified, Figure 3.5E. All silk constructs 
removed silica from solution with the effect being greatest for the two constructs containing 
the R5 peptide. Although different sizes of silica particles were observed to form (Figure 
3.5F) there was little difference in the overall levels of silica condensed for the constructs 
Figure 3.5F. In solution, the non-chimeric control constructs were shown to exert control 
over the morphology of the silicified material and this is probably due to the presence of the 
basic His tagged domain.  This effect is clearly lost when films are formed on a PDMS 
substrate and subsequently annealed suggesting that the His tag may no longer be available 
for interaction with silica but that the R5 on the chimeras still is. An alternative view is that 
the R5 domain may reduce the affinity of the chimeras for the PDMS substrate and allow 
partial solubilisation of the protein back into solution during the silica condensation process 
resulting in a layer of silica particles similar to those observed during the solution chemistry 
study. 
The presence of silica on all surfaces shows that they are not repelling the deposition of 
condensing silica but that the non-chimeric control films appear to be passive rather than 
active in the process. 
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Figure 3.5 Scanning electron microscopy images of the silicified films at different 
magnifications (i-iii) with energy- dispersive X-ray spectroscopy data (iv) of the area 
represented by (iii). A-D) represent the nh-15mer, nh-15mer-R5, 15mer-ch and R5-15mer-
ch respectively, with (i) showing areas of 100-200 µm (ii) 10-20 µm and (iii) 5 µm, E) 
Molybdenum blue assay of the supernatants after 1 hour silicification of the nh-15mer, nh-
15mer-R5, 15mer-ch and R5-15mer-ch samples, N=10. F) Particle size data from SEM 
images for the nh-15mer-R5 and R5-15mer-ch samples, N=100.  
Materials Properties of the films 
The secondary structure of silk gives rise to its high mechanical and tensile strength 
and thus it is instructive to know the natural levels of protein conformers present and 
their susceptibility to change. Using FTIR-ATR the effectiveness of the annealing 
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process on inducing β-sheet structure was evaluated by analysis (peak deconvolution) 
of the amide I band (1600-1700 cm-1). The amide I band arises primarily from the 
stretching vibrations of the C=O bond, with location dependent on the structural 
conformation of the backbone and the hydrogen bonding present.50,51 This analysis 
allows quantification of structural types, distinguishing between random coil and beta 
type structures. Figure 3.6A depicts the β sheet/turn content of the samples before and 
after annealing, quantitative data presented in Table 3.1. Before annealing, the 
samples with the His tag at the N terminus exhibited higher levels of sheet/turn. As 
expected, once annealed, all samples showed increased β-sheet and β-turn content. 
This was observed in the shift of the amide I band (from approximately 1650 cm-1 to 
1630 cm-1), along with the change in peak shape. Example IR spectra with peak 
deconvolution can be seen in Appendix Fig 3.i. 
 
Figure 3.6 A) Nature of the nh-15mer, nh-15mer-R5, 15mer-ch and R5-15mer-ch silk films 
before and after annealing measured as percentage area assigned as β sheet or turn. Error 
statistics are the standard deviation of 3 peak fitting results for each sample. B) Zisman plot 
of the genetic constructs. N=20. C) and D) Representative AFM 3D images for 15mer-ch 
sample C) before annealing D) after annealing, scanned areas 100 x100 µm. 
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The most dramatic change was observed for the R5-15mer-ch sample. In both cases, 
the presence of the R5 domain in the silk constructs enhanced the transformation to 
the structurally more robust beta silk structure.  
The surface properties of the silk materials were assessed before and after annealing 
by atomic force microscopy (surface roughness) and by measurement of contact 
angles using a range of liquids to obtain information on wettability and ‘surface’ 
energy, Figure 3.6 and Table 3.1.  These properties were measured as the surface 
roughness and wettability of a biomedical material can have a large effect on whether 
the materials are accepted or rejected in the body. 
Contact angle measurements were made on the R5 peptide containing film samples 
(nh-15mer-R5, R5-15mer-ch) mounted on PDMS, a known hydrophobic surface, 
before and after annealing using water. However, it was only possible to use the 
annealed film surfaces with liquids having a lower surface tension than water as the 
pre-annealed film samples were too porous/soluble to be assessed further. Films 
prepared with all silk constructs were hydrophilic before annealing with increases in 
hydrophobicity, commensurate with the observed changes in beta sheet content 
(Figure 3.6A) being measured for all samples post annealing, the differences in 
contact angle before/after annealing was greatest for the samples without the R5 
moiety (Table 3.1). The samples containing R5 were more hydrophilic than their 
corresponding His tagged counterparts after annealing. The surface energies of the 
silks containing the R5 constructs were reduced compared to the silk constructs only 
having a His tag, Figure 3.5B and Table 3.1, though the position of the R5 peptide 
had little effect on the values obtained. AFM analysis of the sample surfaces was used 
to measure surface roughness, Figure 3.5C and Table 3.1. All materials containing 
the R5 construct were smoother than their counterparts before annealing with a 
significant reduction in roughness being observed for both constructs containing R5 
after annealing. 
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Sample nh-15mer nh-15mer-R5 15mer-ch R5-15mer-ch 
Contact Angle 
θ 
Preannealed 46.5 ± 1.7 55.0 ± 0.6 56.4 ± 1.2 43.4 ± 0.7 
Annealed 115.7 ± 0.02 74.6 ± 0.003 84.2 ± 0.02 90.9 ± 0.03 
Roughness 
Rq* 
Preannealed 348.9 ± 10.4 229.7 ± 6.8 310.2 ± 9.4 167.1 ± 5.0 
Annealed 332.3 ± 9.9 118.0 ± 3.5 - 99.2 ± 3.0 
Surface 
Energies** 
Annealed 33.9 ±0.4 25.8 ± 2.8 30.3 ± 0.2 26.4 ± 0.9 
% Beta 
Structure 
Preannealed 19.9 ± 0.4 22.7 ± 0.5 13.6 ± 0.3 15.2 ± 0.3 
Annealed 25.6 ± 0.6 35.54 ± 0.8 15.9 ± 0.4 35.2 ± 0.8 
Table 3.1 Roughness and wettability data collected for the nh-15mer, nh-15mer-R5, 
15mer-ch and R5-15mer-ch. Contact angles: N=20, surface roughness N=3, surface 
energies N=3. *Root mean square **2nd order standard deviation used as error.   
3.4.4 Mechanism of silica particle formation on silk films made from the 
genetic constructs 
It has been previously proposed that the formation of structure in silica condensation 
experiments performed in the presence of the silk chimeras was due to the development of 
silk aggregates at pH values corresponding to the natural maximum for silicic acid 
condensation in solution.25 In this study we are additionally investigating the effect of a solid 
interface (silk chimera) with the silicifying medium. In the absence of the spherical 
structures these chimeras generate in solution, we would expect at most to see the silica 
deposited ‘within’ the surface if the monosilicic acid has access to it or ‘on’ the surface with 
electrostatic attachment if silicic acid condensation proceeds in solution in the absence of 
the protein. For the non-chimeric constructs this behaviour may indeed be the case as EDX 
analysis shows the presence of silica ‘on/within’ the films, Figure 3.5A-D. Whether this is 
merely a coating of the normal 2-4nm silica particles produced as for the ‘blank’ 
silicification reaction in the absence of protein, or a layer infused within the protein layer 
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could not be determined but the spheres and porosity generated by the constructs containing 
the silicifying R5 moiety is clearly missing.   
In order to understand the differences in behaviour of the constructs containing the R5 
silicifying domain positioned at either end of the repeating silk domain as well as the role of 
the His tag in silicification the FTIR, AFM and wettability data have to be compared (Table 
3.1).  The annealed silk constructs with the R5 moiety have higher β type content (FTIR 
spectroscopy) and should yield a more hydrophobic surface, however contact angle 
measurements do not support this with the non-chimeric nh-15mer exhibiting the highest 
contact angle (Table 3.1). However the surface roughness is much higher than the R5 
constructs, and the scale according to the AFM data is in the correct range to invoke the 
Cassie-Baxter model of wetting for this surface and the Wenzel model for the R5 containing 
constructs.52 The surface energy measurements support this hypothesis in that the annealed 
chimeric proteins containing the R5 silicifying domain both exhibit lower surface energies 
and are more hydrophobic than films made from the nh-15mer construct. Since entropic 
forces controlled by hydrophobic domains drive the control of aggregation in these types of 
protein then aggregation will be favoured for the R5 constructs.  
The experimental data suggest that when these are immersed in the silicifying medium some 
of the layer becomes re-dispersed near the reaction interface. The R5 constructs due to their 
higher hydrophobic nature more readily collapse through entropic forces to aggregates 
whilst the non-chimeras remain largely isolated at the interfacial layer, Schematic 3.1. As a 
consequence, the silica condenses within the R5 chimera aggregates as for the observed 
solution studies but the same scale of structure does not develop in the presence of the 
protein constructs that only contain a His tag.  
Chapter III: Silk-Silica Composites for Biomedical Application 
70 
 
 
Schematic 3.1 The mechanism for the formation of silica at the protein film surface. The 
none chimeric nh-15mer after dissolution remains mainly as un-associated single molecules 
or small clusters. The nh-15mer-R5 chimera due to its higher hydrophobic nature forms 
entropically favoured aggregates/droplets inside which the silicification process is activated 
through an electron donor/acceptor mechanism and the active elimination of water 
molecules.  
3.4.5 Biological Response of Silk Constructs 
In order to evaluate the silk-silica composites as potential biomaterials it is necessary 
to ensure they do not induce an inflammatory response and promote good mammalian 
cell adhesion once implanted. Assessment of cytotoxicity and cell adhesion was 
completed at Tufts University by observing cell growth on silk films using live/dead 
staining.99 
Films of each R5 containing sample and their corresponding controls were compared 
to cells grown on a tissue culture plate (TCP) via fluorescent live/dead staining. It 
was shown that each silk film seeded with hMSCs promoted healthy cell growth, 
proliferation and adhesion for 2 weeks, resulting in the elongation of the hMSCs 
supporting the use of silk chimeras as biomaterials due to their low cytotoxicity, 
Figure 3.7. Each construct, silk-silica fusion protein or control, exhibited the same 
positive response. 
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Figure 3.7 Human mesenchymal stem cell interactions on recombinant silk and silk-
silica films. Fluorescent staining was performed on hMSCs cells grown on nh-15mer, 
nh-15mer-R5, ch-15mer, ch-R5-15mer and tissue culture plate (TCP) two weeks post 
seeding. The green shows the presence of live cells on the surface, the low levels of 
dead cells (usually observed in red) are not visible here, Scale bars are 100 μm. 
SEM imaging over an 8 week post seeding time period showed typical cell growth 
over the majority of the silk surfaces, elongated hMSCs cells were visible, indicated 
with red arrows, Figure 3.8. There was no difference in cell response between the silk 
R5 chimeras and the control samples. 
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Figure 3.8 SEM images of human mesenchymal stem cells grown on recombinant 
silk and silk-silica films. hMSC were grown on pre-silicified recombinant nh-15mer, 
nh-15mer-R5, 15mer-ch and R5-15mer-ch films. Osteogenesis was induced and cells 
were imaged 8 weeks post-seeding. Scale bars are 10 μm 
The potential of the silk-silica constructs to form osteoinductive biomaterials was 
evaluated through calcium deposition within the hMSC cultures grown on the 
controls, 15mer-ch and nh-15mer, and R5 constructs, R5-15mer-ch and nh-15mer-
R5. Calcium deposition on the cells grown on the silk constructs were compared to 
TCP control samples 4 and 8 weeks post seeding. The silicifying R5 domain present 
in the silk chimeras showed greater potential of osteogenesis than the non-R5 
containing controls or the TCP samples, Figure 3.9A, B. Both the N and C termini 
location of the R5 peptide on the silk backbone allowed the silicifying domain to aid 
calcification, however this was seen to a greater extent by the nh-15mer-R5 sample, 
(R5 located on the C terminal of the silk), at both 4 and 8 weeks post-seeding. 
Quantification of calcium present was completed at 4 weeks showing heightened 
levels in the nh-15mer-R5 sample, Figure 3.9 C. The silk controls used here permitted 
low levels of calcium deposition, three times less than the R5 samples, highlighting 
the importance of the R5 silicifying domain. Despite this, silk samples alone 
permitted more calcium deposition than the control TCP samples. 
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Figure 3.9 Calcium crystal deposition by differentiating human mesenchymal stem 
cell on the recombinant silk and silk-silica films. Calcium crystals (red) staining by 
Alizarin Red S was performed on hMSCs cells grown on nh-15mer, nh-15mer-R5, 
15mer-ch, R5-15mer-ch and TCP A) four and B) eight weeks post seeding. Scale bars 
are 300 μm. C) Calcium deposition of hMSCs grown on recombinant silk-silica 
constructs after 4 weeks in culture. Results for nh-15mer, nh-15mer-R5, 15mer-ch 
and R5-15mer-ch silk-silica constructs and TCP no osteogenesis and TCP 
osteogenesis are shown. Data are represented as the average ± standard deviation 
(n=3, *p < 0.05). 
3.5 Conclusions 
The physical properties of biomedical materials are a principal factor in the acceptance of 
an implant, here the location of the R5 peptide appeared to have little influence on the surface 
properties with respect to the wettability and surface energies of the derived spider silk 
domain selected here. All constructs could undergo manipulation of protein structure via 
annealing to induce a higher content of beta conformers when the R5 peptide was present. 
The N-terminal location of the R5 biomineralization domain in the recombinant 15mer silk 
fusion proteins, R5-15mer-ch, had a higher potential to induce silica precipitation with the 
greatest control of silica particles deposited. 
When investigated in solution, both R5 silicifying domain containing silk constructs gave 
reasonable control over silification. Circumneutral pHs were seen to be optimum suggesting 
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chimeras would have good control over the size of silica particles deposited at an implant 
site. Zeta potential measurements confirmed the addition of the mineralising peptide to the 
silk backbone had no significant effect over silk properties in solution, isoelectric points 
remained unchanged and therefore silks propensity to aggregate allowing heightened control 
over silicification remained unchanged. 
The data supports the use of either of these chimeric silk samples while the chemical and 
physical data suggest that only minor variations occur in the relevant properties of the silk 
with or without the addition of the silicifying peptide in solution. The nh-15mer-R5 and R5-
15mer-ch structures were both capable of controlled silica deposition on to the interface due 
to the control of protein particle sizes during silicification. 
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Chapter IV 
Silk Composites Designed for Bone Regeneration 
Results from this study have been published in “Osteoinductive recombinant silk 
fusion proteins for bone regeneration”.1 
4.1 Introduction 
Recombinant biomaterials hold potential for the development of application-specific 
fine-tuned scaffolding for tissue regeneration and replacement, a major health 
challenge worldwide. Organic-inorganic interfaces are integral to biomaterial 
functions in many areas of repair and regeneration, and the surface modification of 
implantable biomaterial surfaces with bioactive peptides is one approach to design 
materials for bone formation.2,3 Several fibrous proteins have been investigated for 
this purpose.4,5 Collagens are of particular interest as scaffolds for bone tissue 
engineering as they are the major protein fraction of bone extracellular matrix.67 
However, collagen-based biomaterials generally lack mechanical stability and lose 
integrity over time.7 Another unique family of fibrous proteins with impressive 
mechanical properties, biocompatibility and biodegradability are silks.8-12 The 
mechanical strength of spider silk exceeds other natural polymers and most synthetic 
materials, rivalling even high-performance fibres such as Kevlar, making silk a 
suitable candidate for bone-related biomaterials.13  
Biomimetic inorganic-organic hybrid systems have been explored as a route to stiffer 
and stronger materials.14-17 To enhance osseointegration, silk has been specifically 
functionalized with different biological molecules.15-18 Nonetheless, there is limited 
information on how these functional domains influence the material properties of 
silk.16 Previously, silk-silica peptide designs were generated with studies focussing 
on understanding the role of the biomineralisation domain position relative to the silk 
component in the silk-silica fusion proteins in terms of silica formation in vitro.16 The 
silica-binding peptide R5 (SSKKSGSYSGSKGSKRRIL) taken from the silaffin gene 
of the diatom Cerithiopsis fusiformis was fused to the N- or C-terminus of the silk 
sequence (SGRGGLGGQGAGAAAAAGGAGQGGYGGLGSQGT)15, derived 
from the consensus repeat of Nephila clavipes dragline silk protein.16  These fusion 
proteins were around 43 kDa. As a continuation of this approach silk based 
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biomaterials were designed to induce hydroxyapatite formation and enhance in vitro 
bone regeneration. Hydroxyapatite was selected as the target inorganic material due 
to its importance in bone tissues.19  
Optimal peptide candidates for bone regeneration have been identified via phage 
display, with VTKHLNQISQSY (VTK) as a candidate with preferential interactions 
with both bone-like minerals and hydroxyapatite.20,21 Since, the VTK peptide alone 
does not possess adequate mechanical properties for bone graft engineering, 
combination with appropriate scaffolding material is required. 
 
Schematic 4.1 Ideal design for a biomedical silk chimera for coating dental implants, 
with a titanium binding peptide and HAP binding peptide bound at opposing termini. 
Adapted22 
In this study, an artificial silk polymer, 15mer 
((SGRGGLGGQGAGAAAAAGGAGQGGYGGLGSQGT)15, ~39 kDa), derived 
from the consensus repeat of N. clavipes dragline silk protein was genetically 
modified with the hydroxyapatite binding peptide VTK, with the aim to build a 
biomaterial with potential application in bone grafting, exploiting both the remarkable 
mechanical properties of silk and the biomineralisation properties of the VTK 
peptide. To identify optimal protein design with regard to mechanical performance 
and osteoinductive properties, the VTK peptide was fused separately to the N-, C- or 
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both termini of the spider silk, Figure 4.1.  The influence of the designs on calcium 
phosphate deposition with respect to crystallinity was assessed in vitro, along with 
the impact on beta sheet content as a proxy for mechanical strength. These 
assessments provide insight into structure-function relationships and the effect of 
functional domains on silk secondary structure/folding and functionalization for bone 
regeneration. 
 
Figure 4.1 Schematic structures of the silk chimeras discussed in this chapter. A 
15mer silk repeating unit with a His-tag bound at the N or C terminal, and their 
equivalent with the VTK mineralising domain occupying the vacant terminal. Final 
sample has a VTK peptide occupying each terminal of the silk construct. 
4.2 Materials and Methods 
Synthesis, expression and purification of silk chimeras was performed by 
collaborators at Tufts University. 
4.2.1 Construction of recombinant silk and silk-VTK chimeras 
The following constructs were designed: 15mer-ch, nh-15mer, VTK-15mer-ch, nh-
15mer-VTK and VTK-15mer-VTK, Figure 4.1. The 15mer-ch and nh-15mer are 
spider silk constructs built of 15 repeating units (SGRGGLGGQG AGAAAAAGGA 
GQGGYGGLGSQGT)15 that carry a Histidine tag (His6 = h) on the C-terminal and 
N-terminal, respectively. VTK-15mer-ch is a 15mer-ch construct that has the VTK 
sequence (VTKHLNQISQSY),20,21 at the N-terminus, whereas nh-15mer-VTK is a 
nh-15mer that has the VTK sequence at the C-terminus. Plasmids pET30ch and 
pET30nh were used as cloning vectors, where the His-tag was located at the C- or N-
termini of the genetic constructs, respectively. Both pET-30ch and pET-30nh are 
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pET-30a(+) (Novagen, San Diego, CA, USA) derivative vectors. The construction of 
the cloning vectors pET-30ch and pET-30nh was performed as described 
previously.17 Next, a 1485bp DNA NheI/SpeI fragment containing genetic sequence 
coding for the artificial silk protein, 15mer 
(SGRGGLGGQGAGAAAAAGGAGQGGYGGLGSQGT)15, was inserted into 
pET30ch and pET30nh to yield pET30ch-15mer and pET30nh-15mer, respectively. 
To prepare the chimeras with the VTK sequence fused at the C-, N- or both termini 
of the 15mer, pET30ch-15mer and pET30nh-15mer were digested with SpeI and then 
treated with antarctic phosphatase (NEB, Ipswich, MA, USA) to prevent self-ligation. 
The nucleotide sequences of VTK were designed with restriction endonuclease sites 
NheI and SpeI flanked at the 5′ and 3′ termini, respectively. Codons were optimized 
for expression in Escherichia coli strain BL21(DE3) using the on-line tool 
OPTIMIZER and were synthesized commercially (Invitrogen, Grand Island, NY, 
USA). The synthesized nucleotides were annealed to generate double strands and then 
ligated to generate the constructs pET30ch-VTK-15mer, pET30nh-15mer-VTK and 
pET30-VTK-15mer-VTK. E. coli DH5α cells were transformed and positive clones 
were selected with lysogeny broth (LB) plates supplemented with kanamycin 
(50 μg/mL).  
4.2.2 Expression and purification of recombinant silk and silk-VTK chimeras 
The recombinant silk constructs were expressed in E. coli strain BL21 Star (DE3) 
(Invitrogen, Grand Island, NY, USA). A fermenter (Bioflo 3000, New Brunswick 
Scientific, Edison, NJ, USA) was used for the expression. Cells were cultivated at 
37°C in LB medium with 50 μg/mL kanamycin. Once the optical density OD600 
reached 0.8, isopropyl β-d-1-thiogalactopyranoside, IPTG (Sigma-Aldrich, St. Louis, 
MO, USA) was added at a final concentration of 1 mM to induce expression. After 
5 h cells were harvested by centrifugation for 20 min at 8,000 rpm. Recombinant silk 
protein and chimeras were purified by Ni-NTA affinity chromatography as previously 
described,23 while the VTK-15mer-VTK protein that lacked the His-tag was purified 
by heat/ammonium sulphate precipitation.24,25 Once purified, the proteins were 
dialyzed and lyophilized.25 Protein identity and purity were confirmed by SDS-PAGE 
(Invitrogen, Grand Island, NY, USA). 
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4.2.3 Solution Studies 
The charge of each protein sample was determined by zeta potential measurements 
(NanoS Zetasizer, Malvern, UK) over a pH range of 2 to 9. A solution of each 
recombinant protein was prepared at a concentration of 1 mg/mL in 0.1 M citric acid. 
The solutions were filtered using a 200 nm membrane and the pH was adjusted by the 
addition of 0.1 M bis tris propane buffer. Five measurements were collected at each 
pH and an average taken.  
Mineralisation in aqueous media 
Aqueous recombinant silk solutions (1 mg/mL) were prepared using: nh-15mer, nh-
15mer-VTK, 15mer-ch, VTK-15mer-ch and VTK-15mer-VTK. For induction of 
mineralisation, 2 mL of 200 mM calcium chloride and 2 mL of 120 mM sodium 
phosphate were alternately added as 100 µL aliquots to 1 mL of each recombinant 
protein solution. A pH of 7.4 was maintained using 1 M sodium hydroxide (Fisher 
Scientific, Loughborough, UK). The solutions were kept at 37°C for 1 hour before 
the precipitates were collected and washed using dd H2O. 
Precipitate characterization 
Powder x-ray diffraction XRD (PANalytical X’Pert PRO, Cu Kα radiation with 
wavelength of 1.54056 Å) was used to characterize the crystallinity of the precipitates 
produced. Aluminium sample holders were used and packed with 
polydimethylsiloxane (PDMS) (Sylgard 184 PDMS, Mlsolar, Campbell, CA, USA), 
samples were scanned from 5° to 65° of 2θ, accelerating voltage 45 kV, filament 
current 40 mA and scanning speed 0.02° s-1. X’PertHighScore Plus (Version 2.0a) 
was used for pattern manipulation (baseline correcting and smoothing) and analysis. 
4.3.4 Silk Films 
Silk Film production 
The lyophilized recombinant fusion proteins (15mer-ch, nh-15mer, VTK-15mer-ch, 
nh-15mer-VTK, VTK-15mer-VTK) were prepared at a concentration of 2.5% 
(wt/vol) in ultrapure water. The proteins were allowed to dissolve overnight at 4°C. 
PDMS (Sylgard 184 PDMS, Mlsolar, Campbell, CA, USA) disks (R=6 mm) were 
used as substrates on which 30 µL aliquots of each protein solution was deposited, 
ensuring a full coverage on each disk. Films were air-dried overnight and 
subsequently subjected to water vapour annealing using an isotemp vacuum oven for 
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24 h at room temperature and 635 mbar. Afterwards, films were air-dried overnight 
at room temperature.  
Mineralisation of recombinant silk and silk-VTK films 
For induction of chemical mineralisation, the recombinant proteins (15mer-ch, nh-
15mer, VTK-15mer-ch, nh-15mer-VTK, VTK-15mer-VTK) mounted on PDMS 
substrates and a PDMS disk with no protein film, were placed in 24 well plates with 
10 mL of 1:1 solution of 12 mM NaH2PO4 pH 7.4 (adjusted using NaOH) and 20 mM 
CaCl2 (Sigma-Aldrich, Dorset, UK).
26 After incubation for seven days at room 
temperature, the films were rinsed twice with water to remove soluble salts and left 
to dry overnight. Data for the control PDMS disk shown in Appendix 4.ii. 
Scanning electron microscopy (SEM) and energy-dispersive X-ray spectroscopy (EDX) 
SEM-EDX at 20 kV (JEOL 840, UK with Oxford Instruments Inca X-ray 
microanalysis, Oxford, UK) was used to observe the morphology and size of deposits 
post mineralisation of recombinant silk films. Elemental composition of the films was 
analysed. Each sample was mounted onto electrically conducting carbon tape on 
aluminium stubs before being gold coated using an argon gold plasma at 30 mV and 
1.2 kV for 2 minutes.  
Wettability and surface energy measurements  
The wettability and surface energy of each sample was measured using a Theta 
Attension Instrument with OneAttention v 1.7 software (Biolin Scientific, 
Staffordshire, UK). A silk film mounted on a PDMS substrate was placed on the 
stand, and using a syringe, a 10 µL droplet of water, dimethyl formamide (DMF) or 
ethylene glycol was placed on the surface and the contact angle at each side of the 
droplet measured ten times and an average taken. It was not possible to measure 
contact angles of the non-annealed films with DMF and ethylene glycol as the 
proteins dissolved in the solvents. 
Fourier Transform Infrared Attenuated Total Reflectance Spectroscopy (FTIR-ATR) 
Protein conformation was assessed using FTIR-ATR (Frontier, PerkinElmer, Coventry, 
UK), with an average of 40 scans over the range 4000-650 cm-1. Silk films were 
analysed before and after annealing to observe changes in structure. Thermo Grams 
A1 software v8.0 was used for curve fitting including peak deconvolution and 
baseline corrections. Six points were chosen from the amide I band (1700-1580 cm-
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1), and 4 for the conformer absorbances (β-turn 1690−1662 cm−1, α-helix 1662−1645 
cm−1, random coil 1645−1637 cm−1, β-sheet 1637−1613 cm−1). Absorbance bands 
were restricted to these parameters with the width limited to between 8 and 30 cm-1 
(at half height). An iteration was carried out forcing all peaks to have a positive area 
with a linear baseline. This was carried out for 1,000 iterations before curve fitting. 
The sum of the areas under the peaks was found and each conformer expressed as a 
percentage of the total.  
4.3.7 Statistical Analysis 
All data provided are taken from averages with the total number of data points 
denoted by N=X and the error plotted as a function of standard deviation. The protein 
conformation data is based on 3 separate measurements on different samples, all zeta 
potential measurements were repeated 5 times and contact angle measurements were 
performed 20 times, 10 at each of the left and right contact angle. 
4.4 Results  
4.4.1 Recombinant silk fusion protein design and production  
Recombinant silk fusion proteins were designed by fusing the hydroxyapatite-binding 
peptide VTK to the N-, C- or both termini of the artificial silk 15mer, derived from 
the consensus repeat of N. clavipes dragline silk protein. The addition of VTK 
domains to a spider silk resulted in recombinant silk fusion constructs with new 
functions for biomineralisation. The silk domain contributes to the formation of β-
sheet structures leading to crystallinity as a proxy for mechanical strength, while the 
VTK domain was expected to facilitate biomineralisation. Peptide design was focused 
on understanding the role of the hydroxyapatite binding domain position relative to 
the silk component in fusion proteins in terms of protein folding and 
biomineralisation. Fig. 4.2 shows the successful expression and purification of these 
recombinant spider silk fusion proteins.  
Chapter IV: Silk Composites Designed for Bone Regeneration 
86 
 
 
Figure 4.2 SDS-page of purified nh-15mer (~40 kDa), 15mer-ch (~40 kDa), nh-
15mer-VTK (~42 kDa), VTK-15mer-ch (~42 kDa) and VTK-15mer-VTK (~43 kDa), 
run on the 4% - 12% Bis-Tris acrylamide gel and stained with Simple Blue dye. 
Marker (M) sizes are indicated on the left.  
4.4.2 Solution studies  
Protein charge in solution: Zeta potential measurements  
Stability in solution was determined via zeta potential measurements, where particles 
with a zeta potential -5 mV to 5 mV were considered highly unstable and prone to 
aggregation; those with a zeta potential more/less than ±30 mV were considered to 
be stable.27 In order to produce a stable colloidal system using the recombinant silk 
samples, the balance of surface charges of the dispersed phase has to be established 
to inhibit hydrophobic effects and aggregation of silk in solution. Therefore, to assess 
the optimal surface charge that resulted in isolated chains within a solution, the pH of 
the solution was varied. Figure 4.3 shows that all samples had non-stable particles 
between pH 5–7 with isoelectric points between pH 5.5 and pH 6. However, under 
more acidic or more alkaline conditions (pH 3 and pH 9) all silk particles in solution 
could hold charge and increased in stability, Figure 4.3. The location of a single VTK 
peptide relative to the larger silk component had little effect on overall protein charge 
as assessed by zeta potential. However, constructs prepared with two VTK domains 
at either end of the polypeptide chain exhibited the lowest charge at ca. physiological 
pH. 
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Figure 4.3 Solution mineralisation of silk proteins. Zeta potential data over the pH 
range 2–9 for 1 mg/mL aqueous silk solutions, nh-15mer, nh-15mer-VTK, 15mer-ch, 
VTK- 15mer-ch, and VTK-15mer-VTK, (n = 5, p < 0.05). 
Mineralisation in solution  
The effect of each recombinant silk construct on the formation of calcium phosphate 
from solution was explored (Figure 4.5A), a constant pH of 7.4 was maintained 
throughout via addition of reagents in small aliquots as necessary. With no added 
protein, the material formed gives a dominant peak at 11.9° signifying the presence 
of brushite (CaHPO4·2H2O) crystals.
28 Addition of the nh-15mer and 15mer-ch 
control proteins (no VTK domain) appeared to have no effect on the precipitates 
formed, while addition of the nh-15mer-VTK and VTK-15mer-ch proteins had 
similar but limited effects on the precipitates formed producing a mixture of calcium 
phosphates (predominantly hydroxyapatite and brushite), Figure 4.5A. The location 
of the VTK peptide in relation to the silk component did affect the relative proportions 
of each of the mineral phases formed with increased HAP being formed when the 
VTK peptide was located on the C terminus of the silk. In contrast, mineralisation in 
the presence of VTK-15mer-VTK construct produced hydroxyapatite (HAP) alone, 
albeit the positions of peaks in the X-ray diffraction pattern suggested the presence 
of a mineral phase with defects, Figure 4.5A. 29-31 The absence of a peak at 
approximately 11.9° arising from brushite, for materials prepared in the presence of 
the VTK-15mer-VTK protein indicated that significant changes in the mechanism of 
precipitation had occurred which were not observed for the other silk-based 
constructs used in the study, Figure 4.5A. These results suggested that either there 
Chapter IV: Silk Composites Designed for Bone Regeneration 
88 
 
was a minimum VTK peptide concentration required to induce HAP formation or that 
the presence of the His tag hindered the formation of the apatite materials.  
To investigate this, mineralisation in the presence of varying concentrations of the 
VTK-15mer-VTK protein construct were performed, Figure 4.5B. At the lowest 
protein concentrations used both brushite and HAP were identified with the 
contribution from brushite disappearing as the protein concentration was increased 
above 1 mg/mL. A small shift of the peaks arising from the (002) and (004) planes to 
lower values of 2 theta were observed as the level of protein used in the precipitation 
experiments was increased suggesting greater control over crystal growth in the z 
plane of the crystal structure versus the x and y planes. Infra-red (FTIR) spectroscopy 
was used to compare precipitates formed in the presence of the various recombinant 
proteins. FTIR data shown in Figure 4.4 provided further evidence for the formation 
of phosphates in the presence of the silk based proteins, supporting the XRD data. 
There was no evidence of the presence of other organic material such as silk admixed 
in with the sample material though this might have been due to the limits of detection 
of the technique.  
 
Figure 4.4 FTIR of precipitates formed in the presence of each recombinant silk 
sample; nh-15mer, nh-15mer-VTK, 15merch, VTK-15mer-ch and VTK-15mer-
VTK.   
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Figure 4.5 A) XRD data for the precipitates formed in the presence of each recombinant silk sample; nh-15mer, nh-15mer-VTK, 
15merch, VTK-15mer-ch and VTK-15mer-VTK. B) Solution mineralisation of silk proteins, XRD data for the precipitates formed 
in the presence of increasing concentrations of VTK-15mer-VTK.
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4.4.3 Silk films  
In vitro hydroxyapatite mineralisation on silk fusion proteins  
Controlled mineralisation was induced by incubation of the recombinant silk fusion 
proteins with solutions of CaCl2 and NaHPO4. The potential for the different 
constructs to induce mineralisation as annealed films in vitro was assessed by XRD, 
SEM and EDX. Figure 4.6 shows XRD data for the precipitates formed on each silk 
film. All samples containing the VTK peptide; nh-15mer-VTK, VTK- 15mer-ch and 
VTK-15mer-VTK, induced the formation of HAP as shown by the broad peak at 
approx. 32° 2 theta, while mineralisation in the presence of films prepared from the 
constructs without the VTK peptide (nh-15mer and 15mer-ch) did not generate 
crystalline calcium phosphates. The position of the VTK peptide in relation to the silk 
construct did show an effect. When bound to the C terminal of the silk, the VTK 
domain had a greater ability to induce hydroxyapatite formation and, as for the 
mineralisation studies using the protein in solution, films made from the VTK-
15merVTK silk construct were better still, Figure 4.6. FTIR data of the precipitates 
confirmed the presence of phosphates for the nh-15mer-VTK, VTK-15mer-ch and 
VTK-15mer-VTK films (phosphate peaks: 550 cm1 v4(PO4 
3-), 960 cm-1 v2(PO4
3-), 
1010 cm-1 v3(PO4
3-) and with mixtures of phosphates and carbonates being observed 
for the control samples nh-15mer and 15mer-ch (carbonate peaks: 850 cm1 v2(CO3
2-
), 1530 cm1 v3(CO3
2-). These results suggest that the VTK containing constructs are 
still able to direct mineralisation when present as part of a solid construct. SEM 
images coupled with EDX of the recombinant silk films post mineralisation (Figure 
4.6B-F) provide further supporting evidence for Ca/P mineralisation on the nh-
15mer-VTK, ch-15mer-VTK and VTK- 15mer-VTK films. Traces of sodium 
chloride were present on all analysed films arising from the solutions used in the 
mineralisation studies. The nh-15mer control sample showed minimal salt deposition, 
likely sodium chloride, while the 15mer-ch film promoted substantial deposition of a 
mixture of precipitates, containing calcium, chlorine and phosphorous. Figure 4.6 
B,D respectively. Spherical calcium phosphate particles can be seen on films 
produced with a VTK domain containing chimera, Figure 4.6 C, E, F. 
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Figure 4.6 A) XRD patterns of the precipitates formed in the presence of: nh-15mer, nh-15mer-VTK, 15mer-ch, VTK-15mer-ch and 
VTK-15mer-VTK. B, C, D, E, and F) SEM and EDX; nh-15mer and nh-15mer-VTK, 15mer-ch, VTK-15mer-ch and VTK-
15merVTK films respectively after 7 day mineralisation. Scale bars are 500 μm, 100 μm and 10 μm.  
Chapter IV: Silk Composites Designed for Bone Regeneration 
92 
 
Similarly, to what was found for solution based mineralisation, the position and the 
number of hydroxyapatite binding VTK domains in the recombinant silk fusions had 
an impact on the level of mineralisation on the film surfaces. The constructs 
harbouring VTK domains on both the N- and C-termini induced the highest level of 
calcification when compared to all other constructs. This is possibly due to the 
difference in protein folding and exposure of the VTK domains that are the key factor 
in catalysing the process. The effect of peptide location on mineralisation (where the 
VTK domain being attached to the C terminal of silk allows easier access to a greater 
density of hydroxyl groups) was greater for the solid films than the proteins in 
solution, probably due to hindered peptide motion restricting contact with 
mineralizing ions in the immediate environment of the film itself. 
Materials properties of the films  
Silk materials possess high tensile strength due to the naturally occurring beta sheet 
features of the proteins when formed into fibres or other materials.32,33 The percentage 
of beta conformers, both sheet and turn, are directly related to the physical properties 
exhibited by the silk, therefore it is important to measure and explore the ability to 
customise the beta content of such materials. 
The secondary structure of recombinant protein films (nh-15mer, nh-15mer-VTK, 
15mer-ch, VTK-15mer-ch, VTK- 15mer-VTK) was analysed by FTIR-ATR. The 
quantification of protein secondary structure was performed by peak deconvolution 
analysis of the amide I band. The position and shape of the amide I band changed 
with varying beta sheet content as the C=O stretching vibrations are influenced by 
alterations to the conformation of the backbone of the structure and the pattern of 
hydrogen bonding present.34,35 Figure 4.7A shows the changes in structural 
conformation of the silk films before and after annealing. Before annealing the control 
and VTK containing samples exhibited similar percentages of beta sheet with the 
exception of the nh-15mer control sample, which contained more beta sheet initially, 
but showed the smallest structural transformation upon annealing. All samples were 
susceptible to induced beta structure formation, suggesting these samples have the 
potential to be tailored in terms of their physical properties. These changes were seen 
in the shift of the amide I band from 1650 cm-1 to 1630 cm-1. Example deconvoluted 
spectra are shown in Appendix Fig 4.i. The wettability and surface energetics of the 
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films was assessed by contact angle measurements on the silk films before and after 
methanol annealing. Surface energy calculations were only possible for the annealed 
films as the non-annealed films were not stable. Each prepared silk film was 
hydrophilic becoming more hydrophobic after annealing. Non-annealed films 
produced from the VTK containing samples were more hydrophobic than the control 
samples, but exhibited less structural change upon annealing, Figure 4.7B. The 
presence of the VTK peptide at the N terminus of the silk resulted in no significant 
change in surface energy, in direct contrast to the addition of the VTK domain at the 
C-terminus of the silk which resulted in a significant decrease in surface energy (from 
approx. 30–23 Jm-2 ). 
 
Figure 4.7 Physical properties of chimeric silk films. A) Beta-sheet content of each 
silk film before and after annealing (n = 5, p < 0.05). B) Zisman plots for each silk 
sample (n = 5, p < 0.05). C) Table compiling the physical property data to observe 
any changes occurring from the addition of the VTK peptide. 
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4.4.4 Mechanism of Hydroxyapatite formation in solution based mineralisation 
Key parameters for the induction of biomineralisation catalysed by VTK 
functionalized silk in solution was the number of VTK domains alongside the position 
of the VTK domain, Scheme 4.2.  
Addition of nh-15mer-VTK and VTK-15mer-ch chimeras to mineralisation solutions 
resulted in a mixture of HAP and Brushite being formed. A comparison of the XRD 
patterns for materials generated in the presence of these two constructs suggested that 
the nh-15mer-VTK chimera was more effective at directing the formation of HAP as 
the intensities of peaks arising from brushite in comparison to those arising from HAP 
were lower. When the VTK peptide was bound to the C-terminus of the silk, a larger 
density of hydroxyl groups are available for interaction with mineralizing ions, and 
this combined with a greater flexibility of the hydroxyl rich end of the peptide leads 
to a greater effect on mineralisation, Scheme 4.2. The opposite is true for VTK-
15mer-ch, as the end of the VTK peptide with the greater density of hydroxyl groups 
is anchored to the silk domain, likely resulting in limited interactions with the 
reagents in solution and hence the peptide component is less able to affect the 
formation of mineralized precipitates, Scheme 4.2. When the same experiment was 
repeated using the VTK-15mer-VTK chimera, the precipitate formed was solely 
HAP, highlighting the fact that at either terminus the VTK peptide can be effective. 
This outcome is probably caused by the assembly of the proteins into micelle-like 
structures, where the VTK domain is located on the outer surface of the micelle and 
is therefore more exposed to the solution. This effect is exhibited to a lesser extent 
with samples containing only one VTK domain, because as the proteins align to form 
the micelles there is a non-specific arrangement causing peripheral localization of 
some VTK domains and central localization of others. This results in the shielding of 
the VTK domains and exposure of the His-tag. This non-specific arrangement does 
not affect the VTK-15mer-VTK molecules due to either terminus holding the 
hydroxyapatite binding domain, Scheme 4.2. 
In addition, protein concentration was a critical factor to induce biomineralisation. 
The protein concentration required to optimize physical properties to permit the VTK 
peptide to influence the formation of precipitates was defined using the VTK-15mer-
VTK construct. By increasing the concentration of the VTK-15mer-VTK protein a 
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narrowing of the peaks in the XRD pattern was observed, suggesting an increase in 
crystallite domain size. Therefore, modification of protein concentration may  be used 
to tailor the size of crystallites that form in the system. In addition, with increasing 
VTK-15mer-VTK concentration a significant shift in the XRD peaks with miller 
indices (002) and (004) towards apatite-like structure was observed, indicating that 
increased protein concentration leads to a reduction in homogenous strain in the z 
plane.  
 
(Caption overleaf) 
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Scheme 4.2 Structural schematic of the assumed VTK peptide folding in solution 
when bound to the recombinant silk (A) and solution based mineralization comparing 
samples with one or two VTK peptides attached to the 15mer silk repeating unit (B). 
(A) When bound the C termini of the silk, nh-15mer-VTK, the majority of the 
hydroxyl groups on the VTK peptide are at the opposite end to the silk where there 
will be greater mobility and therefore solution interaction allowing heightened control 
over the precipitates formed. The opposite can be said of ch-15mer-VTK, where most 
hydroxyl groups will experience shielding and steric hindrance limiting solution 
interactions and control over mineralization. (B) With one terminus of the silk 
occupied with the HAP binding domain and the other the His Tag when protein 
aggregation occurs the two ends will organise in a non-uniform manner. When both 
ends of the silk are occupied by the VTK peptide non-uniform aggregation has no 
effect, as one HAP domain will always be exposed to the solution regardless of the 
orientation of the chimeric protein. CAC: critical aggregation concentration. 
4.4.5 Biological Response of Silk Chimeras 
Assessment of cytotoxicity and cell adhesion was completed at Tufts University by 
observing cell growth on silk films using live/dead staining. Due to the level of 
similarity to data to obtained in the section 3.4.5, the biological results are discussed 
briefly here with figures omitted. 
The ability of the silk-HAP fusion proteins to support cell growth and proliferation 
whilst inducing osteogenesis was assessed by using human mesenchymal stem cells 
(hMSCs) cultured (after being cultured in control, chondrogenic or osteogenic 
medium) on the surface of each film. Culture-expanded hMSCs maintained the ability 
to selectively undergo chondrogenic and osteogenic differentiation, as assessed 
histologically. Live/dead staining was used to investigate the ability of the 
recombinant silk fusion proteins to support hMSC growth and promote 
differentiation, the cells were grown on the various mineralised film surfaces and 
compared to those cells grown on a control tissue culture plate (TCP). After 2 weeks 
the mineralised films were shown to support good cell growth and proliferation with 
clear elongation of the hMSCs indicating a low cytotoxicity. Strong cell viability and 
metabolic activity of the hMSCs grown on the control silk films and the VTK 
containing constructs was verified using an Alamar blue assay 2 weeks post seeding. 
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Osteogenic parameters were evaluated in the hMSC cultures 8 weeks post seeding. A 
higher bone sialoprotein production was observed for all the VTK containing samples 
when compared to the corresponding His-tagged controls. Despite the single VTK 
bound samples, VTK-15mer-ch and nh-15mer-VTK, showing increased sialoprotein 
levels, it was the VTK-15mer-VTK silk films that showed the highest potential for 
influencing bone regrowth. Calcium deposition on the films was assessed using 
Alizarin Red staining where the importance the HAP binding domain, VTK, was 
proven. Samples containing a single VTK domain showed a higher calcium 
deposition than their control counter parts, whilst the VTK-15mer-VTK sample 
showed the most potential as an osteoinductive biomaterial, permitting 3 times more 
calcium deposition than the control silk films. 
4.5 Conclusions  
Silk materials have been identified for possible biomedical application due to their 
impressive physical properties, here the genetic modification of the spider silk 
derived domain to incorporate the HAP binding peptide, VTK, proved to have no 
detrimental effect on these desired beneficial properties. It was possible to increase 
the beta conformer content in both the control and chimeric silk films, measured as a 
percentage of the secondary protein structure, indicating that the mechanical strength 
of these films can be adapted as required.   
HAP mineralisation performed on chimeras in solution (pH 7.4) showed the VTK 
binding domain to be effective whilst bound to the silk backbone. Samples with a 
single VTK present both exhibited a limited control over HAP mineralisation with 
nh-15mer-VTK having greater control over mineralisation compared with VTK-
15mer-ch, both produced mixtures of HAP and Brushite. The VTK-15mer-VTK 
sample, containing a VTK peptide on both termini was shown to have greater control 
over mineralisation than the singular VTK containing samples. This lead to further 
experiments proving that chimeric sample concentrations are also a key parameter in 
mineralisation as well as number of VTK peptides. 
Solid state mineralisation also showed the same trend, the presence of control samples 
produced Brushite such as that found in a blank system, VTK-15mer-ch and nh-
15mer-VTK had some control over mineralisation, with the latter being moderately 
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better, however it was the VTK-15mer-VTK sample that gave a more complete 
control for inducing HAP formation. 
All the data in this study supports the use of the silk-VTK chimeric samples as 
biomedical materials. Physical and chemical property data showed insignificant 
variation with the addition of VTK peptide to the silk backbone. The VTK peptide 
maintained mineralising capabilities once anchored to the silk and under in vivo 
mimicking conditions. 
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Chapter V 
Quantifying the efficiency of Hydroxyapatite Mineralising 
Peptides via new application of X-ray Diffraction Data  
Work discussed in this chapter resulted in the publication “Quantifying the efficiency 
of Hydroxyapatite Mineralising Peptides” 1 
5.1 Introduction 
The mineralising potential of specific binding peptides has been studied for a wide 
range of materials and reaction conditions.2,3 Methods that allow accurate 
quantification of the mineralised products tend to have one of two distinguishing 
features; either only one product is formed (or not formed) or the by-products of the 
experiment are easily separated from the target compound. 
In peptide driven hydroxyapatite (HAP) synthesis it is often the case that inseparable 
mixtures of various calcium phosphate crystalline materials are produced.4 The range 
of crystal phases produced varies with the method of mineralisation employed, 
however the more commonly used methods tend to be the simplest, and result in two 
significant phases forming, namely HAP and brushite. Analysis of the efficiency of 
peptide directed mineralisation that generates impure products / mixtures is then 
limited to a qualitative discussion of products, for example ‘products produced in the 
presence of sample 1 appears to contain a greater fraction of HAP than sample 2’. 
X-ray diffraction is the most widely used technique for identifying HAP as each 
pattern produced is unique to a mineral’s crystalline structure. Hydroxyapatite exists 
as a hexagonal space group, P63/m, with some minor exceptions (none in calcified 
tissue) as monoclinic systems.5-8 (Specific cell lattice parameters; a=b=9.432 Å and 
c=6.884 Å with γ = 120°, Figure 5.1). In nature, HAP is rarely stoichiometric as 
described above, the Ca to P atomic ratio varies around the stoichiometric 1.67. There 
are trace amounts of the ions; CO3
2-, Mg2+, Na+, F- and Cl- in naturally occurring 
HAP, the concentrations of each vary between the type of tissue with respect to its 
bioactivity and desired properties. The closer the Ca/P atomic ratio is to 1.67 the more 
biologically stable the compound is.9 A decrease in the atomic ratio tends to mean the 
compound will be more bioactive.  
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Figure 5.1 A and B) HAP units cell and hexagonal system layout of HAP 
respectively. Phosphate ions are found in a tetrahedral arrangement, hydroxyl groups 
are located on the c axis. Ca ions are found in two different sites: columns of Ca+ ion 
and equilateral triangles. Phosphorous atoms lie in two height planes: ¼ and ¾. 
Adapted from 10,11 
To explore the possibility of quantifying the amount present of these phases in a 
mixture, a series of HAP/brushite mixtures with increasing molar ratios of HAP to 
brushite (the most commonly formed calcium phosphate without mineralising 
directing influences present)12-15 have been analysed via XRD with the intention of 
creating an analytical method applicable to the quantifiable estimation of, in this case, 
peptides that promote HAP mineralisation.  
Three HAP binding peptides, all of which were previously identified via phage 
display: CaP(S) STLPIPHEFSRE,16-19 CaP(V) VTKHLNQISQSY18,20-23 and CaP(H) 
SVSVGMKPSPRP,16,21,24,25 have used in this study. An extension of the approach to 
quantify the effect on mineralisation of larger proteins such as silk chimeras built 
from mimics of spider silk MASP1 protein and the CaP(V) peptide is also included.26  
5.2 Methods and Materials 
5.2.1 Brushite Synthesis.  
Equal volumes of saturated aqueous solutions of 200 mM calcium chloride (Sigma-
Aldrich, Dorset UK) and 120 mM dibasic sodium phosphate (Sigma-Aldrich, Dorset 
UK) were added together and the solution stirred for 1 hour. The precipitate was 
collected and washed via centrifugation and sonication using dd water. A total of 5 
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washes were performed. Precipitates were dried by lyophilisation  for 24 hours 
(Virtis, Biopharma Process Systems, Winchester UK). 
5.2.2 Producing Mixtures Brushite/HAP Mixtures  
Hydroxyapatite (Sigma-Aldrich, Dorset, UK) and brushite (synthesised for this 
study) were mixed according to percentage weight of each: 0, 20, 40, 50, 60, 70, 80, 
90 and 100% and the molar ratio calculated. The full range was produced to allow 
use in the study of mineralisation with increasing concentrations of known HAP 
binding peptides and non-directed (control) mineralisation. A total of 10 XRD 
patterns were collected for each mixture with thorough stirring of each mixture 
between each scan. 
5.2.3 Assessment of crystalline phases present by powder x-ray diffraction.  
XRD (PANalytical X’Pert PRO, Cu Kα radiation with wavelength of 1.54056 Å) was 
used to characterise the crystallinity of the brushite precipitates produced and 
mixtures formed from brushite and HAP. Aluminium sample holders were packed 
with polydimethylsiloxane (PDMS) (Sylgard 184 PDMS, Mlsolar, Campbell, CA, 
USA), and samples scanned from 5° to 65° of 2θ, accelerating voltage 45 kV, filament 
current 40 mA and scanning speed 0.02° s-1. X’PertHighScore Plus (Version 2.0a) 
was used for pattern manipulation (baseline correcting and smoothing) and analysis. 
Artificially generated mixtures were analysed 10x and materials generated in the 
presence of peptides were analysed 3 times with mixing of the precipitate between 
each scan with samples being kept in the lyophilising chamber until analysis. 
5.2.4 Infra-red Spectroscopy.  
FTIR-ATR (Frontier, PerkinElmer, Coventry, UK), was performed to identify the 
presence of phosphate groups in initial materials, mixtures and mineralised products 
generated in the presence of peptides. For each sample, an average of 40 scans were 
performed over the range 4000-650 cm-1 at 2 cm-1 resolution.  
5.2.5 Inductively Coupled Plasma – Optical Emission Spectroscopy  
The molar ratio of HAP to Brushite was assessed via the Ca:P ratio determined from 
ICP, with data normalised with respect to 100% HAP and 100% Brushite. 
Approximately 5mg of each HAP/Brushite standard (the same standards as used in 
XRD analysis), was digested in 1mL aqua regia overnight then diluted 10 fold using 
dd. water. Measurements are stated as an average of 3 readings per sample.  
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5.2.6 Scanning Electron Microscopy Coupled to Energy Dispersive X-ray Analysis. 
SEM-EDX at 20 kV (JEOL 840,UK with Oxford Instruments Inca X-ray 
microanalysis, Oxford, UK) was used to observe the morphology of crystals and 
obtain information on the elemental composition of the HAP/Brushite mixtures. Each 
standard was mounted onto electrically conducting carbon tape on aluminium stubs 
before being gold coated using an argon gold plasma at 30mV and 1.2 kV for 2 
minutes. A minimum of 3 100µm2 areas were scanned and the Ca:P ratio measured 
as an average of these. 
5.2.7 Hydroxyapatite synthesis using binding peptides.  
1mL aqueous solutions of each peptide; CaP(S) STLPIPHEFSRE, CaP(V) 
VTKHLNQISQSY and CaP(H) SVSVGMKPSPRP (Pepceuticals Limited, Leicester, 
UK - >95% purity), were produced at concentrations of: 0.1 mg/mL, 0.25 mg/mL, 0.5 
mg/mL, 1 mg/mL, and 2 mg/mL. Each solution had equal volumes (4 mL) of calcium 
chloride 200 mM (Sigma-Aldrich, Dorset, UK) and dibasic sodium phosphate 120 
mM (Sigma-Aldrich, Dorset, UK) added in 200 μL aliquots and solutions were kept 
at circumneutral pH, Appendix Fig 5.iii. After addition of all reagents, solutions were 
left to stir for 1 hour before washing the solid product 3 times with dd water. Synthesis 
of mineralised products was then repeated using lower reagent concentrations, 
namely 20mM calcium chloride and 12mM dibasic sodium phosphate.27-31 
5.3 Results 
XRD was selected for this study as it is a well-established non-destructive technique 
for the identification of HAP. Patterns produced from highly crystalline materials 
require little processing so there is a minimal risk of loss of information.32 IR and 
Raman spectroscopy were excluded as both require a higher level of processing 
(baseline correction followed by peak deconvolution of phosphate peaks) on the 
spectra is required to gain quantifiable data. The peaks present in the IR spectra of 
HAP and Brushite are phosphate groups and cannot be easily classified as HAP or 
Brushite in nature. ICP, as a destructive technique, can measure total ion 
concentrations but cannot quantify ions arising from the specific phases, though the 
possibility of normalising measured Ca:P ratios from ICP data is explored here, 
assuming 100% HAP is 1.67 and 100% Brushite is 1.  
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5.3.1 Confirmation of Brushite synthesis 
X-ray diffraction (XRD) and infra-red spectroscopy (IR) were used to confirm the 
formation of Brushite. The XRD pattern showed the distinctive Brushite pattern 
whilst IR confirmed the presence of phosphate groups with minimal water content in 
the sample, Figure 5.2.  
 
Figure 5.2 XRD pattern of the bulk Brushite powder produced for this study. 
5.3.2 Development of a method to assess Hydroxyapatite/Brushite mixtures  
Powder x-ray diffraction has been extensively used for HAP identification since 
Dejong first observed the difference between bone powder and standard highly 
crystalline HAP.33 [The crystal structure of HAP is an hexagonal system, space group 
is P63/m with lattice parameters a=b=9.432 Å and c=6.884 Å with γ = 120°.] This 
gives a complex and distinct XRD pattern that allows in depth analysis where defects 
in structure can be determined.34,35 For quantification of the relative amounts of each 
phase present in mixed samples, a single intense peak was selected from each pattern; 
the (020) peak at approximately 12° for Brushite and initially the (211) peak for HAP 
at approximately 32° to allow smaller quantities of either material to be detected more 
easily, Figure 5.3. Once a trend was established the (002) peak at 25° two theta was 
then used for HAP as there is no risk of peak merging, a common occurrence in 
naturally produced (non-heat treated) HAP XRD patterns due to the smaller crystallite 
sizes present and/or the non-stoichiometric nature of the sample.36  
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Mixtures of HAP and Brushite at pre-defined ratios were produced and studied by 
XRD to establish whether a relationship exists between information extractable from 
the XRD patterns and the molar ratio of the two calcium phosphates present in an 
individual sample. Relationships between concentration and peak height or peak area 
for the two phases were compared Figure 5.4 A and B. Analysis using peak height 
ratios gave the clearer relationship with a clear linear trend between the average peak 
height ratio for the (020) Brushite peak vs the (002) HAP peak and the molar ratio of 
HAP to Brushite for each sample being observed, Figure 5.4. The trend can be 
visualised in example XRD patterns for each mixture in Figure 5.4C, which shows 
that (i) the Brushite (020) peak at 12° decreases in intensity with increasing HAP 
concentration, and (ii) the most intense HAP peak at 32° (211) increases in intensity 
with increasing HAP concentration. Additional confidence in the approach arises 
from the very small variations in the values obtained from multiple independent (N = 
10) sample measurements.  
Figure 5.3 Average peak height 
ratio of the (020) Brushite peak and 
the (211) HAP peak versus the 
molar ration of HAP : Brushite. 
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Figure 5.4 A) Average peak height ratio of the (020) Brushite peak and the (002) 
HAP peak versus the molar ratio of HAP : Brushite B) Average peak area ratio of the 
(020) Brushite peak and the (002) HAP peak vs molar ratio of HAP : Brushite. n=10 
C) Example XRD patterns for the HAP and brushite %/wt mixtures. 
5.3.3 Alternative Techniques 
The method developed here is unique in that it is non-destructive and is a quantitative 
technique solely for comparing crystalline phases present as opposed to 
Chapter V: Quantifying the efficiency of Hydroxyapatite Mineralising Peptides 
109 
 
concentrations of elements, ions or compounds. However, data from alternative 
techniques have been provided here for the HAP/Brushite mixtures as a form of 
method verification.  
Infrared Spectroscopy 
FTIR spectra was used to confirm the presence of phosphates for the mixtures and 
precipitates formed in the presence of a mineralising peptides, Figure 5.5, phosphate 
peaks: 950 cm-1 v1(PO4
3-), 1010 cm-1 v3(PO4
3-). However, this data cannot be readily 
used quantitatively due to; the effect of water presence on the spectra, the difficulty 
of measuring peak heights from a baseline that fluctuates significantly more than that 
of XRD, and problems due to significant overlap between peaks making 
deconvolution difficult. 
 
Inductively Coupled Plasma-Optical Emission Spectrometry 
Measurement of the same standards used in this study were also carried out via ICP-
OES to find the Ca:P ratio of samples. Once normalised to the 0 and 100% HAP 
sample values, (assuming a 1:1 ratio for Brushite presence and a 1:1.67 for HAP 
presence), there was a clear increase in the molar ratio with increased HAP 
percentage, Figure 5.6, and Table 5.1. 
However, calculated values for HAP percentage in the standards was both over and 
underestimated. Normalisation carried out on the Ca:P ratio data for the standards is 
not possible for sample data as it requires the knowledge of phases present, making 
sample data and standard data not directly comparable. Additionally, ICP-OES used 
in this manner relies on two assumptions; that the calcium to phosphorus ratio is based 
on defect free structures and that there are only two crystal phases present in the 
Figure 5.5 Example FTIR (ATR) 
spectra for a selection of the 
HAP/Brushite mixtures, 
phosphate peaks: 950 cm-1 
v1(PO4
3-), 1010 cm-1 v3(PO4
3-). 
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samples, HAP and Brushite. While XRD highlights all phases present, ICP-OES 
cannot, and when multiple phases are present in samples there is no interference in 
the XRD data for the ratio of HAP to Brushite.  
Scanning Electron Microscopy coupled with Energy Dispersive X-ray Analysis 
Each standard mixture was scanned in multiple areas, EDX analysis was performed 
to find the Ca:P ratio. There was no correlation in the data found here and the actual 
molar ratio and therefore %/wt HAP present in the samples, Figure 5.6 and Table 5.1. 
 
Figure 5.6 Exact percentage of HAP present in standards plotted against the 
measured percentage from the different analytical techniques employed: ICP-OES 
data calculated from the Ca:P ratio and normalised to 0% HAP as a 1:1 ratio and 
100% HAP as a 1.67:1 ratio. SEM coupled with EDX data from the measured Ca:P 
ratio from element percentages present. XRD estimation was found using the method 
described above. 
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Actual % wt XRD % wt ICP % wt EDX % wt 
0.00 0.00 0.00 135.75 
20.27 20.73 14.83 48.28 
40.62 43.36 19.98 77.28 
61.87 60.18 64.80 132.33 
80.21 79.96 77.73 159.22 
100.00 100.00 99.38 155.09 
Table 5.1 Tabulated data for the HAP/Brushite mixtures. The actual (%/wt) based on 
masses of the two characterised phases when the mixtures were produced, the XRD 
estimation was found using the method described in this chapter, ICP-OES data was 
calculated from the Ca:P ratio and the data normalised to 0% HAP as a 1:1 ratio and 
100% HAP as a 1.67:1 ratio. SEM coupled with EDX data is from the measured Ca:P 
ratio from element percentages present.  
5.3.4 Quantitative comparison of the ability of hydroxyapatite binding peptides 
to affect mineralisation 
Three known HAP binding peptides, previously identified by phage display were 
included in the study to see if the mineralising capabilities of each could be measured 
quantitatively. The effect of peptide concentration and reagent concentrations were 
both explored. The three peptides, (CaP(S) STLPIPHEFSRE, CaP(V) 
VTKHLNQISQSY and CaP(H) SVSVGMKPSPRP)16,24 had all previously been 
identified as HAP binding peptides. Initial experiments were carried out using the 
same concentrations of calcium chloride (200mM) and dibasic sodium phosphate 
(120 mM) as used to generate brushite for the development of the approach. 
All three peptides were able to direct mineralisation towards HAP formation. Figure 
5.7 A-C shows the XRD patterns produced from precipitates formed in the presence 
of each peptide at initial concentrations; 0.1 mg/mL, 0.25 mg/mL, 0.5 mg/mL, 1 
mg/mL and 2 mg/mL. Table 5.2 shows the estimated percentages of HAP present in 
each precipitate formed. There is a clear increase in the percentage of HAP produced 
with increasing concentration of all peptides. In the XRD patterns this can be 
visualised by the decrease in intensity of the (020) Brushite peak and an increase in 
the (002) peak (and (211) peaks of HAP. 
As the percentage of HAP increases with initial peptide concentration it suggests that 
the concentration of peptide used is a key parameter in HAP mineralisation. This will 
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reach a limit, however, when all precipitated material is present as the HAP phase as 
seen in this study for CaP(V) and CaP(H) when added to the initial reaction at a level 
above 1 mg/ml and for additions of CaP(s) at 2 mg/ml. From this data it suggests that 
for all such peptides a maximum limit on the amount of peptide required for HAP 
mineralisation can be ascertained using XRD as a quantitative tool. The efficacy of 
the peptides in promoting mineralisation can be readily compared, with data on 
CaP(S) and CaP(V) supporting earlier literature studies where more CaP(V) was 
found to bind to HA than CaP(S).20,21,37 
Addition of either CaP(V) and Cap(H) led to a greater degree of control over 
mineralisation at the lower concentrations used, (at 1 mg/mL 99% and 100% HAP 
was produced respectively compared with CaP(S) at 62%). CaP(V) was shown to 
have more influence at the lowest concentrations explored at 0.1 mg/mL and 0.25 
mg/mL. An argument could be made that CaP(V) has greater influence and is 
therefore better at inducing HAP formation, however, all of these peptides could be 
used providing an appropriate concentration level is selected for each, information 
which may be useful for peptide selection if charge or hydrophobicity are important 
factors.  
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Figure 5.7 A-C) XRD patterns of precipitates formed from reaction of 200mM calcium chloride and 120mM sodium phosphate 
dibasic in the presence of CaP(H) SVSVGMKPSPRP, CaP(S) STLPIPHEFSRE and CaP(V) VTKHLNQISQSY at initial 
concentrations: 0.1, 0.25, 0.5, 1 and 2 mg/mL.   
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Concentration 
of peptide used 
Estimated Percentage HAP Produced 
CaP(H) CaP(S) CaP(V) 
0.1 mg/mL 39.11 ± 1.13 33.11 ± 0.96 43.40 ± 1.26 
0.25 mg/mL 47.14 ± 1.36 27.21 ± 0.79 58.84 ± 1.70 
0.5 mg/mL 67.19 ± 1.95 26.39 ± 0.77 82.80 ± 2.40 
1 mg/mL 100 ± 0 62.09 ± 1.80 99.30 ± 0.54 
2 mg/mL 100 ± 0 100 ± 0 100 ± 0 
Table 5.2 Calculated percentage mass of HAP in each precipitate. *Peak from sample 
holder, n=3. 
5.3.5 Quantitative comparison of hydroxyapatite binding peptide with limited 
reagents 
Once each peptide was shown to be capable of inducing HAP formation, the 
concentration of each reagent was reduced tenfold and the experiments repeated as 
above to determine if the three selected HAP binding peptides could still influence 
mineralisation under much reduced ion concentrations. The peptide concentrations 
were chosen to replicate effects (differences in mineralisation activity for the various 
peptides) observed at the lower end of the of peptide concentration range used in the 
initial experiments. Figure 5.8 A-C shows the XRD patterns for precipitates produced 
in the presence of the peptides; CaP(H), CaP(S) and CaP(V) at a range of initial 
concentrations (0.5-2 mg/ml) and Table 5.3 shows the estimated percentages of HAP 
present in the precipitates. All of the peptides influenced precipitation particularly as 
the initial concentration of peptide was increased. Under these conditions, the 
maximum level of HAP formation in the precipitates was of the order of 50%. In 
contrast to results obtained for the effect of peptide on HAP formation at ‘high’ 
reagent concentrations, Figure 5.7, here CaP(S) was the most effective HAP 
‘promoter’ at the lowest reagent concentration level used. The reasons for different 
behaviour of the CaP(H), CaP(S) and CaP(V) probably relate to the specific 
properties of the peptides themselves and will be discussed later in this chapter.  
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Figure 5.8 A-C) XRD patterns of the precipitates formed from the reaction of 20mM calcium chloride and 12mM sodium phosphate 
dibasic in the presence of CaP(S) STLPIPHEFSRE, CaP(V) VTKHLNQISQSY and CaP(H) SVSVGMKPSPRP at initial 
concentrations: 0.5, 1 and 2 mg/mL.  
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Concentration of 
peptide used 
Estimated Percentage HAP Produced 
CaP(H) CaP(S) CaP(V) 
0.5 mg/mL 5 3 6 
1 mg/mL 41 41 21 
2 mg/mL 49 57 44 
Table 5.3 Calculated percentage mass of HAP in each precipitate (it was not possible 
to obtain data from multiple samples owing to the very small amount of sample 
generated). 
5.3.6 Mechanism of peptide directed mineralisation 
The role of the individual peptides in their response during mineralisation has been 
theorised here based on chemical information on the peptide themselves, Scheme 5.1. 
Note, prior research has shown that scrambling of the sequence of CaP(V) had little 
effect on peptide binding to a range of synthetic bone-like and apatitic materials.20 At 
higher reagent concentrations (200 mM CaCl2 and 120 mM NaHPO4), additions of 
CaP(H) and CaP(V) showed greater control over mineralisation, and as both peptides 
have a net positive charge it is suggested that their addition drives mineralisation 
through phosphate ion attraction. Under the conditions of the mineralisation 
experiments, despite CaP(H) having a +2 charge and CaP(V) only +1 charge, Table 5.4 
and Figure 5.9, it is likely that CaP(V) is able to rival the mineralising capabilities of 
CaP(H) as the positively charged lysine group resides at the amino terminal of the 
peptide, thereby creating an area of high charge density; this coupled with the large 
number of hydroxyl groups at the carboxyl terminal, gives the peptide a polar quality. 
CaP(V) would be able to attract both cations and anions thereby providing a site for 
crystal growth, Scheme 5.1. 
 Sequence Net charge at 
pH 7.4 
Average 
Hydrophobicity pI 
CaP(H) SVSVGMKPSPRP +2 +13.87 11.71 
CaP(S) STLPIPHEFSRE -1 +16.67 5.23 
CaP(V) VTKHLNQISQSY +1 +13.05 9.54 
Table 5.4 Properties of the peptides CaP(H), CaP(S) and CaP(V) used in the study.  
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CaP(S) had less of an effect over mineralisation compared to CaP(H) and CaP(V) at 
high ion concentrations, which we suggest is due to the overall negative charge of 
CaP(S) and small changes in pH away from neutral during the mineralisation reaction 
preventing organisation of cations and anions in proximity to the peptide or protein. At 
lower ion concentrations, this effect is felt less and mineralisation where cation 
organisation is key most likely dominates, with CaP(S) becoming a good mineralisation 
promoter. It is possible that the differing physical properties of CaP(S) (negative overall 
charge with an acidic calculated isoelectric point) compared with CaP(H) and CaP(V) 
may allow for a more stable unfolded protein structure in solution which would allow 
for greater exposure of amine groups and therefore greater promotion of mineralisation.  
 
Figure 5.9 Net charge of the CaP(H), CaP(S) and CaP(V) peptides in response to the 
change in environmental pH. 
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Schematic 5.1 influences of each peptide over mineralisation with respect to charged 
species and pH. 
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5.3.7 Extension of approach to silk chimeras 
Previous published work has focused on one of the mineralising peptides, CaP(V) (also 
referred to as VTK), as part of a genetically engineered silk material.26 The prior study 
showed that increased number of peptides attached to the silk backbone resulted in 
greater control over mineralisation. However, discussion of the diffraction data was 
limited to statements of ‘increase or reduction’ in HAP and brushite peaks respectively. 
Using the analytical method described in this chapter, we can show that silk constructs 
based on spider silk MASP1 with a His tag are able to promote HAP formation, Table 
5.5. The location of the peptide at either the N or C terminus had little effect on the 
extent of mineralisation but the presence of peptide at both ends of the fusion protein 
leads to enhanced mineralisation. What is particularly impressive is the low 
concentration of peptide, when attached to the silk construct required to generate pure 
HAP samples, at 0.033mg/ml as compared to when the peptide is used alone when a 
1mg/ml solution is required, Table 5.6.  
Sample 1 mg/mL %/wt HAP 
nh-15mer 32 
nh-15mer-VTK 63 
15mer-ch 44 
VTK-15mer-ch 62 
VTK-15mer-VTK 100 
Table 5.5 Previously published data26 on silk-fusion proteins containing the CaP(V) (or 
VTK) binding peptide with new quantification method applied. %/wt of HAP in the 
precipitates produced from previous samples at 1 mg/mL stating concentrations, nh 
refers to His tag at N-terminus of protein; ch refers to His tag at C-terminus of protein; 
15mer refers to 15 repeats of the spider silk modified MASP1 33 amino acid sequence. 
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Concentration VTK-15mer-
VTK mg/mL %/wt HAP 
0.25 59 
0.5 87 
0.75 92 
1 100 
2 100 
3 100 
Table 5.6 Calculated effect of sample concentration of %/wt of HAP produced for the 
VTK-15mer-VTK sample.18  
5.4 Conclusions 
An analytical calibration tool to quantitatively estimate the % HAP in mixed phase 
precipitates was successfully developed from the previously solely qualitative technique 
XRD. The production of mixtures of HAP and Brushite (known concentrations) allowed 
a direct correlation between average peak height (XRD) and molar ratio to be found, 
which can then be expressed as a % wt HAP presence when the absence of additional 
phases has been established. Other techniques were utilised; ICP-OES, IR and 
SEM/EDX, to authenticate the method and further prove that quantifying crystal phases 
can exclusively be accomplished via this new method. 
It was proven that this method can be applied to compare the mineralisation efficiency 
of peptides and fusion proteins. Using this calibration method, it was possible to 
compare the activity of three known HAP binding peptides. Although it was found that 
CaP(V) showed better control over mineralisation at lower concentrations of peptide, it 
is believed all peptides included in the study would be a suitable choice as a HAP binder 
providing an appropriate concentration is used, meaning other aspects such as physical 
properties of the biomolecules themselves could also be considered.  
It is believed that the general approach should be applicable to other mineralisation 
systems where mixed phases are commonly produced and the assessment of the role(s) 
of additives in mineralisation control is required. 
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Chapter VI 
Silica and Hydroxyapatite Silk Composites: Material Studies 
for Biomedical Application 
Results discussed in this chapter form part of the publication “Intracellular Pathways 
Involved in Bone Regeneration Triggered by Recombinant Silk-silica Chimeras” 
Published pending print in Advanced Functional Materials. 
6.1 Introduction 
Mineralised polymeric based biomaterials provide cell-instructive surfaces with value 
towards tissue repair and regeneration, it is therefore beneficial to gain a 
comprehensive knowledge of the key features of these biomaterials that modulate the 
biological outcomes.  
Silk materials have become increasingly popular as biomedical devices because they 
possess impressive physical properties whilst being biocompatible and 
bioacceptable.1-3 Silk can be processed in many ways that allow it to keep its naturally 
high tensile strength, high mechanical strength and extraordinary elasticity making it 
useful for a wide variety of medical and non-medical applications.4-8 The structure of 
silk makes it possible to produce different material forms such as gels, sponges, films, 
membranes and scaffolds9-13 which can then in turn be adapted to a variety of medical 
applications from controlled release14 to supportive constructs.15,16 Further, silk 
fibroin has the potential for fine-tuning properties through bioengineered sequence 
modification to incorporate diverse functional domains.17-20 
Organic-inorganic biomaterial systems, such as silk-silica and silk-hydroxyapatite 
materials, have shown high potential and worthy of study for tissue regeneration. In 
this study we initially focused on silk-silica chimeras,20-23 these are comprised by a 
core census repeat [(SGRGGLGGQGAGAAAAAGGAGQGGYGGLGSQGT)x15] 
derived from the spider Nephila clavipes major ampullate dragline silk, with a MW 
of ~40 KDa, which serves as an organic scaffold that controls material stability, fused 
with the silica-promoting peptide R5 (SSKKSGSYSGSKGSKRRIL) derived from 
the Cylindrotheca fusiformis silaffin gene, Figure 6.1.24 The R5 peptide has been 
previously used to functionalise recombinant spider silk-like proteins, demonstrating 
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that it did not disrupt the mineral deposition ability of the R5 domain.22,23 In previous 
studies we determined that the N-terminal location of the R5 peptide promoted 
improved control of silica precipitation.23 Computational simulation studies showed 
that the location of the charged biomineralization domain had only a minor effect on 
protein folding and did not alter the surface exposure of charged amino acids, in 
agreement with experimental data. Moreover, cell compatibility and the ability to 
promote hMSC differentiation were demonstrated for variants of these fusion 
proteins.23  
Similar studies were completed using silk-hydroxyapatite chimeras, the same spider 
silk derivative was selected for the backbone repeating unit and paired to the HAP 
binding peptide VTK (VTKHLNQISQSY), identified via phage display,25,26 VTK 
domains were present on the; N, C or both termini of the silk backbone, Figure 6.1. Studies 
showed the VTK domain was capable of controlling HAP deposition independent of location 
on the silk but the number of peptides present dramatically increased the material’s 
mineralising directing capabilities. Genetic modification of the silk to incorporate the HAP 
binding domain showed no adverse effect on the desired chemical and physical properties 
of the silk.27 Strong cell compatibility with the ability to promote hMSC differentiation were 
demonstrated for variants of these fusion proteins. 
 
Figure 6.1 Schematic representation of silk fusion proteins design strategy; His-tag 
(green box) has been added to spider silk 15mer at N-terminal end of nh-15mer, nh-
15mer-R5 and nh-15mer-VTK constructs, and C-terminal end of 15mer-ch, R5-
15mer-ch and VTK-15mer-ch constructs; R5 domain (purple circle) has been added 
to the C-terminal of nh-15mer-R5 and N-terminal of R5-15mer-ch; VTK domain 
(blue circle) has been added to the C-terminal of the nh-15mer-VTK sample, the N-
terminal of the VTK-15mer-ch and both termini of the VTK-15mer-VTK sample. 
Chapter VI: Silica and Hydroxyapatite Silk Composites: 
Material Studies for Biomedical Application 
 
126 
 
This chapter offers the final stage of in vitro study for these silk chimeras designed 
for biomedical application, Figure 6.2. A full material study has been completed to 
highlight the impact of genetic modification to incorporate mineralising domains on 
a repeating unit, further the implication of mineralisation on the chimeric silk films is 
explored with respect to; Young’s modulus, protein structure and biodegradability, 
all key parameters that must be considered when designing biomaterials.    
 
Figure 6.2 Tiers of study using the chimeric silk films for biomedical application 
6.2 Materials and Methods 
6.2.1 Silk fusion protein film preparation and mineralisation 
Silk Film Production 
The lyophilized recombinant fusion proteins (15mer-ch, nh-15mer, nh-15mer-R5, 
R5-15mer-ch, VTK-15mer-ch, nh-15mer-VTK, VTK-15mer-VTK) were prepared at 
a concentration of 2% (wt/vol) in dd water. The proteins were left to dissolve 
overnight at 4°C. PDMS (Sylgard 184 PDMS, Mlsolar, Campbell, CA, USA) disks 
(R=6 mm) were used as substrates on which 30 µL aliquots of each protein solution 
was deposited. Films were air-dried overnight in a fume hood and subsequently 
subjected to methanol vapour annealing using an isotemp vacuum oven for 24 h at 
room temperature and 635 mbar. Afterwards, films were air-dried overnight at room 
temperature.  
Silicification of silk films 
To induce silicification, the recombinant proteins (nh-15mer, nh-15mer-R5, 15mer-
ch, R5-15mer-ch) mounted on a PDMS substrate were placed in a 24 well plate with 
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1 mL of 30 mM tetraethyl orthosilicate-phosphate buffer solution (Sigma-Aldrich, 
Dorset, UK) for 1 hour.28 The films were then rinsed twice with water and left to dry 
overnight in a fume hood.23 
Hydroxyapatite Mineralisation of Silk Films 
For induction of chemical HAP mineralisation, the recombinant proteins (15mer-ch, 
nh-15mer, VTK-15mer-ch, nh-15mer-VTK, VTK-15mer-VTK) mounted on PDMS 
substrates and a PDMS disk with no protein film, were placed in 24 well plates with 
10 mL of 1:1 solution of 12 mM NaH2PO4 pH 7.4 (adjusted using NaOH) and 20 mM 
CaCl2 (Sigma-Aldrich, Dorset, UK). After incubation for seven days at room 
temperature, the films were rinsed twice with water to remove soluble salts and left 
to dry overnight. Data for the control PDMS disk did not show due to no influence 
on mineralisation occurring. 
6.2.2 Analysis techniques for: pre-annealed, annealed and mineralised films 
Fourier Transform Infrared Attenuated Total Reflectance Spectroscopy (FTIR-
ATR) 
Protein conformation was assessed using FTIR-ATR (Frontier, PerkinElmer, 
Coventry, UK), with an average of 40 scans over the range 1750-1450 cm-1. Thermo 
Grams A1 software v8.0 was used for curve fitting (including peak deconvolution), 
and baseline corrections. Eight points were chosen from the amide I band (1700-1580 
cm-1); 4 points corresponding to β conformers: 1693, 1680, 1633 and 1615 cm-1, 2 
points for non-β conformers at 1656 and 1644 cm-1, and 2 at 1712 and 1592 cm-1 to 
allow for peak shifting and amide II band overlap respectively. An iteration was 
carried out forcing all peaks to have a positive area with a linear baseline. This was 
carried out for 1,000 iterations before curve fitting. The sum of the areas under the 
peaks was found and each conformer expressed as a percentage of the total.  
Wettability and surface energy measurements  
The wettability and surface energy of each sample was measured using a Theta 
Attension Instrument with OneAttention v1.7 software (Biolin Scientific, 
Staffordshire, UK). A silk film mounted on a PDMS substrate was placed on the 
stand, and using a syringe, a 10 µL droplet of water, dimethyl formamide (DMF) or 
ethylene glycol was placed on the surface and the contact angle at each side of the 
droplet measured ten times and an average taken. It was not possible to measure 
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contact angles of the non-annealed films with DMF and ethylene glycol as the 
proteins dissolved in the solvents.23 
Atomic Force Microscopy 
A Bruker Dimension Icon with ScanAsyst was used to perform all imaging and 
nanoquantum mapping. Data was collected in PeakForce Tapping mode and 
processed using Nanoscope Analysis software. Young’s modulus values are stated as 
an average of 20 measurements taken across a 20 μm2 area with an assumed Poisson’s 
ratio of 0.3.29 
Biodegradability/Solubility 
Chimeric silk films prepared as above were submerged in 2mL 100mM PBS pH 7.4 
at 37°C, degradation was measured by periodically taking 10 μL aliquots of the PBS 
supernatant and measuring protein concentration by adding 90 μL Coomassie stock 
solution (200mg Brilliant blue dye (Sigma-Aldrich, Dorset, UK), 100 mL methanol, 
20 mL 85% orthophosphoric acid, 200 mL dd water), then measuring the absorbance 
ratio at a wavelengths 590nm and 450 nm.30  
6.3 Results and Discussion 
6.3.1 Parameter Development for Peak Deconvolution of FTIR Spectra 
Previous use of peak fitting on the infrared spectra of protein films across the amide 
I band by the Perry group was reliable but limited, with the use of only six peaks 
across the amide I and amide II bands.20-23,27,28,31 Therefore, development of a new 
method where peak fitting reveals in depth information about protein structure, such 
as specific changes in conformers, was completed. 
Table 6.1 shows the initial literature values considered for secondary structure 
conformer locations within the amide I band. From these, a parameter set was 
established, Table 6.2.  
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 A) Adochitei et al 2010 B) Jilie Kong and Shaoning Yu 2007 C) Susi and Byler 1986 D) Goormaghtigh et al 1990 
Region cm-1 Value cm-1 Assignment Value cm-1 Assignment Value cm-1 Assignment Value cm-1 Assignment 
1682+ 
β-Sheet 
1680-1691 
β Sheet or β 
Turn 
1696 
1691 
1685 
β-Sheet 
β-Sheet 
β-Turn 
1694 
1688 
1683 
β-Turn 
β-Turn 
β-Turn 
1685 β-Sheet 
1662-1682 
Turn 
1677 
1673 
1667 
1661 
β-Turn 
β-Turn 
β-Turn 
β-Turn 
1680 
1675 
1667 
1663 
β-Turn 
β-Turn 
β-Turn 
Helix 
1675 
1670 
1663 
β-Sheet 
turns 
turns 
1678 
1670 
1664 
β-Turn 
β-Turn 
β-Turn 
1645-1662 
Unordered 
Helix 
1653-1657 
1655 
1654 
1642-1657 
1647-1648 
1648 
1649 
Helix 
Helix 
Random Coil 
Random Coil 
β-Sheet 
Random Coil 
Helix 
1656 
1648 
Helix 
Random 
1654 
1645 
alpha-helix 
unordered 
1656 
1648 
alpha-helix 
alpha-helix 
1613-1645 
β-Sheet 
1634-1639 
1630 
1621-1623 
β-Sheet 
β-Sheet 
β-Sheet 
1642 
1638 
1633 
1627 
1624 
β-Sheet 
β-Sheet 
β-Sheet 
β-Sheet 
β-Sheet 
1637 
1631 
1624 
β-Sheet 
β-Sheet 
β-Sheet 
1641 
1633 
1624 
unordered 
β-Sheet 
β-Sheet 
<1620 
 
1615-1620 
 
Aggregated 
protein 
      
Table 6.1 Literature IR peak values for secondary protein structures within the amide I and amide II band. 
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Value cm-1 Assignment 
1712 Side Chain 
1693 intermolecular β sheet 
1680 β turn 
1656 random coil 
1644 α helix 
1628 intramolecular β sheet 
1615 intermolecular β sheet 
1592 
non-baseline amide I and II 
separation compensation 
1568 Amide II 
1546 Amide II 
1526 Amide II 
1511 Amide II 
1497 Amide II 
Table 6.2 Selected values for peak deconvolution of the amide I and amide II band. 
Iterations of the method development saw various parameters explored such as 
Gaussian vs Lorentzian, and fixed vs non-fixed peak: height, width, position and area.  
The final peak parameter settings have peaks limited to a half height width of 10-30 
cm-1 allowing for any positive height/area. Peak are solely based on the Gaussian fit. 
The conformer composition was calculated as the area of the relevant peaks expressed 
as a percentage of the total amide I peak area, (peaks 1615 through 1693 cm-1).  
The new method allows for trends to be more reliably monitored, each conformer is 
monitored with high repeatability displayed. The high statistical merit of this method 
is shown in Figure 6.3, where errors bars represent 1 standard deviation, there are no 
enveloping regions between error bars. 
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Figure 6.3 Estimation of secondary structure of protein for the nh-15mer pre-
annealed film using the new peak fitting parameters discussed above. 
6.3.2 Method Development for Low Volume Biodegradation of Protein Films 
To estimate and observe the effects of annealing and mineralisation on the in vivo 
lifetime of silk chimeric films as biomaterials, the Bradford assay was employed to 
monitor dissolution of protein films over time under in vivo mimicking conditions. A 
new method was developed here to overcome the small quantity of sample material 
available for this study.  
Previous methods for the Braford protein assay in the Perry group are as follows: 
60 μL Bradford reagent (100 mg Coomassie Blue/Brilliant Blue G250 dissolved in 
50 mL methanol with 100 mL 85% orthophosphoric acid and 100 mL deionised 
water), was added to a well of a 96 well plate with 130 μL deionised water and 10 μL 
sample. Shifts in colour from protein-dye binding were measured at 595 nm and 450 
nm, the ratio found, and results compared to appropriate standards. 
Results varied with proteins analysed but this method continually produced a good 
correlation of standards with reliable measurements made when there is an abundance 
of sample. Here the limits of this assay are explored to allow for a degradation study 
of the chimeric silk proteins as films, where 0.6 mg of sample is initially present and 
sampling to monitor degradation can be sustained over a two month period. 
Tabulated in Table 6.3 are the results of the trial studies, briefly Trial 1: two sets of 
standards were prepared using the 15mer spider silk repeating unit; one as described 
above, and the second to explore if a known volume of protein can be preloaded into 
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samples to ensure measurements are performed within the working range. It was 
observed that the solutions were non-homogenous and it was decided that the 
Bradford reagent must first be prediluted with water to ensure a homogenous solution, 
samples can then be added with additional stirring. Trial 2: Samples were prepared as 
in Trial 1 with a Bradford/water stock ready to use. There was no correlation seen for 
the calibration range of 0.001-0.01 mg protein added, which questioned if the 
Bradford assay is suitable for silk proteins or if saturation from the dye had occurred. 
Trial 3: standards were prepared as in Trial 2 using BSA instead of silk proteins, no 
correlation was seen again indicating that the ratio of dye to protein present was too 
high. Trials 4 and 5, the dilution factor of Bradford stock was varied along with the 
total volume of each standard solution prepared, a 3:1 water to Bradford ratio was 
proven optimum and a lower sample volume of 10 μL was proven feasible within a 
total sampling volume of 100 μL. Trial 6 proved that smaller sample volumes 
(<10µL) were beyond the lower limit of this method and Trial 7 demonstrated that at 
lower volumes no preloading of proteins was necessary. 
Final experimental parameters were selected that require 60% less sample 
(protein/silk) than the previous method employed, making a timed study of chimeric 
silk films degradation under in vivo mimicking conditions now possible. The method 
selected is listed in Table 6.3 and labelled trial 5biii, where the optimum stock 
solution ratio (Bradford : Water) was found to be 1:3, and detection was possible with 
0.001mg sample present. This method was proven compatible with silk.  
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Trial Protein 
Water : 
Bradford 
Diluted 
Bradford μL 
Calibration 
standard μL 
Preload 10 μL Prediluted 
Calibration range 
by mass mg 
Total 
μL 
Results 
1a 
15mer 
13:6 190 
10 
no 
No 0.001-0.01 200 
Little to no correlation. Observation: samples 
appeared non-homogeneous. Action: Pre-dilution 
of Bradford dye with water 
1b 2:1 180 0.5 mg/ml 
2a 
15mer 
13:6 190 
10 
no 
Yes 0.001-0.01 200 
Homogenous samples produced. No correlation. 
Not suitable for silk? Bradford Saturation? 2b 2:1 180 0.5 mg/ml 
3a 
BSA 
13:6 190 
10 
no 
Yes 0.001-0.01 200 No correlation: Bradford Saturation 
3b  2:1 180 0.5 mg/ml 
4ai 
15mer 
13:6 
190 
10 
no 
Yes 0.001-0.01 200 
Lower Bradford concentrations saw a poor 
correlation present and poor repeatability. 
Increase sample conc, add another Bradford 
dilution. Pre-load gave better correlation 
4aii 180 0.5 mg/ml 
4bi 
13:3 
190 no 
4bii 180 0.5 mg/ml 
5ai 
15mer 
13:3 
175 
25 
No 
Yes 0.001-0.01 
200 
Correlations from most were reasonable (R
2
 > 
0.9), reduced volumes proved successful meaning 
lower sample concentrations can now be used. 
3:1 Bradford dilute showed to be optimum.  
5aii 165 0.5 mg/ml 
5aiii 90 
10 
No 
100 
5aiv 80 0.5 mg/ml 
5bi 
3:1 
175 
25 
No 
200 
5bii 165 0.5 mg/ml 
5biii 90 
10 
No 
100 
5biv 80 0.5 mg/ml 
5ci 
2:1 
175 
25 
No 
200 
5cii 165 0.5 mg/ml 
5ciii 90 
10 
No 
100 
5civ 80 0.5 mg/ml 
6 15mer 3:1 95 5 No Yes 0.0005-0.005 100 
No Correlation: Protein concentrations too low. 
Next: What is the best preload conc? 
7a 
15mer 3:1 
90 
10 
No 
Yes 0.001-0.01 100 
No pre-load gave optimum correlation 
R
2
 > 0.99 
7b 80 0.5 mg/ml 
7c 80 0.8 mg/ml 
7d 80 1 mg/mL 
 
Table 6.3 Variations to Bradford Assay method with observations and conclusions at each step.  
*Shaded  areas indicate variable being explored.
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6.3.3 Silk Chimeras: Incorporation of a silicifying domain 
The secondary protein structure of each chimeric silk film was quantified using a peak 
fitting method developed in (Belton et al, 2017 – Publication pending in 
Biomacromolecules) applied to FTIR-ATR spectra over the amide I and amide II region. 
The profile of the amide I peak depends largely on the stretching vibrations of the C=O 
groups which is dictated by the samples protein structure. 
As seen previously (Plowright et al, 2016, Chapter III),23 annealing of silk films resulted 
in an increase in the beta conformers with no significant difference between R5 bound 
silk films and their control counter parts, (R5-15mer-ch compared with 15mer-ch and 
nh-15mer-R5 compared to nh-15mer). Here, in depth analysis showed that the increased 
level of β conformer in each silk film arises solely from an increase in β sheet at the 
expense of α helical structures, Figure 6.4. Similar results to this was seen by Izutsu et 
al for near IR spectroscopy of proteins.32 Further, silicification carried out on fully 
annealed films had no significant effect on the protein structure of the silk films, with 
no change in any conformer quantities from annealed to silicified films. These results 
suggest that in vivo, the presence of silica particles would also not affect protein 
structure meaning a predetermined β percentage of biomaterial silk can be selected by 
the surgeon/scientist and assumed stable prior to implantation. The level of random coil 
regions appears unchanged regardless of any process the silk films underwent 
suggesting that initial random coil regions may define the maximum β conformer level 
that can be induced in silk films, Figure 6.4. 
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Figure 6.4 Percentage of secondary protein conformers present in R5 and control silk 
films; pre-annealed, annealed and silicified A) 15mer-ch B) nh-15mer C) R5-15mer-ch 
and D) nh-15mer-R5. N=5 
Mechanical properties of biomaterials were estimated from the measurement of the 
Young’s modulus. Appendix Fig 6.i gives an example of the force separation graphs 
used for this. One aim of incorporating silica into silk to form composites was to produce 
a silk material with heightened resilience to deformation at implant sites. Figure 6.5C 
shows the measured Young’s modulus for the preannealed, annealed and silicified silk 
films. Addition of the R5 binding domain appears to lower the stiffness of the raw state 
silk films. However once annealed, the R5 bound chimeras rivalled the modulus’ of the 
two controls used in the study. Furthermore, a substantially larger increase was seen in 
the Young’s modulus after silicification for the R5-15mer-ch sample compared with the 
control and nh-15mer-R5 samples. The R5-15mer-ch chimera has previously been 
shown to have the greatest control over silicification confirming that the binding of silica 
particles to produce silk composites aids in stiffening the material, particularly as there 
in no change in protein structure (percent β conformer) during the silicification process, 
Figure 6.5D. 
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Topography of the silk surfaces was observed using the images obtained from AFM. 
Figure 6.5 Ai-iii is the nh-15mer control preannealed, annealed and silicified 
respectively. Each process results in further roughening of the surface as the protein film 
undergoes structural changes when annealed and then silica deposition during 
mineralisation. Figure 6.5 Bi and Bii are the R5-15mer-ch and nh-15mer-R5 silicified 
films. The R5-15mer-ch film is a uniform surface with peaks due to uniform silica 
particle presence and nh-15mer-R5 surface has two populations of peak sizes present, 
supporting previous findings of a lesser controlled silicification mechanism occurring.23  
Estimation of in vivo lifetime of biomaterials and the effect of sample processing on this 
life time is an essential parameter that needs to be known prior to in vivo use. Silk 
composites are intended for temporary use in the body, the material is designed to aid 
bone regeneration and then naturally and harmlessly degrade over a designated time 
frame. Figure 6.5E show the solubility of silk films under in vivo mimicking conditions, 
the black lines are preannealed films which are comparatively more soluble (for all 
samples) in PBS than annealed films (blue lines), showing solubility and therefore 
biodegradability of silk biomaterials can be tailored via the annealing process. 
Silicification appears to offer some slight gain in resilience to degradation, however this 
is not to the extent that degradation will be hindered, as previous data suggested that 
silica particle sizes induced to form in the presence of the chimeras were still on a bio-
absorbable scale.31  
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Figure 6.5 A) AFM images for the nh-15mer control silk film i) preannealed ii) 
annealed and iii) silicified B) Silicified films i) R5-15mer-ch ii) nh-15mer-R5 C) 
Young’s modulus measurements for the silk fusion proteins with an assumed Poisson’s 
ratio of 0.3, N=20 D) Beta sheet content of preannealed, annealed and silicified silk 
chimeras and controls, N=3 E) Protein concentration of PBS supernatant in the presence 
of 0.6mg silk films; preannealed (black), annealed (blue) and silicified (red) over time 
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Table 6.4 shows  mechanical property data for the silicified chimeras and control silk 
samples. There is a clear correlation between the increasing percentage β conformer and 
the increasing Young’s modulus of the samples, this is also reflected in the heightened 
tolerance towards dissolution in PBS, Figure 6.5E. 
 15mer-ch nh-15mer 
R5-15mer-
ch 
nh-15mer-
R5 
Percent Beta Structure:     
Preannealed 58.59 ± 0.42 44.87 ± 0.04 49.11 ± 0.11 47.36 ± 0.16 
Annealed 69.41 ± 1.17 71.56 ± 0.15 72.06 ± 0.83 71.55 ± 0.08 
Silicified 70.52 ± 0.18 72.70 ± 0.43 70.32 ± 0.85 71.16 ± 0.85 
Young’s Modulus GPa:     
Preannealed 1.04 ± 0.06 1.50 ± 0.23 0.60 ± 0.08 0.45 ± 0.08 
Annealed 1.26 ± 0.05 2.07 ± 0.22 2.52 ± 0.17 1.86 ± 0.16 
Silicified 2.08 ± 0.17 2.56 ± 0.16 3.94 ± 0.21 1.87 ± 0.23 
Table 6.4 Percent beta conformer and Young’s modulus data collected for the 15mer-
ch, nh-15mer, R5-15mer-ch and nh-15mer-R5. Surface energies: N=3, Young’s 
modulus N=20. 
6.3.4 Silk Chimeras: Incorporation of a Hydroxyapatite Binding Domain 
The effect of the addition of the VTK peptide to the silk backbone on protein secondary 
structure was assessed using peak deconvolution of the amide I band as described above. 
Unlike the incorporation of the R5 silicifying domain, addition of the VTK peptide at 
either termini of the silk repeating unit had no significant effect on the protein secondary 
structure of raw state silk films, Figure 6.6. Silk constructs containing VTK domains 
were able to undergo annealing to induce higher β conformer content to the same extent 
as that observed in their control counter parts, additional β content coming from 
increased β sheet structures with a negative correlation to α helix structures, Figure 6.6. 
At this stage the effect of HAP mineralisation on protein conformers present was to be 
considered, however it was not possible to achieve IR data for the amide I band, it is 
believed this is due to the layer of mineral present being too thick for the IR beam to 
penetrate into the silk, or for minimal beam penetration to occur producing low intensity 
amide peaks that are within background noise levels compared to high intensity 
phosphate peaks present.  
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Similarly to the R5 constructs, the measured quantity of random coil conformers present 
in the VTK and control silk films remained unchanged after annealing, suggesting these 
regions are unaffected by the annealing process and limit the amount of β sheet that can 
be induced using this method.  
 
Figure 6.6 Secondary protein structure of pre-annealed and annealed VTK containing 
silk chimeras with their control counterparts A) 15mer-ch B) nh-15mer C) VTK-15mer-
ch and D) nh-15mer-VTK. N = 5 
The mineralising capabilities of the VTK chimeras was explored previously in Chapter 
IV,27 here a comparison of the silk films mechanical properties is presented to evaluate 
the potential of these samples as biomaterials. Annealing of the control and the VTK 
domain containing constructs resulted in a stiffening of the silk films, to between 1-4 
GPa, Figure 6.7B, correlating with the increased levels of the β conformer, Figure 6.7 
C. Once mineralised the control samples showed no further improvement with respect 
to mechanical properties (Young’s modulus measurements), however the VTK samples 
had varied responses to mineralisation; the nh-15mer-VTK construct had a marked 
increase in Young’s modulus after mineralisation but this was seen to a lesser extent 
compared with the VTK-15mer-ch and VTK-15mer-VTK samples. Young’s modulus 
data for the samples suggests that the crystalline precipitates produced in the presence 
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of the samples is the result of different mineralising mechanism by the VTK peptide to 
produce HAP which is dictated by the location of the VTK domain on the silk backbone. 
Further, stiffness measurements support XRD data shown in Chapter IV (Section 4.4.3), 
where the nh-15mer-VTK sample was seen to have less control over HAP 
mineralisation than the VTK-15mer-ch and VTK-15mer-VTK samples, with a less 
intense HAP pattern being produced, conversely, it is the film/precipitate material 
produced by the nh-15mer-VTK sample that fits best to the Young’s modulus of bone, 
6-30 GPa,33,34 at 18.43 GPa. An argument can be made that precipitates produced by the 
VTK-15mer-ch and VTK-15mer-VTK samples would not integrate neatly into the 
surrounding bone due to much higher Young’s moduli of 148.39 and 168.71 GPa 
respectively. 
Protein dissolution over time in PBS was measured using a Bradford assay to estimate 
in vivo lifetime of the silk films; pre-annealed, annealed and HAP mineralised. Similar 
to what was observed for the R5 constructs, annealing to produce films with higher β 
conformer content provided the control and VTK samples with resilience to degradation 
under in vivo mimicking conditions, suggesting a degree of control over biodegradation 
of silk films can be obtained. Data presented in Figure 6.7 D shows that less protein was 
released into solution from the mineralised films (likely due to protein-solvent 
interactions being reduced by the mineral creating a barrier), however it is believed that 
there was protein loss during the mineralisation of silk films so potentially the maximum 
concentrations presented for mineralised films are likely to be overestimates. Given this, 
HAP mineralisation of VTK-silk chimeras appears to not interfere with the natural break 
down of the silk material, suggesting that if applied in vivo, these films would be 
appropriate for use as temporary biomaterials. 
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Figure 6.7 A) AFM images of HAP mineralised films i) nh-15mer-VTK ii) VTK-
15mer-VTK iii) VTK-15mer-VTK B) Young’s modulus measurements for the silk 
fusion proteins with an assumed Poisson’s ratio of 0.3, N=20 C) Beta sheet content of 
preannealed and annealed films N=3 D) and E) Protein concentration of PBS 
supernatant in the presence of 0.6 mg silk films; preannealed (black), annealed (blue) 
and hydroxyapatite mineralised (red) over time 
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 15mer-ch 
nh-
15mer 
nh-
15mer-
VTK 
VTK-
15mer-ch 
VTK-
15mer-
VTK 
Percent Beta Structure: 
Preannealed 
59.3 
± 0.31 
56.14 
± 0.89 
50.8 
± 0.42 
59.1 
± 0.35 
50.8 
± 0.24 
Annealed 
69.1 
± 0.24 
70.85 
± 0.43 
72.82 
± 0.87 
68.9 
± 0.06 
68.9 
± 0.16 
Young’s Modulus GPa: 
Preannealed 
1.04 
± 0.06 
1.50 
± 0.23 
2.05 
± 0.32 
1.21 
± 0.03 
0.73 
± 0.05 
Annealed 
1.26 
± 0.05 
2.07 
± 0.22 
3.04 
± 0.41 
3.51 
± 0.23 
2.25 
± 0.11 
HAP Mineralised 
2.49 
± 0.26 
0.85 
± 0.6 
18.43 
± 6.38 
148.39 
± 65.34 
169.71 
± 68.45 
Table 6.5 Percent β conformer and Young’s modulus data collected for the 15mer-ch, 
nh-15mer, VTK-15mer-ch, nh-15mer-VTK and VTK-15mer-VTK. Surface energies: 
N=3, Young’s modulus N=20. 
6.4 Conclusions 
A full in vitro study of silk chimeras for use as biomaterials (films) to coat dental and 
bone implants has been performed. The theorised link between β content of a chimeric 
silk film and it’s stiffness has been proven via Young’s modulus measurements of pre-
annealed and annealed films, where an increase in β sheet structure (reduction in α 
helical structures), saw a correlated increase in sample stiffness. Silk films with a greater 
percent β conformer also showed increased resilience towards degradation under in vivo 
mimicking conditions.   
The effect of genetic modification of silk to incorporate mineralising domains was 
evaluated to ensure that the biocompatibility and beneficial physical properties of the 
silk remained unchanged. Addition of the R5 peptide (at either terminus of the silk 
backbone) lowered the rigidity of samples as raw silk films with a reduction of overall 
β structures present, however this could be compensated by annealing the R5 constructs 
proving that these films can be manipulated to have a similar secondary protein structure 
to that of their control counter parts.  
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Presence of the R5 peptide promoted binding of uniform silica particles that further 
enhanced the material stiffness of the composites generated. However silicification had 
little influence on solubility or protein structure of the films indicating the desired 
physical properties of the silk film can be modified via an annealing process prior to in 
vivo insertion. Further development of silk as a biomaterial can by performed by the use 
of varying annealing methods to give predetermined physical properties.    
Unlike the R5 peptide, incorporation of the VTK peptide had no significant effect on 
the raw state films and allowed for induction of β conformers via methanol annealing to 
the same degree as the control samples used. HAP mineralisation was thought to not 
interfere with the breakdown of films in the body, but the location of the VTK  peptide 
on the silk backbone of proteins used to make the mineralised films was shown to be a 
key parameter in determining the physical properties of the samples, with dramatic 
differences in Young’s modulus of the precipitates formed during mineralisation by the 
nh-15mer-VTK sample compared with the VTK-15mer-ch and VTK-15mer-VTK 
samples being observed. Comparison with literature values for the Young’s modulus of 
bone suggests that the less stiff material produced by the nh-15mer-VTK may be more 
compatible with bone as it falls within the generally accepted range of Young’s moduli 
for bone. The Young’s modulus of the more crystalline materials produced in the 
presence of the VTK-15mer-ch and VTK-15mer-VTK was measured to be up to ten 
times greater than that of bone. 
All physical property data suggests that the chimeras are good candidates for biomedical 
use, particularly the R5-15mer-ch given its exceptional silicifying capabilities and the 
nh-15mer-VTK as the crystalline HAP precipitates produced by this sample are the most 
likely to be readily incorporated into surrounding bone tissue due to similar physical 
properties of the materials themselves. 
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Chapter VII 
Silk-Silica Composites as Coatings for Silk Scaffolds and 
Titanium Rods 
7.1 Introduction 
The production of implantable biomedical devices began in 1931 for dentistry, when 
Greenfield produced an iridioplatinum basket implant attached to a gold crown.1  There 
was unmistakable evidence of osseointegration of these implants and they often lasted 
several years. Bothe et al. were the first to use titanium as the implant material, where 
notably elevated levels of osseointegration2 saw this become that preferred material of 
choice for bone and dental implants. Over the years numerous animal studies have 
proven the close proximity a titanium surface can achieve with bone, some studies 
reporting the bone effectively adhering to the implant.3 
The vast majority of modern implants now consist of a titanium screw that is affixed to 
the jaw bone, Figure 7.1, the surface of the implant is treated prior to insertion to produce 
a roughened surface on the macro, micro or nanoscale.4 Texturizing of the surface can 
be done by etching, anodic oxidation or blasting to increase the surface area for 
heightened osseointegration. The macroscale of an implant surface refers to the overall 
geometry of the implant (μm-mm), high levels of roughening on this level has proven 
increased stability of the implant, both in the long and short term.5-7 Studies have shown 
limiting the roughness to between 1-2 μm will lower the risk of infection and ionic 
leakage, this is referred to as roughening on the mesoscale, between 1-10 μm. The 
nanoscale properties of a surface define interactions of proteins with the surface and the 
adhesion of osteoblastic cells.8 
 
Figure 7.1 X-ray showing a titanium dental implant in the 
lower jaw bone upon completion of permanent crown fixture. 
Picture taken at Charles Clifford Dental Hospital. 
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Despite treating the titanium implant surface, it is still comparably inert, 
osseointegration occurs effectively but slowly, and this has led to new research into 
potential coatings for implants. As the composition of the titanium implants surface 
directly effects protein adsorption and cell attachment, careful consideration into the 
design of an implant coating is necessary. Hydrophilic surfaces can be beneficial for 
interactions with biological fluids, cells and tissues9,10 resulting in greater bone-implant 
contact.9 Conversely, reports of in vivo studies on hydrophilic dental implant surfaces 
showed no improvement on osseointegration compared with more hydrophobic 
samples.11 
Coatings of hydroxyapatite on titanium surfaces prior to insertion have been developed. 
Once implanted the coating dissociates from the surface creating a region of high 
calcium and phosphate ion presence. Saturation around the site results in biological 
apatite precipitation containing endogenous proteins aiding cell growth and 
attachment.12-14 This mechanism results in biological implant-bone fixation occurring 
much faster that without HAP coatings,15,16 leading to improved long term success rates 
due to superior osseointegration.17 
Methods for adding HAP coatings to implant surfaces vary widely, there is a growing 
interest in using biomimetic approaches as these avoid the drawbacks of the more 
industrial coating processes, (for example; plasma spraying can cause changes in the 
implant porosity, changes in crystallinity of the HAP, added stress to the bulk material 
and even run the risk of delamination of the coating from the surface). Accelerated 
precipitation from SBF buffer solutions to HAP coated implants has been studied using 
electrodeposition,18,19 hydroxylation of the titanium surface and increased ion 
concentrations.20 
Hydroxyapatite is not the only mineral identified as useful for bone regrowth, there have 
also been many biomimetic studies looking to induce silica deposition for biomedical 
applications. Silica binds strongly with bone whilst also being osteoinductive, it is 
acknowledged that silica plays a fundamental role in the natural formation of bones.21,22  
Previous work by the Perry and Kaplan group has identified the possibility to genetically 
modify spider silk in order to incorporate silica to produce biomaterials. By combining 
silica with the numerous advantages of silk, a material was produced that was versatile23 
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yet hard, fully biodegradable/bioabsorbable over a long time period and osteoinductive 
at the bone interface. 24-29 In the study, a derivative of the major ampullate dragline silk 
of the N. clavipes, was modified to incorporate specific binding peptides. Repeating 
units of the silk, [(SGRGGLGGQGAGAAAAAGGAGQGGYGGLGSQGT)15], were 
used as a backbone to which the R5 silica binding peptide, 
(SSKKSGSYSGSKGSKRRIL), was attach at the N or C termini of the silk. It was 
proven the R5-15mer-ch sample, (ch representing a Hig-tag) had good potential for 
biomedical use with strong silicifying capabilities.24  
Complimentary studies by the Perry and Kaplan groups observed silk-silver 
recombinant proteins, where a silver binding peptide (NPSSLFRYLPSD or 
WSWRSPTPHVVT) was added to the C terminal of the spider silk repeating unit 
(SGRGGLGGQGAGAAAAAGGAGQGGYGGLGSQGT). Chimeric proteins studied 
both in solution and as films resulted in silver nanostructural growth, which were proven 
to be effective antimicrobials.30  
Despite a successful study, the disadvantage of these chimeric silks was the overall cost 
of production, suggesting that the larger quantities needed to produce biological 
scaffolds, would not be cost effective. In this study, the use of chimeric silk as a thin 
coating for biologically inert scaffolds and rods has been explored. Two materials have 
been selected for the bulk of the structures; (the standard) titanium and the Bombyx mori 
(B. mori) silk.  
B. mori silkworm silk has been widely explored as a candidate for biological scaffolds, 
but its use as a biomaterial is not limited to scaffolds, silk biomaterials also include: 
gels,31 membranes32 and films.24,33,34 Silks demonstrate biocompatibility, good 
resilience to degradation and impressive yet tailorable physical properties.35,36  
Silk’s beneficial properties for biomedical application are from the β structures formed 
on expulsion of the protein from the silkworm’s glands.37  β sheet structure consists of 
long strands of protein horizontally connected to one another via hydrogen bonding 
(C=O---H-N) resulting in the formation of a pleated sheet. The strands can be arranged 
either parallel or antiparallel and are interlinked with regions of β turn structures. The 
induction of β conformers in vitro can be achieved through one of serval annealing 
processes, allowing control of the samples physical properties.24 
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Porous silk scaffolds for bone regrowth have proven good suitability allowing the 
transport of nutrients and waste as well as cell attachment, proliferation and migration.38 
Silks ability to be functionalised for purpose has resulted in a variety of structural, 
chemical and biomechanical modifications being produced.39 Despite good 
biocompatibility, silk is not bioactive in the sense it does not promote bone regrowth. It 
is hoped a silicifying coating will change this. 
Figure 7.2 shows the samples produced for this study. B. mori silk scaffolds and titanium 
rods were produced then coated in the R5-15mer-ch silicifying silk chimera. Controls 
for the study included uncoated silk scaffolds and titanium rods to assess the inert 
underlying surface of the bulk materials, and a coating made of non-R5 containing 
spider silk protein in order to evaluate the silicifying capabilities of the R5 domain when 
used as part of a thin layer coating. 
 
Figure 7.2 Sample structures included in this study. A) The bulk material made from 
silkworm silk (B. mori) or titanium, typical size: 2mm (D) x 5mm (L). B) Coatings for 
each material: no coating, 15mer-ch (spider silk derivative) and R5-15mer-ch 
(silicifying spider silk derivative). All samples were characterised after silicification.  
7.2 Methods and Materials 
Preparation of scaffold materials was carried out by Tufts University, Boston. 
7.2.1 Preparation of silk scaffolds 
Aqueous silk solutions were prepared using previously established methods.40 Briefly, 
sericin protein was removed from Bombyx mori silkworm cocoons by placing 5 g of cut 
cocoons (Tajima Shoji, Yokohama, Japan) in 2 L of a boiling 0.02 M sodium carbonate 
solution (Sigma-Aldrich, St. Louis, MO) for 30 min. After rinsing in deionised (DI) 
water three times, the degummed fibres were dried overnight and solubilized in 9.3 M 
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lithium bromide (Sigma-Aldrich, St. Louis, MO) for 4 h at 60°C. The resulting silk 
solution was then dialyzed against DI water using standard grade regenerated cellulose 
dialysis cassettes (3.5 kD MWCO; Pierce, Rockford, IL). After 6 changes over 3 days, 
insoluble silk particulates were removed by centrifugation (two times at 9000 RPM, 
5°C, 20 min). Silk concentration was determined by weighing a dried sample of a known 
volume. The silk was then diluted in DI water to a final concentration of 5% and this 
solution poured into cylindrical-shaped containers with 4 mm in diameter and 6 mm in 
height. The containers were then frozen at -80°C and subsequently lyophilized for 2 
days. The scaffolds were then autoclaved and cut in two equal pieces to final size (2 mm 
in width and 6 mm in height).  
7.2.2 Preparation of titanium rods. 
Medial grade titanium wires with a 2 mm diameter were purchased (Sigma-Aldrich, St. 
Louis, MO) and cut by sawing to final size (2 mm in diameter and 5 mm in height). 
7.2.3 Coating and biosilicification of scaffolds and rods. 
For coating, the lyophilized recombinant fusion proteins (15mer-ch and R5-15mer-ch) 
were prepared at a concentration of 2% (wt/vol) in ultrapure water. The proteins were 
allowed to dissolve overnight at 4°C. Then, titanium rods and silk scaffolds were placed 
in a 24 well plate with 1 mL of 2% silk solution for 5 min. Samples were then subjected 
to water vapour annealing using an isotemp vacuum oven for 24 h at room temperature 
and 635 mbar. Afterwards, samples were air-dried overnight at room temperature. 
For inducing silicification, the silk and titanium coated with recombinant proteins 
(15mer-ch, R5-15mer-ch) were placed in a 24 well plate with 1 mL of 30 mM tetraethyl 
orthosilicate-phosphate buffer solution (Sigma-Aldrich, Dorset, UK) for 1 hour as 
described previously.27 Scaffolds and rods were then rinsed three times with water and 
left to dry overnight in a fume hood.24 
7.2.4 Characterisation Techniques 
Atomic Force Microscopy 
A Bruker Dimension Icon with ScanAsyst was used to perform all imaging, 
topographical measurements and nanoquantum mapping. Data was collected in 
PeakForce Tapping mode and processed using Nanoscope Analysis software. Elastic 
modulus values are stated as an average of 20 measurements taken across a 20 μm2 area. 
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Fourier Transform Infrared Attenuated Total Reflectance Spectroscopy (FTIR-
ATR) 
Protein secondary structure of the coatings was assessed using FTIR-ATR (Frontier, 
PerkinElmer, Coventry, UK), with an average of 64 scans over the range 1750-1450 cm-
1. Thermo Grams A1 software v8.0 was used for curve fitting (including peak 
deconvolution), and baseline corrections. Eight points were chosen from the amide I 
band (1700-1580 cm-1); 4 points corresponding to β conformers: 1693, 1680, 1633 and 
1615 cm-1, 2 points for non-β conformers at 1656 and 1644 cm-1, and 2 at 1712 and 1592 
cm-1 to allow for peak shifting and amide II band overlap respectively. An iteration was 
carried out forcing all peaks to have a positive area with a linear baseline. This was 
carried out for 1,000 iterations before curve fitting. The sum of the areas under the peaks 
was found and each conformer expressed as a percentage of the total.  
Scanning Electron Microscopy and Microanalysis (SEM-EDX).  
SEM-EDX at 20 kV (JEOL 840,UK with Oxford Instruments Inca X-ray microanalysis, 
Oxford, UK) was used to observe the morphology and size of the silica particles and 
obtain information on the elemental composition of the scaffolds and rods. Each sample 
was mounted onto electrically conducting carbon tape on aluminium stubs before being 
gold coated using an argon gold plasma at 30mV and 1.2 kV for 2 minutes. A minimum 
of 50 particle diameters were measured and averaged to determine the particles size. 
Inductively Coupled Plasma – Optical Emission Spectroscopy  
The quantity of silicon present on sample surfaces was assessed via ICP (Perkin Elmer 
ICP-OES Optima 2100DV). One scaffold or rod was digested in 10M sodium hydroxide 
overnight then diluted 10 fold using dd. water. Measurements are stated as an average 
of 3 readings per sample compared against appropriate dilutions of 1000 ppm silicon 
stock solution (BDH Laboratory Supplies).  
Wettability Measurements  
The wettability and surface energy of the titanium rods was measured using a Theta 
Attension Instrument with OneAttention v1.7 software (Biolin Scientific, Staffordshire, 
UK). Samples were placed on the stand, and using a syringe, a 10 µL droplet of water 
was placed on the surface and the contact angle at each side of the droplet measured ten 
times and an average taken.24 Silk scaffolds prepared from B.mori could not be 
measured in this way due to their porous nature. 
Chapter VII: Silk-Silica Composites as Coatings for Silk Scaffolds and Titanium Rods 
153 
 
Biodegradability/Solubility 
Scaffolds/rods prepared as above were submerged in 2mL 100mM PBS pH 7.4 at 37°C, 
degradation was measured by periodically taking 10 μL aliquots of the PBS supernatant 
and measuring protein concentration by adding 90 μL Coomassie stock solution (200mg 
Brilliant blue dye (Sigma-Aldrich, Dorset, UK), 100 mL methanol, 20 mL 85% 
orthophosphoric acid, 200 mL dd water), then measuring the absorbance ratio at a 
wavelengths 590nm and 450 nm.41  
7.3 Results and Discussion 
7.3.1 Silk Scaffolds 
The three B. mori silk scaffolds were synthesised using well established methods for 
silkworm silk processing.40 Coatings of chimeric spider silk proteins were then added 
through submersion, finally the scaffolds were silicified using pre-hydrolysed TEOS as 
previously described.24 
Silk scaffolds were designed with the intended application of aiding bone regrowth 
when repair is needed. The bulk material, B. mori silk, has been widely discussed and 
explored as it is bioacceptable, malleable and impressively strong. The genetically 
synthesised spider silk coatings containing the R5 silica binding domain, (R5-15mer-
ch), was selected based on previous studies highlighting this samples high control over 
silicification under in vivo mimicking conditions. Further, the addition of the R5 peptide 
had been shown to have no effect on the physical or chemical properties of the spider 
silk derivative, suggesting its high biocompatibility and resistance to biodegradation 
remained uncompromised.24  
A silk scaffold has been produced here, where the bulk material is the cheaper B. mori 
silk with a coating of the R5-15mer-ch fusion protein. Control samples for comparison 
included in the study are an uncoated B. mori silk scaffold and a B. mori scaffold coated 
in a spider silk derivative that does not contain the R5 binding domain (15mer-ch). 
These will allow accurate analysis of how chimeric silk coatings of a bulk silk scaffold 
effect its β structures and therefore physical properties and the silicifying capabilities of 
the R5 peptide when used as a coating. 
To observe silica particulate growth on the silk scaffold surface SEM coupled with EDX 
was used. Figure 7.3, showed that there was silica present on the surface of all three 
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samples. Only trace (non-particulate) amounts were present on the non-coated silk 
scaffold suggesting that whilst there is no obvious repulsion of silica particles, the B. 
mori silk surface does not provide nucleation sites for silicification. Both the 15mer-ch 
and R5-15mer-ch coated silk scaffolds promoted silica particle deposition, with particles 
of a similar size and size range, however ICP data, Figure 7.3 D showed the R5 peptide 
containing sample was able to promote more silica deposition per unit surface area (~1.3 
µgmm-2) than the 15mer-ch coated sample (~1 µgmm-2), the uncoated scaffold had no 
measurable volume of silica present. 
Unsurprising, as in nature, the uncoated B. mori silk scaffold had the greatest percentage 
of β conformer present, proving that the annealing process is still affective on silk when 
produced in scaffolds form. However, there was little difference in β content between 
the three scaffolds suggesting the derivative of the dragline spider silk was capable of 
reaching high levels of β conformer, >50%. Proving that the thin layer of chimeric silk 
on the surface is still able to undergo structural reordering even when bound to a 
different silk material via the annealing process. 
Figure 7.3 F shows the measured reduced elastic modulus of the scaffolds, the naturally 
beneficial properties of silk can be seen in the uncoated silk scaffold, where it was shown 
little to no silica binding had occurred but the stiffness was measured at ~6GPa. In this 
case there is an inverse relationship between increase in β content and the measured 
modulus of each sample, the 15mer-ch sample having greater stiffness than the uncoated 
silk scaffold, and the R5-15mer-ch silk scaffold exhibited a greater stiffness than both 
yet had the lowest level of β conformers present. Thus, it can be assumed that the 
production of the silica-silk composite has created a stiffer material, as there is a direct 
relationship between the mass of silica in a scaffold and the measured reduced modulus. 
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Figure 7.3 Imaging and characterisation of the three silicified silk scaffolds: silk 
scaffold, silk scaffold coated in 15mer-ch and silk scaffold coated in R5-15mer-ch. A-
C) SEM with EDX mapping, A, B and C are the silk scaffolds as listed above, i, ii, iii, 
iv are the image and mapping for carbon, oxygen and silicon respectively.  Scale bar: 
10 μm. D) ICP data for the volume of silica present represented as μg of silica per mm-
2 of scaffold surface n = 3 E) Population of silica particle sizes on the scaffold surfaces 
plotted as a function of particles size n = 50 F) Measured reduced elastic modulus of the 
silk scaffold from AFM data n= 20 G) Total β conformer present as a percentage of 
secondary structures measured by IR, n = 3.  
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To assess the porosity of the samples nitrogen gas absorption was performed on each 
scaffold with negligible measurements given suggesting the actual surface area of the 
scaffolds does not differ significantly from that of a flat material of the same shape. The 
implication of the data being these samples do not have pores on the meso scale (2-50 
nm), this is advantageous for biomaterials as mesoporous surfaces are not able to bind 
to cells well and tend to result in the binding of unwanted materials. To further support 
to the gas absorption data, surface area measurements were performed using AFM, 
where the surface area of a material is measured and then compared to that of a flat 
material, Appendix Fig 7.i shows a schematic of this approach. All scaffolds had a less 
than 3% surface area increase per distance measured suggesting no mesopores were 
present on the surface. The percentage increase was highest for the R5-15mer-ch coated 
scaffold likely due to the high volume of silica particles present, Table 7.1. 
 
No Coating 15mer-ch R5-15mer-ch 
Gas Absorption 
m
2
g
-1
 
1/∞ 1/∞ 1/∞ 
Percent surface 
area increase* 
0.083 ± 0.035 1.226 ± 0.467 2.826 ± 0.792 
Reduced 
Modulus GPa 
5.968 ± 0.722 8.214 ± 0.433 9.262 ± 0.607 
% Beta 
Conformer 
64.184 ± 0.523 61.703 ± 0.090 53.090 ± 0.434 
Silica μgmm
-2
 0 1.009 ± 0.000 1.308 ± 0.000 
Silica Particle 
Size μm 
- 0.524 ± 0.128 0.474 ± 0.196 
Table 7.1 All data collected for the silk scaffold materials. *The additional surface area 
increase as a percent when compared to a flat surface. 
Degradation of the silk scaffolds was measured as protein loss to an in vivo mimicking 
solution. Figure 7.4B shows only minimal fluctuation of absorbance readings for the 
solutes of the scaffolds indicating a high resilience to degradation. Figure 7.4A displays 
the secondary structures present in the silk scaffolds, all have high β sheet and β turn 
levels known to give resilience to protein break down. 
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Figure 7.4 A) In depth peak deconvolution results showing the exact percentage of each 
β conformer present in each silk scaffold n = 3 B) Degradation study using protein 
absorbance to compare the silk scaffolds protein release, n= 10. 
Chimeric silica binding silk proteins have proven effective as a coating for a semi-
permanent silk scaffolds for biomedical use. The ability of these proteins to undergo 
structural reordering via annealing provides a degree of tailorability with respect to 
stiffness and degradation in an in vivo mimicking environment. Incorporation of 
nanoscale bioabsorbable silica aided mechanical strength whilst providing a known 
osteogenic material. This additional mineral phase exhibited no effect on the protein 
structures present meaning increased stiffness was a direct result of silica presence. 
7.3.2 Titanium Rods 
Titanium rods have been evaluated to observe if coating the inert titanium surface with 
a silk material will result in silicification on the surface of the material creating a more 
bioactive surface that will heighten bone regrowth around a fracture site. The silk fusion 
protein, R5-15mer-ch, was selected from previous studies as a known silk material with 
silicifying capabilities stemming from the addition of the R5 silica binding peptide; two 
control samples were also included in the study; an uncoated titanium rods and a 
titanium rod coated in the 15mer-ch sample, a non-R5 containing counterpart. All rods 
underwent silicification as previously described and the results shown here were 
collected on the post-silicified rods.24 
The extent of silicification on the titanium implant surfaces was assessed via SEM 
imaging, the uncoated titanium rod displayed no silica particulates deposited on the 
surface suggesting the inert titanium surface did not provide a site for nucleation to 
occur, Figure 7.5 A. Both chimeric coated titanium rods permitted silica deposition on 
Chapter VII: Silk-Silica Composites as Coatings for Silk Scaffolds and Titanium Rods 
158 
 
the rod surface with the R5 containing rod inducing a greater coverage of silica across 
the surface, Figure 7.5 B and C. 
+ 
Figure 7.5 A-C) SEM with EDX mapping for the uncoated titanium rod, the 15mer-ch 
coated titanium rod and the R5-15mer-ch rod respectively, i, ii, iii, iv and v are the image 
and mapping for carbon, oxygen, silicon and titanium respectively.  Scale bar: 10 μm. 
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ICP was employed to find the mass of silica bound to each rod, the uncoated titanium 
rod had no measurable silica present when measured by ICP, validating the images seen 
by SEM with EDX analysis, the 15mer-ch and R5-15mer-ch coatings allowed the 
binding of silica particles to the rod surface with a greater concentration, and larger 
particles, forming on the R5 containing rod as might be expected, Figure 7.6 A and B. 
However, direct comparison to the silk rod coated in the same R5-15mer-ch chimera 
reveals a tenfold less silica presence on the titanium implant surface. 
Measurements to find the reduced elastic modulus for the uncoated titanium rod proved 
impossible due to the hard nature of the titanium surface. Analysis of the 15mer-ch and 
R5-15mer-ch coated titanium rods showed, similarly to the B. mori silk rod counterparts, 
that the greater silica presence on the R5 coated rod surface resulted in an increase in 
the sample’s elastic modulus when compared with the non-R5 silk coated rod, Table 
7.2.  
The secondary structure of the chimera coatings saw similar results to the silk rods of 
~50% β conformer for the 15mer-ch and R5-15mer-ch samples when coating titanium 
rods, Table 7.2, Figure 7.6. This confirms that the chimeras can still undergo β 
conformer induction even as a thin coating layer on a titanium surface.  
 
(Caption overleaf) 
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Figure 7.6 A) volume of silica present on the titanium rods measured by ICP B) the 
average particle size and distribution of silica particles on the surface the titanium rods 
n = 50 C) AFM measured reduced elastic modulus of the 15mer-ch and R5-15mer-ch 
titanium rods (uncoated sample was too stiff to be measured) n = 20 D) Total percentage 
β conformer of the 15mer-ch and R5-15mer-ch coated titanium rods n = 3. 
Sample porosity was assessed via nitrogen gas absorption, and similarly to the silk rods, 
the titanium rod surfaces were not mesoporous, lessening the risk of implant rejection 
from cells being unable to bind, Table 7.2. Point to point measurements however 
suggested that the multi-layering of silica particles as seen in the SEM image for R5-
15mer-ch, Figure 7.4 Ci, resulted in a much larger increase in surface area when 
compared to the two control titanium rods and all B. mori silk rods produced in the 
study. Contact angle measurements were performed on the three rods with data further 
supporting silk coated titanium rods use as biomaterials as addition of the chimeras had 
no significant effect on the wettability of the rod surface, Table 7.2. 
 
No Coating 15mer-ch R5-15mer-ch 
Gas Absorption 
m2g-1 
1/∞ 1/∞ 1/∞ 
Percent surface 
area increase* 
1.868 ± 0.535 6.115 ± 1.515 52.663 ± 7.193 
Reduced Modulus 
GPa 
∞ 28.370 ± 2.617 80.954 ± 5.997 
% Beta Conformer - 53.016 ± 0.267 48.767 ± 0.958 
Silica μgmm-2 0 0.094 ± 0.000 0.132 ± 0.000 
Silica Particle Size 
μm 
- 0.360 ± 0.127 0.514 ± 0.160 
Contact Angle 129.304 ± 3.45 117.553 ± 2.85 125.002 ± 6.68 
Table 7.2 All data collected for the titanium rod materials. *The addition surface area 
increased as a percent when compared to a flat surface. 
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Despite titanium implants intending to be for use as permanent implants, the silk 
coatings employed here are intended to be semi-permanent, slowly degrading over time, 
preferably when no longer needed for bone regrowth. The breakdown of this protein 
film was monitored as protein released into an in vivo mimicking solution. Figure 7.7 
shows that after 5 weeks in in vivo conditions there was no loss of protein to solution 
indicating a high resilience to degradation from these samples.   
 
Figure 7.7 A) In depth protein secondary structure analysis of the two protein coated 
titanium rod using IR data, n = 3 B) Measured protein release from the surfaces of the 
titanium rods: titanium, titanium 15mer-ch and titanium R5-15mer-ch, n = 10 
Material study of titanium rods with and without chimeric silk coatings was preformed 
to judge applicability towards biomedical use. The inert surface of the titanium was 
highlighted when silica deposition on the uncoated titanium surface was inhibited, silk 
coatings provided a barrier to overcome this and limited silica was permitted to bind to 
the surface. Use of silk as a thin coating on the surface of a titanium rod had no adverse 
effect on the protein, reordering of secondary protein structure via annealing was 
successful at inducing β conformers. Despite positive results indicating the high 
potential for silk coated titanium rods for use as biomaterials, further improvements 
targeted towards increasing silica deposition would expand the capability of these 
materials to result in successful implantation. 
7.4 Conclusions 
Silk materials have been widely used as biomaterials thanks to their highly beneficial 
physical properties. Here work from several previous studies were built on to produce 
biomedical silk scaffolds that combine the genetically modified spider silk derivative 
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containing the silicifying domain R5, and B. mori (silkworm) silk as a cheaper bulk 
material or medical grade titanium as a sturdy but inert scaffold bulk. 
Use of the R5-15mer-ch and 15mer-ch fusion proteins as scaffold and rod coatings 
proved that these materials were unaltered in their ability to undergo annealing for 
reordering of secondary protein structure to achieve formation of more β conformers 
when used as thin layer coatings. This was true for coatings on both the silk scaffold 
and the titanium rod. It was also seen that the B. mori silk when produced into a scaffold 
behaved as normal, reaching high levels of β conformers required for mechanical 
strength and degradation resilience.  
When used as a coating the R5-15mer-ch silicifying chimera gave reasonable control 
over silification. Particulates were seen on all silk scaffolds and titanium rods that were 
coated in spider silk when compared to their naked counterpart, suggesting that the B. 
mori silk scaffold and titanium rod surfaces do not support silification. Despite the 
15mer-ch coating permitting silica deposition on the samples surfaces, it was shown, for 
both the titanium rods and silk scaffolds, that the presence of the R5 peptide actively 
promoted silicification on to the surfaces. As silicification was performed under 
circumneutral pHs this suggests the R5 containing coating would be able to replicate 
these results in vivo.  
A major difference between the R5-15mer-ch coated titanium rod and silk scaffold, was 
silification was seen to a much lesser degree. The trend of R5 presence aiding 
silicification was observed, however silica presence on the B. mori silk scaffold was 
seen to be tenfold greater than on the titanium coated rod. It is possible this is due to the 
thin nature of the coating allowing the inert nature of the underlying titanium surface to 
be displayed either discouraging silicification or inhibiting strong binding of silica 
particles meaning there is silica loss in transit.   
The incorporation of silica nanoparticles into the silk scaffolds resulted in a stiffening 
of the material shown through measurements of the reduced elastic modulus of the 
scaffolds after silicification. These data suggest that the presence of silica is 
multifunctional, aiding bone regrowth through collagen ordering and strengthening the 
implantable scaffolds. 
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All data collected supports the use of chimeric coated scaffolds as biomedical devices. 
All scaffolds exhibited no significant loss of protein into solution after 5 weeks of in 
vivo mimicking incubation indicating biological stability over this time frame. The 
chemical and physical data suggest that only minor variations occur in the relevant 
properties of the silk and titanium surfaces, and the R5-15mer-ch was able to function 
as a biomedical silicifying coating on both a silk scaffold and titanium rod. This has 
potential for use as an osteoinductive implantable device. 
It is noteworthy that these samples are currently being used in animal studies to give 
further information on their use as a biomaterial. 
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Conclusions and Further Work 
The biomimetic approach has been successfully utilised here to build on pervious 
work by the Perry/Kaplan collaboration on genetically modified spider silk to produce 
mineralising biomaterials. Previous work had explored using different lengths of the 
33 amino acid consensus sequence of the major ampullate dragline spindroin 1 (MaSp 
1) from Nephila clavipes (SGRGGLGGQG AGAAAAAGGA 
GQGGYGGLGSQGT), specifically a 6mer and 15mer, with a known silicifying 
domain attached at the C terminal of the silk; R5 (SSKKSGSYSGSKGSKRRIL), a 
component of a silaffin protein, and the A1 (SGSKGSKRRIL) and A3 
(MSPHPHPRHHHT) peptides, both derivatives of the R5 peptide. The aim of these 
studies was to combine silk and silica to produce a biomaterial for implant coatings 
that was as versatile and strong as silk with added rigidity from the silica particles as 
well as improved osseointegration from the silica interactions with collagen. It was 
found that the 15mer silk backbone and the R5 silicifying domain showed the most 
promise to be continued in the study. 
Here two samples were produced using the 15mer repeating unit of the spider silk 
modified with an R5 peptide bound at either the C or N termini of the silk to observe 
if the location of the R5 domain affected the overall material properties of silk and 
the silicifying capabilities of the R5 domain. The samples also contained a His-tag 
for purification located at the opposite termini and were compared against non-R5 
containing control counterparts. The major findings here highlighted the use of 
genetically modified silk chimeras as biomaterials, the addition of the peptide still 
allowed the annealing of the silk to achieve higher levels of beta conformer known to 
stiffen the material. Samples observed in solution had the same properties as their 
counterparts in term of charging and isoelectric point. The potential of each material 
to induce silica deposition under in vivo mimicking conditions was evaluated in 
solution and solid state; in solution both R5 silk chimeras exhibited good control of 
the size and volume of silica particles produced however as a film it was the R5-
15mer-ch sample that showed greater potential to induce silica precipitation with the 
greatest control of silica particles deposited. 
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Work on chimeras then progressed into hydroxyapatite binding silk fusion proteins. 
Again, three peptides were identified as mineralising domains but only one, the VTK 
peptide (VTKHLNQISQSY), was able to be expressed under the methods used for 
sample synthesis here. Similar to before, samples were produced with a binding 
peptide at either the C or the N terminal of the silk with a His-tag on the opposing 
termini, non-VTK samples produced as controls, however in addition to these, a 
sample was produced with a VTK domain at both termini to allow the effect of both 
location of the peptide and number of peptides present on the silk on hydroxyapatite 
mineralisation to be measured. Once again, the genetic modification of the 15mer silk 
derivative to incorporate the binding peptide did not alter the physical or chemical 
properties of the silk and more importantly, samples could be successfully annealed 
for beta conformer induction. The hydroxyapatite mineralising capabilities of the 
single VTK samples were reasonable but limited, the location of the VTK on the silk 
backbone influencing the crystallinity of the precipitates formed only slightly for both 
solid state and solution mineralisation. The VTK-15mer-VTK sample, had greater 
control over mineralisation than the singular VTK containing samples. This lead to 
further experiments proving that chimeric sample concentrations are also a key 
parameter in mineralisation as well as number of VTK peptides. Table 8 shows 
publications by the group, including the two new papers from this work, on the 
chimeric silk samples. 
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Silk Domain Sequence 
Silicifying 
Domain 
Sequence Year Ref 
derived from 
N. clavipes 
dragline silk 
(SGRGGLGGQGAGA
AAAAGGAGQGGYG
GLGSQGT)15 
VTK VTKHLNQISQSY 2017 202 
derived from 
N. clavipes 
dragline silk 
(SGRGGLGGQGAGA
AAAAGGAGQGGYG
GLGSQGT)15 
R5 
SSKKSGSYSGSK
GSKRRIL 
2016 99 
derived from 
N. clavipes 
dragline silk 
(SGRGGLGGQGAGA
AAAAGGAGQGGYG
GLGSQGT)6 
A3 MSPHPHPRHHHT 
2015 124 
A1 SGSKGSKRRIL 
R5 
SSKKSGSYSGSK
GSKRRIL 
N. clavipes 
dragline silk 
(SGRGGLGGQGAGA
AAAAGGAGQGGYG
GLGSQGT)15 
A3 MSPHPHPRHHHT 
2012 29 
A1 SGSKGSKRRIL 
R5 
SSKKSGSYSGSK
GSKRRIL 
N. clavipes 
spider 
dragline silk 
[SGRGGLGGQGAGA
AAAAGGAGQGGYG
GLGSQGT]n 
n = 6 or 15 
Pep 1 KSLSRHDHIHHH 
2012 123 
R-Pep1 
RKSLSRHDHIHH
H 
R5 
SSKKSGSYSGSK
GSKRRIL 
B. mori 
silkworm 
cocoons 
- 
Silica 
particles 
- 2010 28 
N. clavipes 
spider 
dragline silk 
(SGRGGLGGQGAGA
AAAAGGAGQGGYG
GLGSQGT)n 
n = 6 or 15* 
R5 
SSKKSGSYSGSK
GSKRRIL 
2006 39 
Table 8 Previous silaffins and silk repeating units used by the Perry/Kaplan 
collaboration to produce silk-silica composites. *a derivative also was produced with 
the cell building domain RGD. Linking section were included between the silk and 
peptide in all publications prior to 2016, sequence:  
SSGLVPRGSGMKETAAAKFERQHMDSPDLGTDDDDKAMA 
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During characterisation of the VTK chimeras it was noted that evaluation of 
mineralising capabilities were limited to a qualitative comparison of XRD data, 
whereas for the R5 chimeras there were several methods for quantifying the amount 
of silica precipitated. This led to method development of a novel way to use XRD 
data. Through the use of calibration samples containing a known mixture of all crystal 
phases being produced, in this case brushite and hydroxyapatite, a calibration curve 
was produced displaying specific peak height ratios against the molar ratio of the 
mixture. This method was proven affective for comparing efficiency of different 
binding peptides and fusion proteins. It is believe that this method may be translatable 
to other crystalline materials where quantification of phases through well-established 
means is not possible. 
To conclude work on silk film chimeras as biomaterials, further studies were 
completed on both the R5 samples and VTK samples. At this stage no sample was 
disregarded as all were shown to be reasonable at mineralisation and likely to be 
biocompatible. Here the theorised proportional link between β content of a chimeric 
silk film and it’s stiffness was proven via Young’s modulus measurements for all 
samples, regardless of the mineralising domain present. Higher β conformer 
percentage additionally resulted in increased resilience towards degradation under in 
vivo mimicking conditions. Silicification performed on the R5 samples, previously 
shown to achieve binding of uniform silica particles, enhanced the material stiffness 
of composites further as desired, particularly for the R5-15mer-ch sample. Silica 
presence will therefore aid material endurance and likely increase osseointegration. 
HAP mineralisation carried out on the VTK samples highlighted the location of the 
VTK peptide as a key parameter influencing the physical properties of the samples. 
Young’s modulus data showed that despite the highly crystalline precipitates 
produced by the VTK-15mer-ch and VTK-15mer-VTK samples, these may not be 
the most compatible with bone, as modulus values were tenfold that of literature 
values for bone. The nh-15mer-VTK sample however, produced a less crystalline 
material that was within the range of stated values for the Young’s modulus of bone. 
All physical property data would suggest the chimeras are good candidates for 
biomedical use, particularly the R5-15mer-ch given its exceptional silicifying 
capabilities and the nh-15mer-VTK as the crystalline HAP precipitates produced by 
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this sample are the most likely to be readily incorporated into surrounding bone tissue 
due to similar physical properties. 
The final part of the study was to begin use of chimeras as implant coatings. Based 
on the conclusions so far, the R5-15mer-ch sample was selected to be taken forward. 
Here both B. mori silk and titanium scaffolds were coated with the chimera silk 
sample. Use of the chimera as a scaffold coating did not change the physical 
properties of the silk and still allowed structural reordering to occur through 
annealing. No protein loss under in vivo mimicking incubation proved the chimeras 
show resilience to degradation was also unaffected. The R5 domain silicifying 
capabilities were shown to be effective at inducing and controlling the size of silica 
particles deposited for the silk scaffold, however comparison to the titanium scaffold 
showed a more than tenfold reduction in silica presence, a likely cause being the inert 
nature of the titanium material itself being exhibited. Incorporation of silica onto the 
silk scaffolds led to a stiffening of the material, suggesting the presence of silica is 
multifunction, aiding bone regrowth through collagen ordering and strengthening the 
implantable scaffolds.  
Future work 
Chimeric silk as scaffold coatings 
The titanium scaffolds included in the study were not able to match the successful 
results produced by the B. mori silk scaffolds. It is likely that the chimeric silk 
coatings used here may have been too thin, to address this different surface processing 
techniques will be explored: 
 Electrospinning the chimeras onto the titanium surface, this process produces 
nanofibers that collect on target surfaces. It is thought, providing there is no 
change in the behaviour of the chimera, this can be used to build up a thicker 
coating. 
 Double layer coatings. The titanium can be first coated in the cheaper B. mori 
silk and once annealed, a chimeric coating can then be applied. 
 Roughening of the titanium surface to give a larger surface to increase chance 
of chimeric silk adhering to the surface. 
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Once a method for improving titanium scaffold coating has been found, the project 
will move on to using the VTK containing chimeras as scaffold coating of both silk 
and titanium scaffolds. 
Prior to this, it is desired that further study into the VTK chimeras can be completed 
to look at the lower concentration limits with respect to mineralisation. It was shown 
that the VTK-15mer-ch produced highly crystalline HAP precipitates with an elastic 
modulus much greater than that of bone. It is believed that if the mass of sample used 
is reduced, by producing films of the same surface area but from a solution mixture 
of chimera and either a control sample or B. mori silk, a more compatible HAP 
precipitate may be produced. This would reduce the overall cost of the coating if a 
mixture can be used in place of a pure chimera solution. The results of this would 
determine which VTK chimera would be taken forward to be studied as a scaffold 
coating. 
As a conclusion to this work, a mixture of the two selected chimeras, R5 and VTK 
containing, would be produced for scaffold coatings. The goal being to premineralise 
the surface of the scaffold with both silica and HAP, or to produce a scaffold coated 
in silica and HAP binding peptides, to increase osseointegration at the implant site. 
Secondary structure of silk: studies at the interface 
The aim of this work would be to fully understand how the annealing process induces 
β conformers. An in depth study would hope to provide answers to questions such as: 
can the annealing process offer control over the β sheet/β turn content induced? What 
variables for the annealing process can be altered to achieve this? Is there a uniform 
affect from annealing across the width and depth of the film? Does the substrate the 
film is mounted on determine protein structures? Is there a correlation between film 
thickness and protein structure? 
To study this, silk films of varying thickness would be produced using dip coating of 
substrates in varying concentrations of aqueous silk solutions at a set withdrawal rate. 
AFM and IR would be used to measure film thickness and the protein structure of the 
films. 
Additionally to this, methods would be developed aiming to reduce the amount of 
helical structures produced when films are first produced. This would build on the 
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observation that structural changes occurring during annealing are the reorganisation 
of random coil regions whilst α helical regions remained unchanged. It is believed 
that the initial percentage of random coil structures present dictates the maximum 
amount of β conformers that can be induced, it is hoped by reducing the initial amount 
of ransom coil there will be greater control over the final percentage of β conformer 
present. 
Knowledge gained from this work would allow for more varied but specialised silk 
materials to be produced, increasing the possible applications of silk in, but not 
limited to, the biomedical field. 
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Appendix 
Chapter III 
 
Fig 3i Peak deconvolution of chimeric silk films pre and post annealing. 
a) nh-15mer 
i) pre-annealing         ii) post-annealing 
b) nh-15mer-R5 
i) pre-annealing          ii) post-annealing 
c) 15mer-ch 
i) pre-annealing           ii) post-annealing 
d) R5-15mer-ch 
i) pre-annealing            ii) post-annealing 
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Chapter IV 
 
Figure 4.i XRD pattern of calcium phosphate precipitate produced after 
mineralisation in the presence of the control PDMS (no sample). 
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Fig 4.ii Comparison of recombinant silk films, nh-15mer, nh-15mer-VTK, 15mer-ch, 
VTK-15mer-ch, before and after the methanol annealing process with respect to the 
changes in protein secondary structure.  
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Chapter V 
 
Fig 5.i Confirmation of the presence of brushite A) XRD B) FTIR (ATR). 
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Fig 5.ii Calculated peptide properties for the three HAP binding peptides included in 
the study. A) Tabulated physical property data for each peptide B) Graphical 
representations of peptide net charges with response to pH. C) pH of the peptide 
mineralising solution after each addition of 200 μL 120 mM sodium phosphate 
dibasic and 200 μL 200 mM calcium chloride. 
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Chapter VI 
 
Fig 6.i Example of a force separation curve from PeakForce tapping mode AFM 
scanning of a chimeric silk film. 
Chapter VII 
 
Fig 7.i Schematic of how percentage surface area increase has been calculated. 
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